Document:

Indenture

 Exhibit 4.1 
 FIRST AMERICAN FINANCIAL CORPORATION 
 as Issuer 

and 

U.S. BANK NATIONAL ASSOCIATION 
 as Trustee 
 Indenture 

Dated as of January 24, 2013 

					
	 Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE
	  	 	1	  
	 Section 1.01 Definitions
	  	 	1	  
	 Section 1.02 Other Definitions
	  	 	7	  
	 Section 1.03 Incorporation by Reference of Trust Indenture Act
	  	 	8	  
	 Section 1.04 Rules of Construction
	  	 	8	  
		
	 Article 2 THE SECURITIES
	  	 	9	  
	 Section 2.01 Form and Dating
	  	 	9	  
	 Section 2.02 Execution and Authentication
	  	 	9	  
	 Section 2.03 Amount Unlimited; Issuable in Series
	  	 	11	  
	 Section 2.04 Denomination and Date of Securities; Payments of Interest
	  	 	14	  
	 Section 2.05 Registrar and Paying Agent; Agents Generally
	  	 	14	  
	 Section 2.06 Paying Agent to Hold Money in Trust
	  	 	15	  
	 Section 2.07 Transfer and Exchange
	  	 	16	  
	 Section 2.08 Replacement Securities
	  	 	19	  
	 Section 2.09 Outstanding Securities
	  	 	20	  
	 Section 2.10 Temporary Securities
	  	 	21	  
	 Section 2.11 Cancellation
	  	 	21	  
	 Section 2.12 CUSIP Numbers
	  	 	21	  
	 Section 2.13 Series May Include Tranches
	  	 	22	  
		
	 Article 3 REDEMPTION
	  	 	22	  
	 Section 3.01 Applicability of Article
	  	 	22	  
	 Section 3.02 Notice of Redemption; Partial Redemptions
	  	 	22	  
	 Section 3.03 Payment Of Securities Called For Redemption
	  	 	24	  
	 Section 3.04 Exclusion of Certain Securities from Eligibility for Selection for Redemption
	  	 	25	  
	 Section 3.05 Mandatory and Optional Sinking Funds
	  	 	25	  
		
	 Article 4 COVENANTS
	  	 	26	  
	 Section 4.01 Payment of Securities
	  	 	26	  
	 Section 4.02 Maintenance of Office or Agency
	  	 	27	  
	 Section 4.03 Compliance Certificate
	  	 	27	  
	 Section 4.04 Taxes
	  	 	28	  
	 Section 4.05 Stay, Extension and Usury Laws
	  	 	28	  
	 Section 4.06 Securityholders’ Lists
	  	 	28	  
	 Section 4.07 Corporate Existence
	  	 	28	  
	 Section 4.08 Reports
	  	 	29	  
		
	 Article 5 CONSOLIDATION, MERGER OR SALE OF ASSETS
	  	 	29	  
	 Section 5.01 Consolidation, Merger or Sale of Assets by the Company
	  	 	29	  
	 Section 5.02 Successor Corporation Substituted
	  	 	30	  
		
	 Article 6 DEFAULT AND REMEDIES
	  	 	30	  
	 Section 6.01 Events of Default
	  	 	30	  
	 Section 6.02 Acceleration
	  	 	32	  

  
 i 

					
	 Section 6.03 Other Remedies
	  	 	33	  
	 Section 6.04 Waiver of Past Defaults
	  	 	33	  
	 Section 6.05 Control by Majority
	  	 	33	  
	 Section 6.06 Limitation on Suits
	  	 	34	  
	 Section 6.07 Rights of Holders to Receive Payment
	  	 	34	  
	 Section 6.08 Collection Suit by Trustee
	  	 	34	  
	 Section 6.09 Trustee May File Proofs of Claim
	  	 	34	  
	 Section 6.10 Application of Proceeds
	  	 	35	  
	 Section 6.11 Restoration of Rights and Remedies
	  	 	35	  
	 Section 6.12 Undertaking for Costs
	  	 	35	  
	 Section 6.13 Rights and Remedies Cumulative
	  	 	36	  
	 Section 6.14 Delay or Omission not Waiver
	  	 	36	  
		
	 Article 7 TRUSTEE
	  	 	36	  
	 Section 7.01 General
	  	 	36	  
	 Section 7.02 Certain Rights of Trustee
	  	 	36	  
	 Section 7.03 Individual Rights of Trustee and Others
	  	 	38	  
	 Section 7.04 Trustee’s Disclaimer
	  	 	38	  
	 Section 7.05 Notice of Default
	  	 	38	  
	 Section 7.06 Reports by Trustee to Holders
	  	 	39	  
	 Section 7.07 Compensation and Indemnity
	  	 	39	  
	 Section 7.08 Replacement of Trustee
	  	 	40	  
	 Section 7.09 Acceptance of Appointment by Successor
	  	 	41	  
	 Section 7.10 Successor Trustee By Merger, Etc.
	  	 	42	  
	 Section 7.11 Eligibility
	  	 	42	  
	 Section 7.12 Money Held in Trust
	  	 	42	  
		
	 Article 8 SATISFACTION AND DISCHARGE OF INDENTURE; UNCLAIMED MONEYS
	  	 	42	  
	 Section 8.01 Satisfaction and Discharge of Indenture
	  	 	42	  
	 Section 8.02 Application by Trustee of Funds Deposited for Payment of Securities
	  	 	44	  
	 Section 8.03 Repayment of Moneys Held by Paying Agent
	  	 	44	  
	 Section 8.04 Return of Moneys Held by Trustee and Paying Agent Unclaimed for Two Years
	  	 	44	  
	 Section 8.05 Defeasance and Discharge of Indenture
	  	 	44	  
	 Section 8.06 Defeasance of Certain Obligations
	  	 	46	  
	 Section 8.07 Reinstatement
	  	 	46	  
	 Section 8.08 Indemnity
	  	 	47	  
	 Section 8.09 Excess Funds
	  	 	47	  
	 Section 8.10 Qualifying Trustee
	  	 	47	  
		
	 Article 9 AMENDMENTS, SUPPLEMENTS AND WAIVERS
	  	 	47	  
	 Section 9.01 Amendments Without Consent of Holders
	  	 	47	  
	 Section 9.02 Amendments with Consent of Holders
	  	 	48	  
	 Section 9.03 Revocation and Effect of Consent
	  	 	49	  
	 Section 9.04 Notation on or Exchange of Securities
	  	 	50	  

  
 ii 

					
	 Section 9.05 Trustee to Sign Amendments, Etc.
	  	 	50	  
	 Section 9.06 Conformity with Trust Indenture Act
	  	 	50	  
		
	 Article 10 MISCELLANEOUS
	  	 	50	  
	 Section 10.01 Trust Indenture Act of 1939
	  	 	50	  
	 Section 10.02 Notices
	  	 	50	  
	 Section 10.03 Certificate and Opinion as to Conditions Precedent
	  	 	52	  
	 Section 10.04 Statements Required in Certificate or Opinion
	  	 	52	  
	 Section 10.05 Forms of Documents Delivered to Trustee
	  	 	52	  
	 Section 10.06 Evidence of Ownership
	  	 	53	  
	 Section 10.07 Rules by Trustee, Paying Agent or Registrar
	  	 	53	  
	 Section 10.08 Payment Date Other Than a Business Day
	  	 	53	  
	 Section 10.09 Governing Law
	  	 	54	  
	 Section 10.10 No Adverse Interpretation of Other Agreements
	  	 	54	  
	 Section 10.11 Successors
	  	 	54	  
	 Section 10.12 Duplicate Originals
	  	 	54	  
	 Section 10.13 Separability
	  	 	54	  
	 Section 10.14 Table of Contents, Headings, Etc.
	  	 	54	  
	 Section 10.15 No Personal Liability of Directors, Officers, Employees and Stockholders
	  	 	54	  
	 Section 10.16 Force Majeure
	  	 	54	  
	 Section 10.17 Communication by Holders of Securities with Other Holders of Securities
	  	 	55	  

  
 iii

 CROSS-REFERENCE TABLE* 

 

			
	 Trust Indenture

Act Section
	  	Indenture Section
	 310(a)
	  	7.11
	 310(b)
	  	7.03; 709
	 311
	  	7.03
	 311(b)(4)
	  	7.03
	 311(b)(6)
	  	7.03
	 312
	  	4.06
	 312(b)
	  	10.17
	 312(c)
	  	10.17
	 313(a)
	  	7.06
	 313(c)
	  	7.05
	 313(c)(2)
	  	3.02; 10.02
	 315(a)
	  	7.02
	 315(b)
	  	7.02; 10.02
	 315(c)
	  	7.02
	 315(d)
	  	7.02

  

	*	This Cross Reference Table is not part of the Indenture. 

  
 iv 

 INDENTURE, dated as of January 24, 2013, between FIRST AMERICAN FINANCIAL CORPORATION, a
Delaware corporation (the “Company”), and U.S. BANK NATIONAL ASSOCIATION, a national banking association duly incorporated and existing under the laws of the United States of America (the “Trustee”). 

RECITALS 

WHEREAS, the Company has duly authorized the issue from time to time of its debentures, notes, bonds or other evidences of indebtedness
to be issued in one or more series (the “Securities”) up to such principal amount or amounts as may from time to time be authorized in accordance with the terms of this Indenture and to provide, among other things, for the general terms
and conditions for the authentication, delivery and administration thereof, the Company has duly authorized the execution and delivery of this Indenture; and 
 WHEREAS, all things necessary to make this Indenture a valid indenture and agreement according to its terms have been done; 
 NOW, THEREFORE, in consideration of the premises and the purchases of the Securities by the holders thereof, the Company covenants and agrees with the Trustee for the equal and proportionate benefit of
the respective holders from time to time of the Securities or of any and all series thereof and of the coupons, if any, appertaining thereto as follows: 
 ARTICLE 1 
 DEFINITIONS AND INCORPORATION BY REFERENCE 

The following terms (except as herein otherwise expressly provided or unless the context otherwise requires) for all purposes of this
Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section. All other terms used in this Indenture which are defined (either directly or by reference) in the Trust Indenture Act (except as herein
otherwise expressly provided or unless the context otherwise requires) shall have the meanings so assigned to such terms. 

Section 1.01 Definitions. 
 “Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person. For
the purposes of this definition, “control” (including, with correlative meanings, the terms “controlling”, “controlled” and “under common control with”) when used with respect to any specified Person means the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise; provided that beneficial ownership
of 10% or more of the Voting Stock of a Person will be deemed to be control. 
 “Agent” means any Registrar,
co-registrar, Paying Agent, additional paying agent, Calculation Agent, transfer agent or Authenticating Agent. 

 “Authorized Newspaper” means a newspaper (in the City of New York, which,
if practicable, shall be The Wall Street Journal (U.S. Edition) or, with respect to any Security the interest on which is based on the offered quotations in the interbank Eurodollar Market for debtor deposits, in London, which, if practicable, shall
be the Financial Times (U.K. Edition)) published at least once a day for at least five days in each calendar week and of general circulation in the City of New York or London, as applicable. If it shall be impractical in the opinion of the Trustee
to make any publication of any notice required hereby in an Authorized Newspaper, any publication or other notice in lieu thereof which is made or given with the approval of the Trustee shall constitute a sufficient publication of such notice.

 “Bankruptcy Law” means Title 11, U.S. Code or any similar federal or state law for the relief of debtors.

 “Board of Directors” means: 
 (1) with respect to a corporation, the board of directors of the corporation or any committee thereof duly authorized to act for the corporation; 

(2) with respect to a partnership, the Board of Directors of the general partner of the partnership; 

(3) with respect to a limited liability company, the managing member or members or any controlling committee of managing members thereof;
and 
 (4) with respect to any other Person, the board or committee of such Person serving a similar function. 

“Board Resolution” means one or more resolutions of the Board of Directors of the Company or any authorized committee
thereof, certified by the secretary or an assistant secretary of the Company to have been duly adopted and to be in full force and effect on the date of certification, and delivered to the Trustee. 

“Business Day” means, unless otherwise provided with respect to a series of Securities, any day other than a Legal
Holiday. 
 “Capital Lease Obligation” means, at the time any determination is to be made, the amount of the
liability in respect of a capital lease that would at that time be required to be capitalized on a balance sheet prepared in accordance with GAAP, and the stated maturity thereof shall be the date of the last payment of rent or any other amount due
under such lease prior to the first date upon which such lease maybe prepaid by the lessee without payment of a penalty. 

“Capital Stock” means: 
 (1) in the case of a corporation, corporate stock; 
 (2) in the case of an
association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock; 

  
 2 

 (3) in the case of a partnership or limited liability company, partnership or membership
interests (whether general or limited); and 
 (4) any other interest or participation that confers on a Person the right to
receive a share of the profits and losses of, or distributions of assets of, the issuing Person; 
 but excluding from all of the foregoing any
debt securities convertible into Capital Stock, whether or not such debt securities include any right of participation in distributions with Capital Stock. 
 “Calculation Agent” means a financial institution appointed by the Company to calculate the interest rate payable in respect of each interest period on any floating rate notes issued
pursuant to this Indenture. 
 “Commission” means the United States Securities and Exchange Commission, as from
time to time constituted, created under the Exchange Act or, if at any time after the execution and delivery of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture Act, then the body
performing such duties at such time. 
 “Company” means First American Financial Corporation, a Delaware
corporation, until a successor replaces it pursuant to Article 5 of this Indenture and thereafter means the successor. 

“Corporate Trust Office” means the office of the Trustee, which at the date of this Indenture is located at the offices
of U.S. Bank National Association, 1349 West Peachtree Street, Suite 1050, Atlanta, Georgia 30309. 

“Default” means any event that is, or after notice or passage of time or both would be, an Event of Default. 

“Depositary” means, with respect to the Securities of any series issuable or issued, in whole or in part, in the form of
one or more Registered Global Securities, the Person designated as Depositary by the Company pursuant to Section 2.03 until a successor Depositary shall have become such pursuant to the applicable provisions of this Indenture, and thereafter
“Depositary” shall mean or include each Person who is then a Depositary hereunder, and if at any time there is more than one such Person, “Depositary” as used with respect to the Securities of any such series shall mean the
Depositary with respect to the Registered Global Securities of that series. 
 “Exchange Act” means the United
States Securities Exchange Act of 1934, as amended. 
 “Fair Market Value” means the value that would be paid
by a willing buyer to an unaffiliated willing seller in a transaction not involving distress or necessity of either party, determined in good faith by the Board of Directors of the Company (unless otherwise provided in this Indenture). 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment
of the accounting profession, which are in effect from time to time. 

  
 3 

 “Guarantee” means a guarantee other than by endorsement of negotiable
instruments for collection in the ordinary course of business, direct or indirect, in any manner, including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any
part of any Indebtedness (whether arising by virtue of partnership arrangements, or by agreements to keep-well, to purchase assets, goods, securities or services, to take or pay or to maintain financial statement conditions or otherwise).

 “Hedging Obligations” means, with respect to any specified Person, the obligations of such Person under:

 (1) interest rate agreements, interest rate cap agreements and interest rate collar agreements or other similar agreements or
arrangements; 
 (2) foreign exchange contracts and currency protection agreements or other similar agreements or arrangements;
and 
 (3) any commodity futures contract, commodity option or other similar agreements or arrangements. 

“Holder” or “Securityholder” means the registered holder of any Security with respect to Registered
Securities and the bearer of any Unregistered Security or any coupon appertaining thereto, as the case may be. 

“Indebtedness” means, with respect to any specified Person, any indebtedness of such Person (excluding accrued expenses
and trade payables), whether or not contingent: 
 (1) in respect of borrowed money; 

(2) evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements in respect thereof);

 (3) in respect of bankers’ acceptances; 
 (4) representing Capital Lease Obligations; 
 (5) representing the balance
deferred and unpaid of the purchase price of any property due more than six months after such property is acquired; or 
 (6)
representing any Hedging Obligations, 
 if and to the extent any of the preceding items (other than letters of credit and Hedging Obligations)
would appear as a liability upon a balance sheet of the specified Person prepared in accordance with GAAP. In addition, the term “Indebtedness” includes all indebtedness of others secured by a Lien on any asset of the specified Person
(whether or not such Indebtedness is assumed by the specified Person) and, to the extent not otherwise included, the Guarantee by the specified Person of any Indebtedness of any other Person. 

  
 4 

 “Indebtedness for Borrowed Money” of any Person means, without duplication,
(a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments and (c) all guarantee obligations of such Person with respect to Indebtedness for
Borrowed Money of others. 
 “Indenture” means this Indenture as originally executed and delivered or as it may
be amended or supplemented from time to time by one or more indentures supplemental to this Indenture entered into pursuant to the applicable provisions of this Indenture and shall include the forms and terms of the Securities of each series
established as contemplated pursuant to Sections 2.01 and 2.03. 
 “Legal Holiday” means a Saturday, a Sunday
or a day on which banking institutions in the City of New York or at a place of payment are authorized by law, regulation or executive order to remain closed. 
 “Lien” means any mortgage, pledge, security interest, encumbrance, lien or charge of any kind (including any conditional sale or other title retention agreement). 

“Obligations” means any principal, interest, penalties, fees, indemnifications, reimbursements, damages and other
liabilities payable under the documentation governing any Indebtedness. 
 “Officer” means, with respect to the
Company, the Chairman of the Board, the Chief Executive Officer, the President, the Chief Operating Officer, the Chief Financial Officer, the Treasurer, any Assistant Treasurer, the Controller, the Secretary, any Assistant Secretary or any
Vice-President of such Person. 
 “Officer’s Certificate” means a certificate signed on behalf of the
Company by one Officer of the Company that meets the requirements of Section 10.04 hereof. 
 “Opinion of
Counsel” means a written opinion signed by legal counsel, who may be an employee of or counsel to the Company, a Subsidiary of the Company or the Trustee, and who is reasonably acceptable to the Trustee. Each such opinion shall comply with
Section 314 of the Trust Indenture Act, if applicable, and include the statements provided in Section 10.04, if and to the extent required thereby. 
 “Original Issue Date” of any Security (or portion thereof) means the earlier of (a) the date of authentication of such Security or (b) the date of any Security (or portion
thereof) for which such Security was issued (directly or indirectly) on registration of transfer, exchange or substitution. 

“Original Issue Discount Security” means any Security that provides for an amount less than the principal amount thereof
to be due and payable upon a declaration of acceleration of the maturity thereof pursuant to Section 6.02. 

  
 5 

 “Periodic Offering” means an offering of Securities of a series from time
to time, the specific terms of which Securities, including, without limitation, the rate or rates of interest, if any, thereon, the stated maturity or maturities thereof and the redemption provisions, if any, with respect thereto, are to be
determined by the Company or its agents upon the issuance of such Securities. 
 “Person” means an individual,
corporation, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, limited liability company or government or other entity. 
 “Registered Global Security” means a Security evidencing all or a part of a series of Registered Securities, issued to the Depositary for such series in accordance with Section 2.02,
and bearing the legend prescribed in Section 2.02. 
 “Registered Security” means any Security registered
on the Security Register (as defined in Section 2.05). 
 “Responsible Officer” when used with respect to
the Trustee, shall mean an officer of the Trustee in the Corporate Trust Office, having direct responsibility for the administration of this Indenture, and also, with respect to a particular matter, any other officer to whom such matter is referred
because of such officer’s knowledge of and familiarity with the particular subject. 
 “Securities Act”
means the United States Securities Act of 1933, as amended. 
 “Security” or “Securities”
means any of the securities, as described in the first paragraph of the recitals hereof, that are authenticated and delivered under this Indenture and, unless the context indicates otherwise, shall include any coupon appertaining thereto.

 “Significant Subsidiary” means any Subsidiary that would be a “significant subsidiary” as defined
in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as such Regulation is in effect on the date of this Indenture. 
 “Subsidiary” means, with respect to any specified Person: 
 (1)
any corporation, association or other business entity of which more than 50% of the total Voting Stock is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person (or a
combination thereof); and 
 (2) any partnership (a) the sole general partner or the managing general partner of which is
such Person or a Subsidiary of such Person or (b) the only general partners of which are such Person or one or more Subsidiaries of such Person (or any combination thereof). 

“Trust Indenture Act” means the United States Trust Indenture Act of 1939, as amended (15 U.S. Code §§
77aaa-77bbbb), as it may be amended from time to time. 
 “Trustee” means U.S. Bank National Association until
a successor replaces it in accordance with the provisions of Article 7 and thereafter shall mean or include each Person who is then a Trustee hereunder, and if at any time there is more than one such Person, “Trustee” as used with respect
to the Securities of any series shall mean the Trustee with respect to Securities of that series. 

  
 6 

 “Unregistered Security” means any Security other than a Registered
Security. 
 “U.S. Government Obligations” means securities that are (i) direct obligations of the United
States of America for the payment of which its full faith and credit is pledged or (ii) obligations of an agency or instrumentality of the United States of America the full and timely payment of which is unconditionally guaranteed as a full
faith and credit obligation by the United States of America, and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest on or
principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depository receipt; provided that (except as required by law) such custodian is not authorized to make any deduction from the amount
payable to the holder of such depository receipt from any amount received by the custodian in respect of the U.S. Government Obligation or the specific payment of interest on or principal of the U.S. Government Obligation evidenced by such
depository receipt. 
 “Voting Stock” of any specified Person as of any date means the Capital Stock of such
Person that is at the time entitled to vote in the election of the board of directors, managers or trustees of such Person. 

“Yield to Maturity” means, as the context may require, the yield to maturity (i) on a series of Securities or
(ii) if the Securities of a series are issuable from time to time, on a Security of such series, calculated at the time of issuance of such series in the case of clause (i) or at the time of issuance of such Security of such series in the
case of clause (ii), or, if applicable, at the most recent redetermination of interest on such series or on such Security, and calculated in accordance with the constant interest method or such other accepted financial practice as is specified in
the terms of such Security. 
 Section 1.02 Other Definitions. Each of the following terms is defined in the section set
forth opposite such term: 
  

			
	 Term
	  	    Section    
	 Authenticating Agent
	  	2.02
	 Cash Transaction
	  	7.03
	 Dollars
	  	4.02
	 Event of Default
	  	6.01
	 Mandatory Sinking Fund Payment
	  	3.05
	 Optional Sinking Fund Payment
	  	3.05
	 Paying Agent
	  	2.05
	 Payment Default
	  	6.01
	 record date
	  	2.04
	 Registrar
	  	2.05
	 Security Register
	  	2.05
	 self-liquidating paper
	  	7.03
	 Sinking Fund Payment Date
	  	3.05
	 Tranche
	  	2.13

  
 7 

 Section 1.03 Incorporation by Reference of Trust Indenture Act. Whenever this
Indenture refers to a provision of the Trust Indenture Act, the provision is incorporated by reference in and made a part of this Indenture. The following terms used in this Indenture that are defined by the Trust Indenture Act have the following
meanings: 
 “indenture securities” means the Securities; and 

“obligor” on the indenture securities means the Company and any other obligor on the Securities. 

All other terms used in this Indenture that are defined by the Trust Indenture Act, defined by reference in the Trust Indenture Act to
another statute or defined by a rule of the Commission under the Trust Indenture Act and not otherwise defined herein have the meanings assigned to them therein. 
 Section 1.04 Rules of Construction. Unless the context otherwise requires: 
 (a) a term has the meaning assigned to it; 
 (b) unless otherwise
specified herein, an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP; 
 (c) “or” is not exclusive; 
 (d) words in the singular
include the plural, and words in the plural include the singular; 
 (e) “will” shall be interpreted as
a command; 
 (f) provisions apply to successive events and transactions; 

(g) “herein,” “hereof” and other words of similar import refer to this Indenture as a whole and not to
any particular Article, Section or other subdivision of this Indenture; 
 (h) all references to Sections or
Articles refer to Sections or Articles of this Indenture unless otherwise indicated; 
 (i) references to
sections of or rules under the Securities Act and the Exchange Act will be deemed to include substitute, replacement of successor sections or rules adopted by the Commission from time to time; and 

(j) use of masculine, feminine or neuter pronouns should not be deemed a limitation, and the use of any such pronouns
should be construed to include, where appropriate, the other pronouns. 

  
 8 

 ARTICLE 2 
 THE SECURITIES 
 Section 2.01 Form and Dating. The
Securities of each series shall be substantially in such form or forms (not inconsistent with this Indenture) as shall be established by or pursuant to one or more Board Resolutions or in one or more indentures supplemental hereto, in each case with
such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this Indenture and may have imprinted or otherwise reproduced thereon such legend or legends or endorsements, not inconsistent with the
provisions of this Indenture, as may be required to comply with any law, or with any rules of any securities exchange or usage, all as may be determined by the officers executing such Securities as evidenced by their execution of the Securities.
Unless otherwise so established, Unregistered Securities shall have coupons attached. 
 Section 2.02 Execution and
Authentication. An Officer shall execute the Securities and the coupons appertaining thereto, if any, for the Company by facsimile or manual signature, which may be imprinted or otherwise reproduced on the Securities, in the name and on behalf
of the Company. If an Officer whose signature is on a Security or coupon appertaining thereto no longer holds that office at the time the Security is authenticated, the Security and such coupon shall nevertheless be valid. 

The Trustee may appoint an authenticating agent (the “Authenticating Agent”) to authenticate Securities. The
Authenticating Agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such Authenticating Agent. Each Authenticating Agent shall be acceptable to
the Company and shall at all times meet the qualifications of the Trustee required by Article 7 of this Indenture. If at any time an Authenticating Agent shall cease to be eligible in accordance with the previous sentence, such Authenticating Agent
shall resign immediately. 
 If an Authenticating Agent consolidates with, merges or converts into, or transfers all or
substantially all of its corporate trust business to, another corporation or national banking association, the resulting, surviving or transferee corporation or national banking association without any further act shall be an Authenticating Agent
under this Indenture with the same effect as if the successor Authenticating Agent had been appointed as an Authenticating Agent as provided herein, provided such successor shall otherwise be eligible to be an Authenticating Agent under this
Indenture. 
 A Security and the coupons appertaining thereto, if any, shall not be valid or obligatory for any purpose or be
entitled to the benefits of this Indenture until the Trustee or Authenticating Agent executes the certificate of authentication on the Security or on the Security to which such coupon appertains by an authorized officer. The signature shall be
conclusive evidence that the Security or the Security to which the coupon appertains has been duly authenticated and delivered under this Indenture. 

  
 9 

 At any time and from time to time after the execution and delivery of this Indenture, the
Company may deliver Securities of any series having attached thereto appropriate coupons, if any, executed by the Company to the Trustee for authentication together with the applicable documents referred to below in this Section, and the Trustee
shall thereupon authenticate and deliver such Securities to or upon the written order of the Company, signed by an Officer, or pursuant to such procedures acceptable to the Trustee, without any further action by the Company. In authenticating such
Securities, the Trustee shall be entitled to receive prior to the authentication of any Securities of such series each of the following, and (subject to Article 7) shall be fully protected in relying upon, unless and until such documents have been
superseded or revoked: 
 (a) any Board Resolution and/or executed supplemental indenture referred to in Sections
2.01 and 2.03 by or pursuant to which the forms and terms of the Securities of that series were established; 

(b) an Officer’s Certificate stating that all covenants and conditions precedent to the execution, authentication and
delivery of the Securities have been complied with, and no Default or Event of Default has occurred and is continuing, and setting forth the form or forms and terms of the Securities, stating that the form or forms and terms of the Securities of
such series have been, or, in the case of a Periodic Offering, will be when established in accordance with such procedures as shall be referred to therein, established in compliance with this Indenture; and 

(c) an Opinion of Counsel substantially to the following effect, which Opinion of Counsel may contain such assumptions,
qualifications and limitations as such counsel shall reasonably deem appropriate: (i) the form or forms and terms of the Securities of such series have been, or, in the case of a Periodic Offering, will be when established in accordance with
such procedures as shall be referred to therein, established in compliance with this Indenture and the supplemental indenture, to the extent applicable, and (ii) the Indenture and such Securities have been duly authorized and, if executed and
authenticated in accordance with the provisions of the Indenture and delivered and duly paid for, will be entitled to the benefits of the Indenture and will constitute valid and legally binding obligations of the Company, enforceable against the
Company in accordance with their respective terms, subject to bankruptcy, insolvency, reorganization, receivership, moratorium and other similar laws affecting creditors’ rights generally and general principles of equity (regardless of whether
enforceability is considered in a proceeding of equity or law). 
 The Trustee shall not be required to authenticate such
Securities if the Trustee reasonably determines that the issue of such Securities pursuant to this Indenture will affect the Trustee’s own rights, duties or immunities under the Securities and this Indenture in any material respect or may not
be lawfully taken. 
 Notwithstanding the provisions of Sections 2.01 and this Section 2.02, if, in connection with a
Periodic Offering, all Securities of a series are not to be originally issued at one time, it shall not be necessary to deliver the Board Resolution otherwise required pursuant to Section 2.01 or the written order, Officer’s Certificate
and Opinion of Counsel otherwise required pursuant to this Section 2.02 at or prior to the authentication of each Security of such series if such documents are delivered at or prior to the authentication upon original issuance of the first
Security of such series to be issued. 

  
 10 

 With respect to Securities of a series offered in a Periodic Offering, the Trustee may rely,
as to the authorization by the Company of any of such Securities, the forms and terms thereof and the legality, validity, binding effect and enforceability thereof, upon the Opinion of Counsel and the other documents delivered pursuant to
Section 2.01 and this Section 2.02, as applicable, in connection with the first authentication of Securities of such series. 
 If the Company shall establish pursuant to or as contemplated by Section 2.03 that the Securities of a series or a portion thereof are to be issued in the form of one or more Registered Global
Securities, then the Company shall execute and the Trustee shall authenticate and deliver one or more Registered Global Securities in temporary or permanent form that (i) shall represent and shall be denominated in an amount equal to the
aggregate principal amount of all of the Securities of such series issued in such form and not yet cancelled, (ii) shall be registered in the name of the Depositary for such Registered Global Security or Securities or the nominee of such
Depositary, (iii) shall be delivered by the Trustee to such Depositary or pursuant to such Depositary’s instructions and (iv) shall bear a legend substantially to the following effect: 

“THIS SECURITY IS A REGISTERED GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A
DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS
EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO THE NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER
NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.” 
 Section 2.03 Amount Unlimited; Issuable in Series. The aggregate principal amount of Securities which may be authenticated and delivered under this Indenture is unlimited. 

There shall be established in or pursuant to a Board Resolution and set forth in an Officer’s Certificate, or established in one or
more indentures supplemental hereto, prior to the initial issuance of Securities of any series, subject to the last sentence of this Section 2.03, any or all of the following: 

(a) title and aggregate principal amount; 

(b) any applicable subordination provisions for any subordinated debt Securities; 

(c) whether the Securities will be secured or unsecured; 

  
 11 

 (d) the guarantors, if any, and the terms of any Guarantees (including
provisions relating to seniority, subordination, security and release of any Guarantees); 
 (e) whether the
Securities are exchangeable for other securities; 
 (f) percentage or percentages of principal amount at which
the Securities will be issued; 
 (g) issue and maturity date(s); 

(h) interest rate(s) or the method for determining the interest rate(s); 

(i) dates on which interest will accrue or the method for determining dates on which interest will accrue; 

(j) dates on which interest will be payable and record dates for the determination of the Holders to which interest will
be payable on such payment dates; 
 (k) the places where payments on the Securities will be payable; 

(l) redemption or early repayment provisions; 

(m) authorized denominations; 
 (n) form; 
 (o) amount of discount or premium, if any, with which
the Securities will be issued; 
 (p) whether the Securities will be issued in whole or in part in the form of
one or more Registered Global Securities; 
 (q) identity of the Depositary for Registered Global Securities;

 (r) whether a temporary security is to be issued with respect to a series and whether any interest payable
prior to the issuance of definitive securities of the series will be credited to the account of the persons entitled thereto; 
 (s) the terms upon which beneficial interests in a temporary global security may be exchanged in whole or in part for beneficial interests in a definitive global security or for individual definitive
securities; 
 (t) any covenants applicable to the particular Securities being issued; 

(u) any Defaults and Events of Default applicable to the particular Securities being issued; 

(v) currency, currencies or currency units in which the purchase price for, the principal of and any premium and any
interest on, such Securities will be payable; 

  
 12 

 (w) time period within which, the manner in which and the terms and
conditions upon which the purchaser of the Securities can select the payment currency; 
 (x) securities
exchange(s) on which the Securities will be listed, if any; 
 (y) the Company’s obligation or right to
redeem, purchase or repay Securities under a sinking fund, amortization or analogous provision; 
 (z) provisions
relating to covenant defeasance and legal defeasance; 
 (aa) provisions relating to satisfaction and discharge
of this Indenture; 
 (bb) provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; and 
 (cc) any other terms of the Securities
of such series and Guarantees thereof, if any (which terms are not inconsistent with the provisions of the Trust Indenture, but may modify, amend, supplement or delete any of the terms of this Indenture with respect the Securities of such series and
Guarantees thereof, if any). 
 Each Depositary designated pursuant to this Section 2.03 must, at the time of its
designation and at all times while it serves as Depositary, be either a clearing agency registered under the Exchange Act and any other applicable statute or regulation or a foreign clearing agency regulated by a foreign financial regulatory
authority as defined in Section 3(a)(52) of the Exchange Act, including, without limitation, Euroclear Bank S.A./N.V. and Clearstream Banking, société anonyme. 

All Securities of any one series and coupons, if any, appertaining thereto shall be substantially identical, except in the case of
Registered Securities as to date and denomination, except in the case of any Periodic Offering and except as may otherwise be provided by or pursuant to the Board Resolution referred to above or as set forth in any such indenture supplemental
hereto. All Securities of any one series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to such Board Resolution or in any such indenture
supplemental hereto and any forms and terms of Securities to be issued from time to time may be completed and established from time to time prior to the issuance thereof by procedures described in such Board Resolution or supplemental indenture.

 Unless otherwise expressly provided with respect to a series of Securities, the aggregate principal amount of a series of
Securities may be increased and additional Securities of such series may be issued up to the maximum aggregate principal amount authorized with respect to such series as increased. 

  
 13 

 Section 2.04 Denomination and Date of Securities; Payments of Interest.
The Securities of each series shall be issuable as Registered Securities or Unregistered Securities in denominations established as contemplated by Section 2.03 or, if not so established with respect to Securities of any series, in
denominations of $1,000 and any integral multiple thereof. The Securities of each series shall be numbered, lettered or otherwise distinguished in such manner or in accordance with such plan as the Officers of the Company executing the same may
determine, as evidenced by their execution thereof. 
 Unless otherwise specified with respect to a series of Securities, each
Security shall be dated the date of its authentication. The Securities of each series shall bear interest, if any, from the date, and such interest and shall be payable on the dates, established as contemplated by Section 2.03. 

The person in whose name any Registered Security of any series is registered at the close of business on any record date applicable to a
particular series with respect to any interest payment date for such series shall be entitled to receive the interest, if any, payable on such interest payment date notwithstanding any transfer or exchange of such Registered Security subsequent to
the record date and prior to such interest payment date. The term “record date” as used with respect to any interest payment date (except a date for payment of defaulted interest) for the Securities of any series shall mean the date
specified as such in the terms of the Registered Securities of such series established as contemplated by Section 2.03, or, if no such date is so established, the fifteenth day next preceding such interest payment date, whether or not such
record date is a Business Day. 
 Except as the Company and the Trustee may otherwise agree, the Company shall promptly deliver
to the Trustee following the end of each calendar year a written notice specifying the amount of original issue discount accrued on any outstanding Securities that are Original Issue Discount Securities or otherwise are issued with more than a de
minimis amount of original issue discount (as defined in Section 1273(a) of the Internal Revenue Code of 1986, as amended) for such calendar year, including daily rates and accrual periods, and such other information relating to original issue
discount reasonably necessary in order to complete any required tax information reports for such calendar year. 

Section 2.05 Registrar and Paying Agent; Agents Generally. The Company shall maintain an office or agency where
Securities may be presented for registration, registration of transfer or for exchange (the “Registrar”) and an office or agency where Securities may be presented for payment (the “Paying Agent”). The Company shall
cause the Registrar to keep a register of the Registered Securities and of their registration, transfer and exchange (the “Security Register”). The Company may have one or more additional Paying Agents or transfer agents with
respect to any series. 
 The Company shall enter into an appropriate agency agreement with any Agent not a party to this
Indenture. The agreement shall implement the provisions of this Indenture and the Trust Indenture Act that relate to such Agent. The Company shall give prompt written notice to the Trustee of the name and address of any Agent and any change in the
name or address of an 

  
 14 

 
Agent. If the Company fails to maintain a Registrar or Paying Agent, the Trustee shall act as such. The Company may remove any Agent without prior notice to the Holders; provided that no
such removal shall become effective until (i) the acceptance of an appointment by a successor Agent to such Agent as evidenced by an appropriate agency agreement entered into by the Company and such successor Agent and delivered to the Trustee
or (ii) notification to the Trustee that the Trustee shall serve as such Agent until the appointment of a successor Agent in accordance with clause (i) of this proviso. The Company or any Subsidiary of the Company may act as Paying Agent
or Registrar; provided that neither the Company nor a Subsidiary of the Company shall act as Paying Agent in connection with the defeasance of the Securities or the discharge of this Indenture under Article 8. 

The Company initially appoints the Trustee as Registrar, Paying Agent, Calculation Agent and Authenticating Agent. If, at any time, the
Trustee is not the Registrar, the Registrar shall make available to the Trustee ten days prior to each interest payment date and at such other times as the Trustee may reasonably request the names and addresses of the Holders as they appear in the
Security Register. 
 Prior to due presentment of a Registered Security for registration of transfer, the Company, the Trustee
and any agent of the Company or of the Trustee may treat the Person in whose name such Registered Security is registered as the owner of such Registered Security for the purpose of receiving payment of principal of (and premium, if any) and interest
on such Registered Security and for all other purposes whatsoever, whether or not such Registered Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary.

 The Company, the Trustee and any agent of the Company or the Trustee may treat the bearer of any Unregistered Security and
the bearer of any coupon as the absolute owner of such Unregistered Security or coupon for the purpose of receiving payment thereof or on account thereof and for all other purposes whatsoever, whether or not such Unregistered Security or coupon be
overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 
 None of the Company, the Trustee, any Paying Agent or the Security Registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial
ownership interests of a Global Security or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests, or any notice which is permitted or required to be given under the Indenture, any consent given or
other action taken by the Depositary as Registered Holder, or any selection by the Depositary of any Person to receive payment of principal, premium, if any, interest or other amounts payable on the Securities. 

Section 2.06 Paying Agent to Hold Money in Trust. Not later than 10:00 a.m. New York City time on each due date or, in the
case of Unregistered Securities, 10:00 a.m. New York City time on the Business Day prior to the due date, of any principal, interest or premium, if any, on any Securities, the Company shall deposit with the Paying Agent money in immediately
available funds sufficient to pay such principal, interest or premium becoming due. The Company shall require each Paying Agent other than the Trustee to agree in writing that such Paying Agent shall hold in trust for the benefit of the Holders of
such Securities or the Trustee all 

  
 15 

 
money held by the Paying Agent for the payment of principal of and interest or premium, if any, on such Securities and shall promptly notify the Trustee of any Default by the Company in making
any such payment. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee and account for any funds disbursed, and the Trustee may at any time during the continuance of any Payment Default, upon written request
to a Paying Agent, require such Paying Agent to pay all money held by it to the Trustee and to account for any funds disbursed. Upon doing so, the Paying Agent shall have no further liability for the money so paid over to the Trustee. If the Company
or any Affiliate of the Company acts as Paying Agent, it shall, on or before each due date of any principal, interest or premium on any Securities, segregate and hold in a separate trust fund for the benefit of the Holders thereof a sum of money
sufficient to pay such principal, interest or premium so becoming due until such sum of money shall be paid to such Holders or otherwise disposed of as provided in this Indenture, and shall promptly notify the Trustee in writing of its action or
failure to act as required by this Section 2.06. 
 Section 2.07 Transfer and Exchange. Unregistered Securities
(except for any temporary global Unregistered Securities) and coupons (except for coupons attached to any temporary global Unregistered Securities) shall be transferable by delivery. 

At the option of the Holder thereof, Registered Securities of any series (other than a Registered Global Security, except as set forth
below) may be exchanged for a Registered Security or Registered Securities of such series and like tenor, of any authorized denominations and like aggregate principal amount and maturity, upon surrender of such Registered Securities to be exchanged
at the agency of the Company that shall be maintained for such purpose in accordance with Section 2.05 and upon payment, if the Company shall so require, of the charges hereinafter provided. If the Securities of any series are issued in both
registered and unregistered form, except as otherwise established pursuant to Section 2.03, at the option of the Holder thereof, Unregistered Securities of any series may be exchanged for Registered Securities of such series and tenor having
authorized denominations and an equal aggregate principal amount, upon surrender of such Unregistered Securities to be exchanged at the agency of the Company that shall be maintained for such purpose in accordance with Section 4.02, with, in
the case of Unregistered Securities that have coupons attached, all unmatured coupons and all matured coupons in default thereto appertaining, and upon payment, if the Company shall so require, of the charges hereinafter provided. At the option of
the Holder thereof, if Unregistered Securities of any series, maturity date, interest rate and Original Issue Date are issued in more than one authorized denomination, except as otherwise established pursuant to Section 2.03, such Unregistered
Securities may be exchanged for Unregistered Securities of such series and tenor having authorized denominations and an equal aggregate principal amount, upon surrender of such Unregistered Securities to be exchanged at the agency of the Company
that shall be maintained for such purpose in accordance with Section 4.02, with, in the case of Unregistered Securities that have coupons attached, all unmatured coupons and all matured coupons in default thereto appertaining, and upon payment,
if the Company shall so require, of the charges hereinafter provided. Registered Securities of any series may not be exchanged for Unregistered Securities of such series. Whenever any Securities are so surrendered for exchange, the Company shall
execute, and the Trustee shall authenticate and deliver, the Securities which the Holder making the exchange is entitled to receive. 

  
 16 

 Upon surrender for registration of transfer of any Registered Security of a series at the
agency of the Company that shall be maintained for that purpose in accordance with Section 2.05 and upon payment, if the Company shall so require, of the charges hereinafter provided, the Company shall execute, and the Trustee shall
authenticate and deliver, in the name of the designated transferee or transferees, one or more new Registered Securities of the same series, of any authorized denominations and of like tenor and aggregate principal amount and maturity. 

All Registered Securities presented or surrendered for registration of transfer, exchange, redemption or payment shall (if so required by
the Company or Trustee) be duly endorsed by, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and the Trustee duly executed by the Holder thereof or his attorney duly authorized in writing.

 The Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in
connection with any exchange or registration of transfer of Securities. No service charge shall be made for any such transaction. 
 Notwithstanding any other provision of this Section 2.07, unless and until it is exchanged in whole or in part for Securities in definitive registered form, a Registered Global Security representing
all or a portion of the Securities of a series may not be transferred except as a whole by the Depositary for such series to a nominee of such Depositary or by a nominee of such Depositary to such Depositary or another nominee of such Depositary or
by such Depositary or any such nominee to a successor Depositary for such series or a nominee of such successor Depositary. 

If at any time the Depositary for any Registered Global Securities of any series notifies the Company that it is unwilling or unable to
continue as Depositary for such Registered Global Securities or if at any time the Depositary for such Registered Global Securities ceases to be a clearing agency registered under the Exchange Act, the Company shall use its commercially reasonable
efforts to appoint a successor Depositary eligible under applicable law with respect to such Registered Global Securities. If a successor Depositary eligible under applicable law for such Registered Global Securities is not appointed by the Company
within 90 days after the Company receives such notice or becomes aware of such ineligibility, the Company shall execute, and the Trustee, upon receipt of the Company’s order for the authentication and delivery of definitive Registered
Securities of such series shall authenticate and deliver, as specified in such order, Registered Securities of such series in definitive form, in an aggregate principal amount equal to the principal amount of such Registered Global Securities, in
exchange for such Registered Global Securities. 
 If at any time an Event of Default has occurred and is continuing and the
Depositary for any Registered Global Securities requests the issuance of definitive Registered Securities, the Company shall execute, and the Trustee, upon receipt of the Company’s order for the authentication and delivery of definitive
Registered Securities of such series shall authenticate and deliver, as specified in such order, Registered Securities of such series in definitive form, in an aggregate principal amount equal to the principal amount of such Registered Global
Securities, in exchange for such Registered Global Securities. 

  
 17 

 The Company may at any time and in its sole discretion determine that any Registered Global
Securities of any series shall no longer be maintained in global form. In such event, the Company shall execute, and the Trustee, upon receipt of the Company’s order for the authentication and delivery of definitive Registered Securities of
such series shall authenticate and deliver, as specified in such order, Registered Securities of such series in definitive form, in an aggregate principal amount equal to the principal amount of such Registered Global Securities, in exchange for
such Registered Global Securities. 
 Any time the Registered Securities of any series are not in the form of Registered Global
Securities pursuant to the preceding two paragraphs, the Company agrees to supply the Trustee with a reasonable supply of certificated Registered Securities without the legend required by Section 2.02 and the Trustee agrees to hold such
Registered Securities in safekeeping until authenticated and delivered pursuant to the terms of this Indenture. 
 If
established by the Company pursuant to Section 2.03 with respect to any Registered Global Security, the Depositary for such Registered Global Security may surrender such Registered Global Security in exchange in whole or in part for Registered
Securities of the same series in definitive registered form on such terms as are acceptable to the Company and such Depositary. Thereupon, the Company shall execute, and the Trustee shall authenticate and deliver, without service charge, 

(a) to each Person specified by such Depositary, new Registered Securities of the same series, of any authorized
denominations as requested by such Person, in an aggregate principal amount equal to and in exchange for such Person’s beneficial interest in the Registered Global Security; and 

(b) to such Depositary, a new Registered Global Security in a denomination equal to the difference, if any, between the
principal amount of the surrendered Registered Global Security and the aggregate principal amount of Registered Securities authenticated and delivered pursuant to clause (a) above. 

Registered Securities issued in exchange for a Registered Global Security pursuant to this Section 2.07 shall be registered in such
names and in such authorized denominations as the Depositary for such Registered Global Security, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities
to or as directed by the Persons in whose names such Securities are so registered. The Registered Global Security exchanged shall be cancelled by the Trustee. 
 All Securities issued upon any registration of transfer or exchange of Securities shall be valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this
Indenture, as the Securities surrendered upon such registration of transfer or exchange. 
 Notwithstanding anything herein or
in the forms or terms of any Securities to the contrary, none of the Company, the Trustee or any agent of the Company or the Trustee shall be required to exchange any Unregistered Security for a Registered Security if such exchange would result in
adverse federal income tax consequences to the Company (such as, for example, the inability of the Company to deduct from its income, as computed for federal income tax purposes, the interest payable on the Unregistered Securities) under then
applicable United States federal income tax laws. The Trustee and any such agent shall be entitled to rely on an Officer’s Certificate or an Opinion of Counsel in determining such result. 

  
 18 

 The Company shall not be required (i) to issue, register the transfer of, or exchange
Securities of any particular series during the period from the opening of business 15 days before the day a notice of redemption relating to such Securities selected for redemption is sent to the close of business on the day that notice is sent, or
(ii) to register the transfer of or exchange any Security so selected for redemption in whole or part, except for the unredeemed portion of any Security being redeemed in part. 

Section 2.08 Replacement Securities. If any mutilated Security or a Security with a mutilated coupon appertaining to it is
surrendered to the Trustee, the Company shall execute and the Trustee shall authenticate and deliver, in exchange for such mutilated Security or in exchange for the Security to which a mutilated coupon appertains, a new Security of the same series
and of like tenor and principal amount and bearing a number not contemporaneously outstanding, with coupons corresponding to the coupons, if any, appertaining to such mutilated Security or to the Security to which such mutilated coupon appertains.

 If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss
or theft of any Security or coupon and (ii) such security or indemnity as may be required by them to hold each of them and any agent of any of them harmless, then, in the absence of notice to the Company or the Trustee that such Security or
coupon has been acquired by a bona fide purchaser, the Company shall execute and the Trustee shall authenticate and deliver, in lieu of any such destroyed, lost or stolen Security or in exchange for the Security to which a destroyed, lost or stolen
coupon appertains (with all appurtenant coupons not destroyed, lost or stolen), a new Security of the same series and of like tenor and principal amount and bearing a number not contemporaneously outstanding, with coupons corresponding to the
coupons, if any, appertaining to such destroyed, lost or stolen Security or to the Security to which such destroyed, lost or stolen coupon appertains. 
 In case any such mutilated, destroyed, lost or stolen Security or coupon has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security, pay such
Security or coupon (without surrender thereof except in the case of a mutilated Security or coupon) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as may be required by them to hold each of
them and any agent of any of them harmless, and in the case of destruction, loss or theft, evidence satisfactory to the Company and the Trustee and any agent of them of the destruction, loss or theft of such Security and the ownership thereof;
provided, however, that the principal of, premium, if any, and any interest on Unregistered Securities shall, except as otherwise provided in Section 4.02, be payable only at an office or agency located outside the United States.

 Upon the issuance of any new Security under this Section, the Company may require payment of a sum sufficient to cover any
tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. 

  
 19 

 Every new Security of any series, with its coupons, if any, issued pursuant to this Section
in lieu of any destroyed, lost or stolen Security or in exchange for any mutilated Security, or in exchange for a Security to which a mutilated, destroyed, lost or stolen coupon appertains, shall constitute an original additional contractual
obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Security and its coupons, if any, or the mutilated, destroyed, lost or stolen coupon shall be at any time enforceable by anyone, and any such new Security and
coupons, if any, shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that series and their coupons, if any, duly issued hereunder. 

The provisions of this Section are exclusive and shall preclude (to the extent lawful) any other rights and remedies with respect to the
replacement or payment of mutilated, destroyed, lost or stolen Securities or coupons. 
 Section 2.09 Outstanding
Securities. Securities outstanding at any time are all Securities that have been authenticated by the Trustee except for those cancelled by it, those delivered to it for cancellation, those described in this Section as not outstanding and those
that have been defeased pursuant to Section 8.05. 
 If a Security is replaced pursuant to Section 2.08, it ceases to
be outstanding unless and until the Trustee and the Company receive proof satisfactory to them that the replaced Security is held by a holder in due course. 
 If the Paying Agent (other than the Company or an Affiliate of the Company) holds on the maturity date or any redemption date or date for repurchase of the Securities money sufficient to pay Securities
payable or to be redeemed or repurchased on that date, then on and after that date such Securities cease to be outstanding and interest on them shall cease to accrue. 
 A Security does not cease to be outstanding because the Company or one of its Affiliates holds such Security unless cancelled pursuant to Section 2.11, provided, however, that, in
determining whether the Holders of the requisite principal amount of the outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, Securities owned by the Company or any Affiliate of the
Company shall be disregarded and deemed not to be outstanding, except that, in determining whether the Trustee shall be protected in relying upon any such request, demand, authorization, direction, notice, consent or waiver, only Securities as to
which a Responsible Officer of the Trustee has received written notice to be so owned shall be so disregarded. Any Securities so owned which are pledged by the Company, or by any Affiliate of the Company, as security for loans or other obligations,
otherwise than to another such Affiliate of the Company, shall be deemed to be outstanding, if the pledgee is entitled to act with respect to such Securities. 
 In determining whether the Holders of the requisite principal amount of the outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, the
principal amount of an Original Issue Discount Security that shall be deemed to be outstanding shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon acceleration of the maturity thereof
pursuant to Section 6.02. 

  
 20 

 Section 2.10 Temporary Securities. Until definitive Securities of any series are
ready for delivery, the Company may execute and the Trustee shall authenticate and deliver temporary Securities of such series. Temporary Securities of any series shall be substantially in the form of definitive Securities of such series but may
have insertions, substitutions, omissions and other variations determined to be appropriate by the Officers executing the temporary Securities, as evidenced by their execution of such temporary Securities. If temporary Securities of any series are
issued, the Company shall cause definitive Securities of such series to be prepared without unreasonable delay. 
 After
preparation of definitive Securities of any series, the temporary Securities of such series shall be exchangeable for definitive Securities of such series upon surrender of such temporary Securities at the office or agency of the Company designated
for such purpose pursuant to Section 4.02, without charge to the Holder. Upon surrender for cancellation of any one or more temporary Securities of any series the Company shall execute and the Trustee shall authenticate and deliver in exchange
therefor a like principal amount of definitive Securities of such series and tenor and authorized denominations. Until so exchanged, the temporary Securities of any series shall be entitled to the same benefits under this Indenture as definitive
Securities of such series. 
 Section 2.11 Cancellation. The Company or one of its Affiliates at any time may
deliver to the Trustee for cancellation any Securities previously authenticated and delivered hereunder which the Company or one of its Affiliates may have acquired in any manner whatsoever, and may deliver to the Trustee for cancellation any
Securities previously authenticated hereunder which the Company has not issued and sold. The Registrar, any transfer agent and the Paying Agent shall forward to the Trustee any Securities surrendered to them for transfer, exchange or payment. The
Trustee shall promptly cancel and dispose of in accordance with its customary procedures all Securities surrendered for transfer, exchange, payment or cancellation and upon written request shall deliver a certificate of disposition to the Company.
The Company may not issue new Securities to replace Securities it has paid in full or delivered to the Trustee for cancellation. 
 Section 2.12 CUSIP Numbers. The Company in issuing the Securities may use “CUSIP” and “ISIN” numbers (if then generally in use), and, if so, the Trustee shall, as a
convenience, use CUSIP numbers or ISIN numbers, as the case may be, in notices to Holders and no representation shall be made as to the correctness of such numbers either as printed on the Securities or as contained in any notice, and reliance may
be placed only on the other identification numbers printed on the Securities. 

  
 21 

 Section 2.13 Series May Include Tranches. A series of Securities may include one
or more tranches (each a “tranche”) of Securities, including Securities issued in a Periodic Offering. The Securities of different tranches may have one or more different terms, including authentication dates and public offering prices,
but all the Securities within each such tranche shall have identical terms, including authentication date and public offering price. Notwithstanding any other provision of this Indenture, with respect to Sections 2.02 (other than the fourth, sixth
and seventh paragraphs thereof) through 2.04, 2.07, 2.08, 2.10, 3.01 through 3.05, 4.02, 6.01 through 6.14, 8.01 through 8.06, Section 9.02 through 9.04 and 10.08, if any series of Securities includes more than one tranche, all provisions of
such sections applicable to any series of Securities shall be deemed equally applicable to each tranche of any series of Securities in the same manner as though originally designated a series unless otherwise provided with respect to such series or
tranche pursuant to Section 2.03. In particular, and without limiting the scope of the next preceding sentence, any of the provisions of such sections which provide for or permit action to be taken with respect to a series of Securities shall
also be deemed to provide for and permit such action to be taken instead only with respect to Securities of one or more tranches within that series (and such provisions shall be deemed satisfied thereby), even if no comparable action is taken with
respect to Securities in the remaining tranches of that series. 
 ARTICLE 3 

REDEMPTION 

Section 3.01 Applicability of Article. The provisions of this Article 3 shall be applicable to the Securities of any series
which are redeemable before their maturity or to any sinking fund for the retirement of Securities of a series except as otherwise specified as contemplated by Section 2.03 for Securities of such series. 

Section 3.02 Notice of Redemption; Partial Redemptions. Notice of redemption to the Holders of Registered Securities of any
series to be redeemed as a whole or in part at the option of the Company shall be given by mailing notice of such redemption by first class mail, postage prepaid, at least 20 days and not more than 60 days prior to the date fixed for redemption
(except that a redemption notice may be mailed more than 60 days prior to a redemption date if the notice is issued in connection with a defeasance of the Securities of such series or a satisfaction and discharge of this Indenture for such series)
to such Holders of Registered Securities of such series at their last addresses as they shall appear upon the registry books. Notice of redemption to the Holders of Unregistered Securities of any series to be redeemed as a whole or in part who have
filed their names and addresses with the Trustee pursuant to Section 313(c)(2) of the Trust Indenture Act shall be given by mailing notice of such redemption, by first class mail, postage prepaid, at least 20 days and not more than 60 days
prior to the date fixed for redemption (except that a redemption notice may be mailed more than 60 days prior to a redemption date if the notice is issued in connection with a defeasance of the Securities of such series or a satisfaction and
discharge of this Indenture for such series), to such Holders at such addresses as were so furnished to the Trustee (and, in the case of any such notice given by the Company, the Trustee shall make such information available to the Company for such
purpose). Notice of redemption to all other Holders of Unregistered Securities of any series to be redeemed as a whole or in part shall be published in an Authorized Newspaper, once in each of three successive calendar weeks, the first publication
to be not less than 20 days nor more than 60 days prior to the date fixed for redemption (except that a redemption notice may be mailed more than 60 days prior to a redemption date if the notice is issued in connection with a defeasance of the
Securities of such series or a satisfaction and discharge of this Indenture for such series). Notices of redemption may not be conditional. Any notice which is mailed or published in the manner herein provided shall be

  
 22 

 
conclusively presumed to have been duly given, whether or not the Holder receives the notice. Failure to give notice by mail, or any defect in the notice to the Holder of any Security of a series
designated for redemption as a whole or in part shall not affect the validity of the proceedings for the redemption of any other Security of such series. 
 The notice of redemption to each such Holder shall specify the principal amount of each Security of such series held by such Holder to be redeemed, the CUSIP numbers of the Securities to be redeemed, the
date fixed for redemption, the redemption price, or if not then ascertainable, the manner of calculation thereof, the place or places of payment, that payment will be made upon presentation and surrender of such Securities and, in the case of
Securities with coupons attached thereto, of all coupons appertaining thereto maturing after the date fixed for redemption, that such redemption is pursuant to the mandatory or optional sinking fund, or both, if such be the case, that interest
accrued to, but excluding, the date fixed for redemption will be paid as specified in such notice and that on and after said date interest thereon or on the portions thereof to be redeemed will cease to accrue and that such Securities subject to
such redemption shall cease to be outstanding and the Holders thereof shall have no rights with respect thereto other than the right to receive the redemption price upon presentment and surrender. In case any Security of a series is to be redeemed
in part only, the notice of redemption shall state the portion of the principal amount thereof to be redeemed and shall state that on and after the date fixed for redemption, upon surrender of such Security, a new Security or Securities of such
series in principal amount equal to the unredeemed portion thereof will be issued. 
 The notice of redemption of Securities of
any series to be redeemed at the option of the Company shall be given by the Company or, at the Company’s request, by the Trustee in the name and at the expense of the Company. 

On or before 10:00 a.m. New York City time on the redemption date or, in the case of Unregistered Securities, on or before 10:00 a.m. New
York City time on the Business Day prior to the redemption date specified in the notice of redemption given as provided in this Section, the Company shall deposit with the Trustee or with one or more Paying Agents (or, if the Company is acting as
its own Paying Agent, set aside, segregate and hold in trust as provided in Section 2.06) an amount of money sufficient to redeem on the redemption date all the Securities of such series so called for redemption at the appropriate redemption
price, together with accrued interest to, but excluding the date fixed for redemption. If all of the outstanding Securities of a series are to be redeemed, the Company shall deliver to the Trustee at least five days prior to the last date on which
notice of redemption may be given to Holders pursuant to the first paragraph of this Section 3.02 (or such shorter period as shall be acceptable to the Trustee) an Officer’s Certificate stating that all such Securities are to be redeemed.
If less than all the outstanding Securities of a series are to be redeemed, the Company shall deliver to the Trustee at least five days prior to last date on which notice of redemption may be given to Holders pursuant to the first paragraph of this
Section 3.02 (or such shorter period as shall be acceptable to the Trustee) an Officer’s Certificate stating the aggregate principal amount of such Securities to be redeemed. In the case of any redemption of Securities (a) prior to
the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, or (b) pursuant to an election of the Company which is subject to a condition specified in the terms of such
Securities or elsewhere in this Indenture, the Company shall deliver to the Trustee, not later than the giving of any notice of redemption to Holders pursuant to this Section, an Officer’s Certificate evidencing compliance with such restriction
or condition. 

  
 23 

 If less than all the Securities of a series are to be redeemed, and if the Securities are
held by a Depositary, the applicable operational procedures of the Depositary for selection of Securities for redemption will apply. If the Securities are not held by a Depositary, the Trustee shall select, pro rata, by lot or in such manner as it
shall deem appropriate and fair, Securities of such series or portions thereof to be redeemed in whole or in part. Securities may be redeemed in part in principal amounts equal to authorized denominations for Securities of such series. The Trustee
shall promptly notify the Company and Paying Agent in writing of the Securities of such series or portions thereof selected for redemption and, in the case of any Securities of such series selected for partial redemption, the principal amount
thereof to be redeemed. For all purposes of this Indenture, unless the context otherwise requires, all provisions relating to the redemption of Securities shall relate, in the case of any Security redeemed or to be redeemed only in part, to the
portion of the principal amount of such Security which has been or is to be redeemed. 
 Section 3.03 Payment Of Securities
Called For Redemption. If notice of redemption has been given as above provided, the Securities or portions of Securities specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable
redemption price, together with interest accrued to, but excluding, the date fixed for redemption, and on and after such date (unless the Company shall default in the payment of such Securities or portions thereof at the redemption price, together
with interest accrued to, but excluding, such date) any interest on the Securities or portions of Securities so called for redemption shall cease to accrue, and the unmatured coupons, if any, appertaining thereto shall be void and, except as
provided in Sections 7.12 and 8.02, such Securities shall be deemed not to be outstanding and shall cease from and after the date fixed for redemption to be entitled to any benefit under this Indenture, and the Holders thereof shall have no right in
respect of such Securities except the right to receive the redemption price thereof and unpaid interest to the date fixed for redemption. On presentation and surrender of such Securities at a place of payment specified in said notice, together with
all coupons, if any, appertaining thereto maturing after the date fixed for redemption, said Securities or the specified portions thereof shall be paid and redeemed by the Company at the applicable redemption price, together with interest accrued
thereon to, but excluding, the date fixed for redemption; provided that payment of interest becoming due on or prior to the date fixed for redemption shall be payable in the case of Securities with coupons attached thereto to the Holders of
the coupons for such interest upon surrender thereof, and in the case of Registered Securities, to the Holders of such Registered Securities registered as such on the relevant record date subject to the terms and provisions of Section 2.04 hereof.

 If any Security called for redemption shall not be so paid upon surrender thereof for redemption, the principal shall, until
paid or duly provided for, bear interest from the date fixed for redemption at the rate of interest or Yield to Maturity (in the case of an Original Issue Discount Security) borne by such Security. 

If any Security with coupons attached thereto is surrendered for redemption and is not accompanied by all appurtenant coupons maturing
after the date fixed for redemption, the surrender of such missing coupon or coupons may be waived by the Company and the Trustee, if there be furnished to each of them such security or indemnity as they may require to save each of them harmless.

  
 24 

 Upon presentation and surrender of any Security of any series redeemed in part only, the
Company shall execute and the Trustee shall authenticate and deliver to or on the order of the Holder thereof, at the expense of the Company, a new Security or Securities of such series (with any unmatured coupons attached), of authorized
denominations, in principal amount equal to the unredeemed portion of the Security so presented. 
 Section 3.04 Exclusion of
Certain Securities from Eligibility for Selection for Redemption. Securities shall be excluded from eligibility for selection for redemption if they are identified by registration and certificate number in a written statement signed by an
Officer of the Company and delivered to the Trustee at least 10 days prior to the last date on which notice of redemption may be given as being owned of record and beneficially by, and not pledged or hypothecated by, either (a) the Company or
(b) an entity specifically identified in such written statement as being an Affiliate of the Company. 
 Section 3.05
Mandatory and Optional Sinking Funds. The provisions of this Section shall be applicable to any sinking fund for the retirement of Securities of any series except as otherwise specified in the Officer’s Certificate or indenture
supplemental hereto for such Securities. The minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a “Mandatory Sinking Fund Payment”, and any payment in excess of
such minimum amount provided for by the terms of the Securities of any series is herein referred to as an “Optional Sinking Fund Payment”. The date on which a sinking fund payment is to be made is herein referred to as the
“Sinking Fund Payment Date”. If provided for by the terms of any Securities, the cash amount of any sinking fund payment may be subject to reduction as provided in the following paragraph. Each sinking fund payment shall be applied
to the redemption of Securities as provided for by the terms of such Securities. 
 The Company (1) may deliver outstanding
Securities of a series (other than any previously called for redemption) and (2) may apply as a credit Securities of a series which have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the
application of permitted Optional Sinking Fund Payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to any Securities of such series required to be made pursuant
to the terms of such Securities as and to the extent provided for by the terms of such Securities; provided that the Securities to be so credited have not been previously so credited. The Securities to be so credited shall be received and
credited for such purpose by the Trustee at the redemption price, as specified in the Securities so to be redeemed, for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.

 Not less than 60 days prior to each Sinking Fund Payment Date for any Securities, the Company will deliver to the Trustee an
Officer’s Certificate specifying the amount of the next ensuing sinking fund payment for such Securities pursuant to the terms of such Securities, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof,
if any, which is to be satisfied by delivering and crediting Securities pursuant to the preceding paragraph and will also deliver to the Trustee any Securities to be so delivered. Not less than 30

  
 25 

 
days prior to each such Sinking Fund Payment Date, the Trustee shall select the Securities to be redeemed upon such Sinking Fund Payment Date in the manner specified in Section 3.02 and
cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section 3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and
in the manner stated in Section 3.03. 
 ARTICLE 4 
 COVENANTS 
 Unless otherwise specified as contemplated by
Section 2.03, the covenants contained in this Article 4 shall be applicable to the Securities of any series. 
 Section
4.01 Payment of Securities. The Company shall pay the principal of, premium, if any, and interest, if any, on the Securities of a series on the dates and in the manner provided in the Securities of that series and this Indenture. The interest
on Securities with coupons attached (together with any additional amounts payable pursuant to the terms of such Securities) shall be payable only upon presentation and surrender of the several coupons for such interest installments as are evidenced
thereby as they severally mature. The interest on any temporary Unregistered Securities (together with any additional amounts payable pursuant to the terms of such Securities) shall be paid, as to the installments of interest evidenced by coupons
attached thereto, if any, only upon presentation and surrender thereof, and, as to the other installments of interest, if any, only upon presentation of such Unregistered Securities for notation thereon of the payment of such interest. The interest
on Registered Securities (together with any additional amounts payable pursuant to the terms of such Securities) shall be payable only to the Holders thereof (subject to Section 2.04) and at the option of the Company may be paid by mailing
checks for such interest payable to or upon the written order of such Holders at their last addresses as they appear on the Security Register of the Company. 
 Notwithstanding any provisions of this Indenture and the Securities of any series to the contrary, if the Company and a Holder of any Registered Security so agree, payments of interest on, premium, if
any, and any portion of the principal of, such Holder’s Registered Security shall be made by the Paying Agent, upon receipt from the Company of immediately available funds by 1:00 P.M., New York City time (or such other time as may be agreed to
between the Company and the Paying Agent), directly to the Holder of such Security (by federal funds wire transfer or otherwise) if the Holder has delivered written instructions to the Trustee 15 days prior to such payment date requesting that such
payment will be so made and designating the bank account to which such payments shall be so made and in the case of payments of principal, surrenders the same to the Trustee in exchange for a Security or Securities aggregating the same principal
amount as the unredeemed principal amount of the Securities surrendered. The Trustee shall be entitled to rely on the last instruction delivered by the Holder pursuant to this Section 4.01 unless a new instruction is delivered 15 days prior to
a payment date. The Company shall indemnify and hold each of the Trustee and any Paying Agent harmless against any loss, liability or expense (including attorneys’ fees) resulting from any act or omission to act on the part of the Company or
any such Holder in connection with any such agreement or from making any payment in accordance with any such agreement. 

  
 26 

 Section 4.02 Maintenance of Office or Agency. The Company shall maintain an office or
agency where Securities of any series may be surrendered for registration of transfer or exchange or for presentation for payment and where notices and demands to or upon the Company in respect of the Securities of such series and this Indenture may
be served. The Company hereby initially designates the Corporate Trust Office of the Trustee as such office or agency of the Company. The Company shall give prompt written notice to the Trustee of the location, and any change in the location, of
such office or agency. If at any time the Company fails to maintain any such required office or agency or fails to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the
Corporate Trust Office of the Trustee. 
 The Company may maintain one or more agencies in a city or cities located outside the
United States (including any city in which such an agency is required to be maintained under the rules of any stock exchange on which the Securities of any series are listed) where the Unregistered Securities, if any, of each series and coupons, if
any, appertaining thereto may be presented for payment. No payment on any Unregistered Security or coupon shall be made upon presentation of such Unregistered Security or coupon at an agency of the Company within the United States nor shall any
payment be made by transfer to an account in, or by mail to an address in, the United States unless, pursuant to applicable United States laws and regulations then in effect, such payment can be made without adverse tax consequences to the Company.
Notwithstanding the foregoing, if full payment in United States Dollars (“Dollars”) at each agency maintained by the Company outside the United States for payment on such Unregistered Securities or coupons appertaining thereto is illegal
or effectively precluded by exchange controls or other similar restrictions, payments in Dollars of Unregistered Securities of any series and coupons appertaining thereto which are payable in Dollars may be made at an agency of the Company.

 The Company may also from time to time designate one or more other offices or agencies where the Securities of any series may
be presented or surrendered for any or all such purposes and may from time to time rescind such designations; provided that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or
agency for such purposes. The Company shall give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. 

Section 4.03 Compliance Certificate. (a) The Company shall deliver to the Trustee, within 120 days after the end of each
fiscal year, an Officer’s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing Officer with a view to determining whether the
Company has kept, observed, performed and fulfilled its obligations under this Indenture, and further stating, as to such Officer signing such certificate, that to the best of his or her knowledge the Company has kept, observed, performed and
fulfilled each covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions of this Indenture (or, if a Default or Event of Default has occurred, describing all such
Defaults or Events of Default of which he or she may have knowledge and what action the Company is taking or proposes to take with respect thereto) and that to the best of his or her knowledge no event has occurred and remains in existence by reason
of which payments on account of the principal of, premium or interest, if any, on the Securities is prohibited or if such event has occurred, a description of the event and what action the Company is taking or proposes to take with respect thereto.

  
 27 

 (b) So long as any of the Securities of any series are outstanding, the Company will deliver
to the Trustee, forthwith upon any Officer becoming aware of any Default or Event of Default, an Officer’s Certificate specifying such Default or Event of Default, what action the Company is taking or proposes to take with respect thereto and
whether the Securities are listed on any exchange. 
 Section 4.04 Taxes. The Company will pay, and will cause each of
its Subsidiaries to pay, prior to delinquency, all material taxes, assessments, and governmental levies except such as are contested in good faith and by appropriate proceedings or where the failure to effect such payment is not adverse in any
material respect to the Holders of the Securities. 
 Section 4.05 Stay, Extension and Usury Laws. The Company covenants
(to the extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in
force, that may affect the covenants or the performance of this Indenture; and the Company (to the extent that it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any
such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted. 

Section 4.06 Securityholders’ Lists. The Company shall furnish or cause to be furnished to the Trustee a list in such form as
the Trustee may reasonably require of the names and addresses of the holders of the Securities pursuant to Section 312 of the Trust Indenture Act (a) not more than 15 days after each record date for the payment of interest on the
Securities, as hereinabove specified, as of such record date, and (b) at such other times as the Trustee may request in writing, within thirty days after receipt by the Company of any such request as of a date not more than 15 days prior to the
time such information is furnished; provided, however, in each case that so long as the Trustee shall be the Registrar, such lists shall not be required to be furnished. 

Section 4.07 Corporate Existence. Subject to Article 5 hereof, the Company shall do or cause to be done all things necessary to
preserve and keep in full force and effect: 
 (a) its corporate existence, and the corporate, partnership or
other existence of each of its Subsidiaries, in accordance with the respective organizational documents (as the same may be amended from time to time) of the Company or any such Subsidiary; and 

(b) the rights (charter and statutory), licenses and franchises of the Company and its Subsidiaries; 

  
 28 

 provided, however, that the Company shall not be required to preserve any such right, license
or franchise, or the corporate, partnership or other existence of any of its Subsidiaries, if the Company shall determine that the preservation thereof is no longer desirable in the conduct of the business of the Company and its Subsidiaries, taken
as a whole, and that the loss thereof is not adverse in any material respect to the Holders of the Securities. 
 Section
4.08 Reports. The Company will furnish to the Trustee, within 30 days after the Company is required to file such reports with the Commission, copies of its annual, quarterly and current reports that it is required to file with the Commission
pursuant to Section 13 or 15(d) of the Exchange Act. The Company shall be deemed to have complied with the previous sentence to the extent that such reports are filed with the Commission via EDGAR, or any successor electronic delivery procedure.

 If at any time the Company is not required to file with the Commission the reports required by the preceding paragraph of
this Section 4.08, the Company will furnish to the Holders of the Securities the information required to be delivered pursuant to 

Rule 144A(d)(4) under the Securities Act. The Company will be deemed to have provided the information to Holders if it has filed reports containing
such information with the Commission via EDGAR, or any successor electronic delivery procedure. 
 ARTICLE 5 

CONSOLIDATION, MERGER OR SALE OF ASSETS 
 Section 5.01 Consolidation, Merger or Sale of Assets by the Company. The Company shall not consolidate with or merge into any other entity or convey, transfer or lease all or substantially all
of its assets to any Person, unless: 
 (a) the Person formed by such consolidation (if other than the Company)
or into which the Company is merged or the Person which acquires by conveyance or transfer all or substantially all the assets of the Company shall be organized and existing under the laws of the United States of America or any State or the District
of Columbia, and shall expressly assume, by supplemental indenture, executed and delivered to the Trustee, the due and punctual payment of the principal, and premium, if any and interest on the Securities and the performance of every covenant of the
Indenture on the part of the Company to be performed or observed; and 
 (b) immediately after giving effect to
that type of transaction, no default or Event of Default exists. 
 The Company shall deliver to the Trustee prior to the
proposed transaction, an officer’s certificate and an opinion of counsel each stating that the proposed transaction and such supplemental indenture comply with the indenture and that all conditions precedent to the consummation of the
transaction under the indenture have been met. 

  
 29 

 This Section 5.01 will not apply to a merger of the Company with an Affiliate solely
for the purpose of reincorporating the Company in another jurisdiction. 
 Section 5.02 Successor Corporation
Substituted. Upon any consolidation or merger, or any sale, assignment, transfer, lease, conveyance or other disposition of all or substantially all of the properties or assets of the Company in a transaction that is subject to, and that
complies with the provisions of, Section 5.01 hereof, the successor Person formed by such consolidation or into or with which the Company is merged or to which such sale, assignment, transfer, lease, conveyance or other disposition is made
shall succeed to, and be substituted for (so that from and after the date of such consolidation, merger, sale, assignment, transfer, lease, conveyance or other disposition, the provisions of this Indenture referring to the “Company” shall
refer instead to the successor Person and not to the Company), and may exercise every right and power of the Company under this Indenture with the same effect as if such successor Person had been named as the Company herein; provided,
however, that the predecessor Company shall not be relieved from the obligation to pay the principal of, premium, if any, and interest on the Securities except in the case of a sale of all of the Company’s assets in a transaction that is
subject to, and that complies with the provisions of, Section 5.01 hereof. 
 ARTICLE 6 

DEFAULT AND REMEDIES 
 Section 6.01 Events of Default. Each of the following is an “Event of Default” with respect to the Securities of any series (whatever the reason for such Event of Default and
whether it shall be voluntary or involuntary or be effected by operation of law, pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body): 

(a) a default in payment when due of any principal of, or premium, if any, on the Securities of such series, whether at
maturity, upon any redemption or otherwise; or 
 (b) a default for 30 days in payment when due of interest on
the Securities of such series; or 
 (c) a default for 60 days after written notice from the Trustee or Holders
of at least 25% in principal amount of the outstanding Securities of such series in the compliance with any other covenant in this Indenture or such Securities; or 

  
 30 

 (d) a default under any instrument evidencing Indebtedness for Borrowed
Money of the Company, whether such Indebtedness now exists or is created after the date of this Indenture, if that default: 
 (i) is caused by a failure to pay principal when due at final (and not any interim) maturity of such Indebtedness on or prior to the expiration of the grace period provided in such Indebtedness (a
“Payment Default”), or 
 (ii) results in the acceleration of such Indebtedness prior to its
stated maturity (without such acceleration having been rescinded, annulled or otherwise cured, or such Indebtedness having been paid in full, or there having been deposited into trust a sum of money sufficient to pay in full such Indebtedness,
within 30 days after receipt of written notice of such default or breach to the Company by the Trustee or to the Company and the Trustee by Holders of at least 25% in aggregate principal amount of the Securities of such series), 

and, in each case, the principal amount of any such Indebtedness, together with the principal amount of any other such Indebtedness under which there has
been a Payment Default or the maturity of which has been so accelerated (without such acceleration having been rescinded, annulled or otherwise cured as described in clause (ii) above), aggregates $100.0 million or more; or 

(e) the Company or any of its Subsidiaries that is a Significant Subsidiary or any group of Subsidiaries of the Company
that, taken together, would constitute a Significant Subsidiary pursuant to or within the meaning of Bankruptcy Law: 
 (i) commences a voluntary case, 
 (ii) consents to the entry of an
order for relief against it in an involuntary case, 
 (iii) consents to the appointment of a custodian of it or
for all or substantially all of its property, 
 (iv) makes a general assignment for the benefit of its
creditors, or 
 (v) generally is not paying its debts as they become due; or 

(f) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

(i) is for relief against the Company or any of its Subsidiaries that is a Significant Subsidiary or any group of
Subsidiaries of the Company that, taken together, would constitute a Significant Subsidiary in an involuntary case; 
 (ii) appoints a custodian of the Company or any of its Subsidiaries that is a Significant Subsidiary or any group of Subsidiaries of the Company that, taken together, would constitute a Significant
Subsidiary or for all or substantially all of the property of the Company or any of its Subsidiaries that is a Significant Subsidiary or any group of Subsidiaries of the Company that, taken together, would constitute a Significant Subsidiary; or

  
 31 

 (iii) orders the liquidation of the Company or any of its Subsidiaries that
is a Significant Subsidiary or any group of Subsidiaries of the Company that, taken together, would constitute a Significant Subsidiary; 
 and the order or decree remains unstayed and in effect for 60 consecutive days; or 
 (g) any other Event of Default established pursuant to Section 2.03 with respect to the Securities of such series occurs. 
 Section 6.02 Acceleration. In the case of an Event of Default specified in clause (e) or (f) of Section 6.01 hereof, with respect to the Company, any Subsidiary of the Company that
is a Significant Subsidiary or any group of Subsidiaries of the Company that, taken together, would constitute a Significant Subsidiary, all outstanding Securities of any series will become due and payable immediately without further action or
notice. If any other Event of Default with respect to the Securities of any series then outstanding occurs and is continuing, then, and in each such case, except for any series of Securities the principal of which shall have already become due and
payable, either the Trustee or the Holders of not less than 25% in aggregate principal amount of the Securities of any such series then outstanding hereunder (each such series treated as a separate class) by notice in writing to the Company (and to
the Trustee if given by Securityholders), may declare the entire principal (or, if the Securities of any such series are Original Issue Discount Securities, such portion of the principal amount as may be specified in the terms of such series
established pursuant to Section 2.03) of all Securities of such series, and the interest accrued thereon, if any, and premium, if any, to be due and payable immediately, and upon any such declaration the same shall become immediately due and
payable. 
 The foregoing provision, however, is subject to the condition that if, at any time after the principal (or, if the
Securities are Original Issue Discount Securities, such portion of the principal as may be specified in the terms thereof established pursuant to Section 2.03) of the Securities of any series (or of all the Securities, as the case may be) shall
have been so declared or become due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained by the Trustee as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum
sufficient to pay all overdue installments of interest or other payments with respect to coupons on all the Securities of each such series (or of all the Securities, as the case may be) and the principal of, premium, if any, and interest on any and
all Securities of each such series (or of all the Securities, as the case may be) which shall have become due otherwise than by such declaration and acceleration (with interest upon such overdue installments of interest or other payments with
respect principal and, to the extent that payment of such interest is enforceable under applicable law, on overdue installments of interest or other payments with respect to coupons on all Securities of each series, at the same rate as the rate of
interest or Yield to Maturity (in the case of Original Issue Discount Securities) specified in the Securities of each such series to the date of such payment or deposit) and such amount as shall be sufficient to cover all amounts owing the Trustee
under Section 7.07, and if any and all Events of Default under the Indenture, other than the non-payment of the principal of Securities which shall have become due by acceleration, shall have been cured, waived or otherwise remedied as provided
herein, then and in every such case the Holders of a majority in aggregate principal amount of all the then outstanding Securities of all such series that have been accelerated (voting as a single

  
 32 

 
class), by written notice to the Company and to the Trustee, may waive all Defaults with respect to all such series (or with respect to all the Securities, as the case may be) and rescind and
annul such declaration and its consequences, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent Default or shall impair any right consequent thereon. 

For all purposes under this Indenture, if a portion of the principal of any Original Issue Discount Securities shall have been
accelerated and declared or become due and payable pursuant to the provisions hereof, then, from and after such declaration, unless such declaration has been rescinded and annulled, the principal amount of such Original Issue Discount Securities
shall be deemed, for all purposes hereunder, to be such portion of the principal thereof as shall be due and payable as a result of such acceleration, and payment of such portion of the principal thereof as shall be due and payable as a result of
such acceleration, together with interest or premium, if any, thereon and all other amounts owing thereunder, shall constitute payment in full of such Original Issue Discount Securities. 

Section 6.03 Other Remedies. If an Event of Default with respect to the Securities of any series occurs and is continuing, the
Trustee may pursue, in its own name or as trustee of an express trust, any available remedy by proceeding at law or in equity to collect the payment of principal of, premium, if any, and interest on the Securities of such series or to enforce the
performance of any provision of the Securities of such series or this Indenture. 
 The Trustee may maintain a proceeding even
if it does not possess any of the Securities or does not produce any of them in the proceeding. 
 Section 6.04 Waiver of
Past Defaults. Subject to Sections 6.02, 6.07 and Section 9.02, the Holders of a majority in aggregate principal amount of the outstanding Securities of any series affected (voting as a single class), by notice to the Trustee, may, on
behalf of the Holders of all of the Securities of such series, waive an existing Default or Event of Default with respect to the Securities of such series and its consequences, except a Default or Event of Default in the payment of principal of,
premium or interest, if any, on any Security as specified in clause (a) or (b) of Section 6.01 or in respect of a covenant or provision of this Indenture which cannot be modified or amended without the consent of the Holder of each
outstanding Security of such series affected. Upon any such waiver, such Default shall cease to exist, and any Event of Default with respect to the Securities of such series arising therefrom shall be deemed to have been cured for every purpose of
this Indenture and the Company, Trustee and Holders restored to their former position and rights hereunder; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereto. 

Section 6.05 Control by Majority. Subject to Sections 7.01 and 7.02(e), the Holders of a majority in aggregate principal amount of
the outstanding Securities of any series affected (voting as a single class) may direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with
respect to the Securities of such series by this Indenture; provided, that the Trustee may refuse to follow any direction that conflicts with law or this Indenture, that may involve the Trustee in personal liability or that the Trustee
determines in good faith may be unduly prejudicial to the rights of Holders not joining in the giving of such direction; and provided further, that the Trustee may take any other action it deems proper that is not inconsistent with any
directions received from Holders of Securities pursuant to this Section 6.05. 

  
 33 

 Section 6.06 Limitation on Suits. No Holder of any Security of any series may
institute any proceeding, judicial or otherwise, in equity or at law, with respect to this Indenture or the Securities of such series, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless: 

(a) such Holder has previously given to the Trustee written notice of an Event of Default with respect to the Securities
of such series and such Event of Default continues; 
 (b) the Holders of at least 25% in aggregate principal
amount of outstanding Securities of such series affected shall have requested the Trustee to institute such action and offered the Trustee indemnity reasonably satisfactory to it; 

(c) the Trustee has not instituted such action within 60 days of receipt of such request; and 

(d) the Trustee has not received a direction inconsistent with such written request by the Holders of a majority in
aggregate principal amount of the outstanding Securities of such affected series. 
 A Holder may not use this Indenture to
prejudice the rights of another Holder or to obtain a preference or priority over such other Holder. 
 Section 6.07 Rights
of Holders to Receive Payment. Notwithstanding any other provision of this Indenture, the right of any Holder of a Security to receive payment of principal of or interest or premium, if any, on such Holder’s Security on or after the
respective due dates expressed on such Security, or to bring suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder. 

Section 6.08 Collection Suit by Trustee. If an Event of Default with respect to the Securities of any series in payment of
principal, premium or interest specified in clause 6.01(a) or (b) occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust against the Company for the whole amount (or such portion thereof as
specified in the terms established pursuant to Section 2.03 of Original Issue Discount Securities) of principal of, premium, if any, and accrued interest remaining unpaid on, together with interest on overdue principal specified in such
Securities, and such further amount as shall be sufficient to cover all amounts owing the Trustee under Section 7.07, except for such amounts arising out of the Trustee’s negligence or bad faith. 

Section 6.09 Trustee May File Proofs of Claim. The Trustee may file such proofs of claim and other papers or documents as may be
necessary or advisable in order to have the claims of the Trustee (including any claim for amounts due the Trustee under Section 7.07) and the Holders allowed in any judicial proceedings relative to the Company (or any other obligor on the
Securities), its creditors or its property and shall be entitled and empowered to collect and 

  
 34 

 
receive any moneys, securities or other property payable or deliverable upon conversion or exchange of the Securities or upon any such claims and to distribute the same, and any custodian,
receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making
of such payments directly to the Holders, to pay to the Trustee any amount due to it under Section 7.07, except for such amounts arising out of the Trustee’s negligence or bad faith. Nothing herein contained shall be deemed to empower the
Trustee to authorize or consent to, or accept or adopt on behalf of any Holder, any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof, or to authorize the Trustee to vote in
respect of the claim of any Holder in any such proceeding. 
 Section 6.10 Application of Proceeds. If the Trustee
collects any money pursuant to this Article 6 in respect of the Securities of any series, it shall pay out the money in the following order: 
 FIRST: to the Trustee, its agents and attorneys for amounts due under Section 7.07 with respect to such series of Securities, including payment of all compensation, expenses and liabilities incurred,
and all advances made, by the Trustee and the costs and expenses of collection; 
 SECOND: to Holders of
Securities of the applicable series for amounts due and unpaid on such Securities for principal, premium, and interest, ratably, without preference or priority of any kind, according to the amounts due and payable on the Securities of such series
for principal, premium, and interest, respectively; and 
 THIRD: to the Company or to such party as a court of
competent jurisdiction shall direct. 
 The Trustee may fix a record date and payment date for any payment to Holders of
Securities pursuant to this Section 6.10. 
 Section 6.11 Restoration of Rights and Remedies. If the Trustee or any
Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then, and in every
such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored to their former positions hereunder and thereafter all rights and remedies of the Company, Trustee and the Holders shall continue
as though no such proceeding had been instituted. 
 Section 6.12 Undertaking for Costs. In any suit for the enforcement
of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted by it as Trustee, in either case in respect to the Securities of any series, a court may require any party litigant in such suit to file
an undertaking to pay the costs of the suit, and the court may assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in the suit having due regard to the merits and good faith of the claims or defenses made
by the party litigant. This Section 6.12 does not apply to a suit by a Holder pursuant to Section 6.06, a suit 
 instituted by the
Trustee or a suit by Holders of more than 10% in principal amount of the outstanding Securities of such series. 

  
 35 

 Section 6.13 Rights and Remedies Cumulative. Except as otherwise provided with
respect to the replacement or payment of mutilated, destroyed, lost or wrongfully taken Securities in Section 2.08, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other
right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 
 Section 6.14 Delay or Omission not Waiver. No delay or omission of the Trustee or of any Holder to exercise any right or remedy accruing upon any Event of Default shall impair any such right or
remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Subject to Section 6.06, every right and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as
often as may be deemed expedient, by the Trustee or by the Holders, as the case may be. 
 ARTICLE 7 

TRUSTEE 

Section 7.01 General. Except during the continuance of an Event of Default, the Trustee’s duties and responsibilities under
this Indenture shall be only those duties and responsibilities specifically set forth in this Indenture and no implied duties or responsibilities shall be read into this Indenture against the Trustee. In case an Event of Default has occurred and is
continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture, and shall use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his
or her own affairs. Notwithstanding the foregoing, no provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder, or in the
exercise of any of its rights or powers, if it shall have reasonable grounds for believing that repayment of such funds or adequate indemnity against such risk or liability is not reasonably assured. Whether or not therein expressly so provided,
every provision of this Indenture relating to the conduct or affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this Article 7. 

Section 7.02 Certain Rights of Trustee. Subject to Trust Indenture Act Sections 315(a) through (d): 

(a) the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate,
Officer’s Certificate, Opinion of Counsel (or both), statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document believed by it to be
genuine and to have been signed or presented by the proper person or persons; 

  
 36 

 (b) before the Trustee acts or refrains from acting, it may require an
Officer’s Certificate and/or an Opinion of Counsel, which shall conform to Section 10.04 and shall cover such other matters as the Trustee may reasonably request. The Trustee shall not be liable for any action it takes or omits to take in
good faith in reliance on such certificate or opinion. Subject to Section 7.01 and this Section 7.02, whenever in the administration of the trusts of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved
or established prior to taking or suffering or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be
deemed to be conclusively proved and established by an Officer’s Certificate delivered to the Trustee, and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any
action taken, suffered or omitted by it under the provisions of this Indenture upon the faith thereof; 
 (c) the
Trustee may act through its attorneys and agents not regularly in its employ and shall not be responsible for the misconduct or negligence of any agent or attorney appointed and retained with due care, and the rights, privileges, protections,
immunities and benefits given to the Trustee, including without limitation its right to be compensated, reimbursed, and indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and to each agent,
custodian and other Person employed to act hereunder; 
 (d) any request, direction, order or demand of the
Company mentioned herein shall be sufficiently evidenced by an Officer’s Certificate (unless other evidence in respect thereof be herein specifically prescribed); 

(e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the
request, order or direction of any of the Holders pursuant to the provisions of this Indenture, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that might be incurred
by it in compliance with such request, order or direction; 
 (f) the Trustee shall not be liable for any action
it takes or omits to take in good faith that it believes to be authorized or within its rights or powers or for any action it takes or omits to take in accordance with the direction of the Holders in accordance with Section 6.05 relating to the
time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture; 

(g) the Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel shall be full
and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon; and 
 (h) prior to the occurrence of an Event of Default hereunder and after the curing or waiving of all Events of Default, the Trustee shall not be bound to make any investigation into the facts or matters
stated in any resolution, certificate, Officer’s 

  
 37 

 
Certificate, Opinion of Counsel, Board Resolution, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security or other
paper or document with respect to such series of Securities, unless requested in writing so to do by the Holders of not less than a majority in aggregate principal amount of the Securities of any series affected then outstanding; provided
that, if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the
security afforded to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such expenses or liabilities as a condition to proceeding. 
 Section 7.03 Individual Rights of Trustee and Others. The Trustee, in its individual or any other capacity, may become the owner or pledgee of Securities and may otherwise deal with the Company or
any of its Affiliates with the same rights it would have if it were not the Trustee. Any Agent may do the same with like rights. However, the Trustee is subject to Trust Indenture Act Sections 310(b) and 311, and the rights, privileges, protections,
immunities and benefits given to the Trustee, including without limitation its right to be compensated, reimbursed, and indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and to each agent,
custodian and other Person employed to act hereunder. For purposes of Trust Indenture Act Section 311(b)(4) and (6), the following terms shall have the following meanings: 

(a) “Cash Transaction” means any transaction in which full payment for goods or securities sold is made
within seven days after delivery of the goods or securities in currency or in checks or other orders drawn upon banks or bankers and payable upon demand; and 
 (b) “self-liquidating paper” means any draft, bill of exchange, acceptance or obligation which is made, drawn, negotiated or incurred by the Company for the purpose of financing the
purchase, processing, manufacturing, shipment, storage or sale of goods, wares or merchandise and which is secured by documents evidencing title to, possession of, or a lien upon, the goods, wares or merchandise or the receivables or proceeds
arising from the sale of the goods, wares or merchandise previously constituting the security, provided the security is received by the Trustee simultaneously with the creation of the creditor relationship with the Company arising from the making,
drawing, negotiating or incurring of the draft, bill of exchange, acceptance or obligation. 
 Section 7.04 Trustee’s
Disclaimer. The recitals contained herein and in the Securities (except the Trustee’s certificate of authentication) shall be taken as statements of the Company and not of the Trustee and the Trustee assumes no responsibility for the
correctness of the same. Neither the Trustee nor any of its agents (a) makes any representation as to the validity or adequacy of this Indenture or the Securities or (b) shall be accountable for the Company’s use or application of the
proceeds from the Securities. 
 Section 7.05 Notice of Default. If any Default with respect to the Securities of any
series occurs and is continuing and if such Default is known to the actual knowledge of a Responsible Officer of the Trustee, the Trustee shall give to each Holder of Securities of such 

  
 38 

 
series notice of such Default within 120 days after it occurs (a) if any Unregistered Securities of such series are then outstanding, to the Holders thereof, by publication at least once in
an Authorized Newspaper and (b) to all Holders of Securities of such series in the manner and to the extent provided in Section 313(c) of the Trust Indenture Act, unless such Default shall have been cured or waived before the mailing or
publication of such notice; provided, however, that, except in the case of a Default or Event of Default in the payment of the principal of, premium, if any, or interest on any Security of such series, the Trustee shall be protected in
withholding such notice if the Trustee in good faith determines that the withholding of such notice is in the interests of the Holders. 
 Section 7.06 Reports by Trustee to Holders. The Trustee shall transmit to Holders such reports concerning the Trustee and its actions under this Indenture as may be required pursuant to the Trust
Indenture Act at the times and in the manner provided pursuant thereto. If required by Section 313(a) of the Trust Indenture Act, the Trustee shall, within 60 days after each May 15 following the date of this Indenture, deliver to Holders
a brief report, dated as of such May 15, which complies with the provisions of such Section 313(a). 
 A copy of each
such report shall, at the time of such transmission to Holders, be filed by the Trustee with each stock exchange upon which any Securities are listed, with the Commission and with the Company. The Company shall promptly notify the Trustee when any
Securities are listed on any stock exchange. 
 Section 7.07 Compensation and Indemnity. The Company shall pay to the
Trustee such reasonable compensation as shall be agreed upon in writing from time to time for its services. The compensation of the Trustee shall not be limited by any law on compensation of a Trustee of an express trust. The Company shall reimburse
the Trustee upon request for all reasonable out-of-pocket expenses, disbursements and advances incurred or made by the Trustee or in accordance with the provisions of this Indenture, except for any such expense, disbursement or advance as may arise
from its negligence or bad faith. Such expenses shall include the reasonable compensation and expenses of the Trustee’s counsel and other persons not regularly in their employ. 

The Company shall indemnify the Trustee and any predecessor Trustee for, and hold them harmless against, any loss or liability or expense
incurred by them without negligence, bad faith or willful misconduct on their part arising out of or in connection with the acceptance or administration of this Indenture and the Securities of any series or the issuance of the Securities or of
series thereof or the trusts hereunder and the performance of duties under this Indenture and the Securities, including the costs and expenses of defending themselves against or investigating any claim or liability and of complying with any process
served upon them or any of their officers in connection with the exercise or performance of any of their powers or duties under this Indenture and the Securities; provided that the Company need not pay for any settlement made without its
consent, which consent shall not be unreasonably withheld. The Trustee may have separate counsel and the Company will pay the reasonable fees and expenses of such counsel. The Trustee shall notify the Company promptly of any claim for which it may
seek indemnification; provided, however, the failure to give such notice shall not affect the right to indemnification hereunder except to the extent of actual prejudice. 

  
 39 

 To secure the Company’s payment obligations in this Section 7.07, the Trustee
shall have a lien prior to the Securities on all money or property held or collected by the Trustee, in its capacity as Trustee, except money or property held in trust for the benefit of the Holders of particular Securities. 

The obligations of the Company under this Section to compensate and indemnify the Trustee and each predecessor Trustee and to pay or
reimburse the Trustee and each predecessor Trustee for expenses, disbursements and advances shall constitute additional indebtedness hereunder and shall survive the defeasance or satisfaction and discharge of this Indenture, the registration or
removal of the Trustee, or the rejection or termination of this Indenture under Bankruptcy Law. Such additional indebtedness shall be a senior claim to that of the Securities upon all property and funds held or collected by the Trustee as such,
except funds held in trust for the benefit of the Holders of particular Securities or coupons, and the Securities are hereby subordinated to such senior claim. Without prejudice to any other rights available to the Trustee under applicable law, if
the Trustee renders services and incurs expenses following an Event of Default under Section 6.01(e) or Section 6.01(f) hereof, the parties hereto and the holders by their acceptance of the Securities hereby agree that such expenses are
intended to constitute expenses of administration under any Bankruptcy Law. 
 Section 7.08 Replacement of Trustee. A
resignation or removal of the Trustee as Trustee with respect to the Securities of any series and appointment of a successor Trustee as Trustee with respect to the Securities of any series shall become effective only upon the successor
Trustee’s acceptance of appointment as provided in this Section 7.08. 
 The Trustee may resign as Trustee with
respect to the Securities of any series at any time by so notifying the Company and the Holders as specified in this Indenture in writing. The Holders of a majority in aggregate principal amount of the outstanding Securities of any series may at any
time remove the Trustee as Trustee with respect to the Securities of such series by so notifying the Trustee in writing and may appoint a successor Trustee with respect thereto with the consent of the Company. The Company may remove the Trustee as
Trustee with respect to the Securities of any series if: (i) the Trustee is no longer eligible under Section 7.11; (ii) the Trustee is adjudged a bankrupt or insolvent; (iii) a receiver or other public officer takes charge of the
Trustee or its property; or (iv) the Trustee becomes incapable of acting. 
 If the Trustee resigns or is removed as
Trustee with respect to the Securities of any series, or if a vacancy exists in the office of Trustee with respect to the Securities of any series for any reason, the Company shall use its commercially reasonable efforts to promptly appoint a
successor Trustee with respect thereto. If the successor Trustee with respect to the Securities of any series does not deliver its written acceptance required by Section 7.09 within 30 days after the retiring Trustee mails the notice of
resignation or is removed, the retiring Trustee, the Company or the Holders of a majority in aggregate principal amount of the outstanding Securities of such series may petition any court of competent jurisdiction for the appointment of a successor
Trustee with respect thereto. 
 If a successor Trustee does not take office within 60 days after the retiring Trustee resigns
or is removed, the retiring Trustee, the Company, or the Holders of at least 10% in aggregate principal amount of the then outstanding Securities of any series may petition any court of competent jurisdiction for the appointment of a successor
Trustee. 

  
 40 

 The Company or successor Trustee shall give notice of any resignation or removal of the
Trustee with respect to the Securities of any series and each appointment of a successor Trustee in respect of the Securities of such series to all Holders of Securities of such series. Each notice shall include the name of the successor Trustee and
the address of its Corporate Trust Office. 
 Notwithstanding replacement of the Trustee with respect to the Securities of any
series pursuant to this Section 7.08 and Section 7.09, the Company’s obligations under Section 7.07 shall continue for the benefit of the retiring Trustee. 
 Section 7.09 Acceptance of Appointment by Successor. In case of the appointment hereunder of a successor Trustee with respect to all Securities, every such successor Trustee so appointed shall
execute, acknowledge and deliver to the Company and to the retiring Trustee with respect to any and all applicable series an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become
effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties with respect to any and all applicable series of the retiring Trustee; but, on the request of the
Company or the successor Trustee, such retiring Trustee shall, upon payment of its charges and subject to the lien provided for in Section 7.07, execute and deliver an instrument transferring to such successor Trustee all the rights, powers and
trusts with respect to any and all applicable series of the retiring Trustee and shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee hereunder. 

In case of the appointment hereunder of a successor Trustee with respect to the Securities of one or more (but not all) series, the
Company, the retiring Trustee and each successor Trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor Trustee shall accept such appointment and which
(1) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor Trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or
those series to which the appointment of such successor Trustee relates, (2) if the retiring Trustee is not retiring with respect to all Securities, shall contain such provisions as shall be deemed necessary or desirable to confirm that all the
rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee and (3) shall add to or change
any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall
constitute such Trustees co-trustees of the same trust and that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee; and upon the execution
and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided therein and each such successor Trustee, without any further act, deed or conveyance, shall become vested
with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor Trustee relates; 

  
 41 

 
but, on request of the Company or any successor Trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring
Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor Trustee relates. 
 Upon request of any such successor Trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and
trusts referred to in the first or second preceding paragraph, as the case may be. 
 No successor Trustee shall accept its
appointment unless at the time of such acceptance such successor Trustee shall be eligible under this Article 7 and have no conflict of interest under Section 310(b) of the Trust Indenture Act. 

Section 7.10 Successor Trustee By Merger, Etc. If the Trustee consolidates with, merges or converts into, or transfers all or
substantially all of its corporate trust business to, another corporation or national banking association, the resulting, surviving or transferee corporation or national banking association without any further act shall be the successor Trustee
hereunder with the same effect as if the successor Trustee had been named as the Trustee herein; provided that such successor shall be otherwise eligible under this Article 7. In case any Securities shall have been authenticated, but not
delivered, by the Trustee then in office, any successor Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities. 

Section 7.11 Eligibility. This Indenture shall always have a Trustee who satisfies the requirements of Trust Indenture Act
Section 310(a). The Trustee shall have a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition. 
 Section 7.12 Money Held in Trust. The Trustee shall not be liable for interest on any money received by it hereunder except as the Trustee may agree in writing with the Company. Money held in trust
by the Trustee need not be segregated from other funds except to the extent required by law and except for money held in trust under Article 8 of this Indenture. 
 ARTICLE 8 
 SATISFACTION AND DISCHARGE OF INDENTURE; UNCLAIMED MONEYS

 Section 8.01 Satisfaction and Discharge of Indenture. If at any time: 

(a) (i) the Company shall have paid or caused to be paid the principal of, premium, if any, and interest on all the
Securities of any series outstanding hereunder (other than Securities of such series which have been destroyed, lost or stolen and which have been replaced or paid as provided in Section 2.08) as and when the same shall have become due and
payable, 

  
 42 

 (ii) the Company shall have delivered to the Trustee for cancellation all
Securities of any series theretofore authenticated (other than any Securities of such series which shall have been destroyed, lost or stolen and which shall have been replaced or paid as provided in Section 2.08), or 

(iii) all the Securities of such series not theretofore delivered to the Trustee for cancellation shall have become due
and payable, or are by their terms to become due and payable within one year (or, in the case of securities that pay interest at a floating rate, within the remaining term of the then current interest period) or are to be called for redemption
within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, 
 and, in the case of clause (iii), the
Company shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds the entire amount in U.S. dollars (other than moneys repaid by the Trustee or any paying agent to the Company in accordance with Section 8.04) or
U.S. Government Obligations, maturing as to principal, premium, if any, and interest in such amounts and at such times as will insure (without consideration of the reinvestment of such interest) the availability of cash, or a combination thereof,
sufficient to pay at maturity or upon redemption all Securities of such series (other than any Securities of such series which shall have been destroyed, lost or stolen and which shall have been replaced or paid as provided in Section 2.08 or
delivered to the Trustee for cancellation), including principal, premium, if any, and interest due or to become due on or prior to such date of maturity or redemption as the case may be; 

(b) the Company shall have paid or caused to be paid all other sums payable hereunder by the Company with respect to the
Securities of such series; and 
 (c) the Company shall have delivered to the Trustee an Officer’s
Certificate and an Opinion of Counsel, each stating that all conditions precedent relating to the satisfaction, defeasance and discharge of the Indenture with respect to the Securities of such series have been complied with, 

then this Indenture shall cease to be of further effect with respect to any Securities of such series (except as to (i) rights of registration of
transfer and exchange, and the Company’s right of optional redemption, if any, (ii) substitution of mutilated, defaced, destroyed, lost or stolen Securities, (iii) rights of holders to receive payments of principal thereof, premium,
if any, and interest thereon, upon the original stated due dates therefor (but not upon acceleration) and remaining rights of the holders to receive Mandatory Sinking Fund Payments, if any, (iv) the rights, obligations and immunities of the
Trustee hereunder and (v) the rights of the Securityholders of such series as beneficiaries hereof with respect to the property so deposited with the Trustee payable to all or any of them), and the Trustee, on demand of the Company accompanied
by an Officer’s Certificate and an Opinion of Counsel and at the cost and expense of the Company, shall execute proper instruments acknowledging such satisfaction of and discharging this Indenture with respect to such series; provided,
that the rights of Holders of the Securities to receive amounts in respect of principal of, premium, if any, and interest on the Securities held by them shall not be delayed longer than required by then-applicable mandatory rules or policies of any
securities exchange upon which the Securities are listed. The Company 

  
 43 

 
agrees to reimburse the Trustee for any costs or expenses thereafter reasonably and properly incurred and to compensate the Trustee for any services thereafter reasonably and properly rendered by
the Trustee in connection with this Indenture or the Securities of such series. 
 Section 8.02 Application by Trustee of
Funds Deposited for Payment of Securities. Subject to Section 8.04, all moneys (including U.S. Government Obligations and the proceeds thereof) deposited with the Trustee pursuant to Section 8.01, Section 8.05 or Section 8.06
shall be held in trust and applied by the Trustee in accordance with the provisions of such Securities and the Indenture to the payment, either directly or through any Paying Agent (other than the Company acting as its own Paying Agent) to the
Holders of the particular Securities of such series for the payment or redemption of which such moneys have been deposited with the Trustee, of all sums due and to become due thereon for principal, premium, if any, and interest, if any; but such
money need not be segregated from other funds except to the extent required by law. 
 Section 8.03 Repayment of Moneys Held
by Paying Agent. In connection with the satisfaction and discharge of this Indenture with respect to Securities of any series, all moneys then held by any Paying Agent, other than the Trustee, under the provisions of this Indenture with respect
to such series of Securities shall, upon and in accordance with the demand of the Company, be repaid to it or paid to the Trustee and thereupon such Paying Agent shall be released from all further liability with respect to such moneys. 

Section 8.04 Return of Moneys Held by Trustee and Paying Agent Unclaimed for Two Years. Any moneys deposited with or paid to the
Trustee or any Paying Agent for the payment of the principal of or interest or premium, if any, on any Security of any series and not applied but remaining unclaimed for two years after the date upon which such principal, interest or premium, if
any, shall have become due and payable, shall, upon the written request of the Company and unless otherwise required by mandatory provisions of applicable escheat or abandoned or unclaimed property law, be repaid to the Company by the Trustee for
such series or such Paying Agent, and the Holder of the Security of such series shall, unless otherwise required by mandatory provisions of applicable escheat or abandoned or unclaimed property laws, thereafter look only to the Company for any
payment which such Holder may be entitled to collect, and all liability of the Trustee or any Paying Agent with respect to such moneys shall thereupon cease. 
 Section 8.05 Defeasance and Discharge of Indenture. The Company shall be deemed to have paid and shall be discharged from any and all obligations in respect of the Securities of any series upon the
deposit referred to in clause (a) hereof and the provisions of this Indenture shall no longer be in effect with respect to the Securities of such series (and the Trustee, upon request and at the expense of the Company, shall execute proper
instruments acknowledging the same), except as to: (1) rights of registration of transfer and exchange, and the Company’s right of optional redemption, if any, (2) substitution of mutilated, defaced, destroyed, lost or stolen
Securities, (3) rights of holders to receive payments of principal thereof, premium, if any, and interest thereon, upon the original stated due dates therefor (but not upon acceleration) and remaining rights of the Holders to receive Mandatory
Sinking Fund Payments, if any, (4) the rights, obligations and immunities of the Trustee hereunder and (5) the rights of the Securityholders of such series as beneficiaries hereof with respect to the property so deposited with the Trustee
payable to all or any of them; provided that the following conditions shall have been satisfied: 

  
 44 

 (a) with reference to this provision, the Company has deposited or caused to
be irrevocably deposited with the Trustee, in trust, specifically pledged as security for, and dedicated solely to, the benefit of the Holders of the Securities of such series, money or the equivalent in U.S. Government Obligations, or any
combination thereof, sufficient, in the opinion of a nationally recognized investment bank, appraisal firm or firm of independent public accountants, for payment of all (x) the principal of, premium, if any, and each installment of interest on
the outstanding Securities of such series on the due dates thereof and (y) any Mandatory Sinking Fund Payments or analogous payments applicable to the Securities of such series on the day on which such payments are due and payable in accordance
with the terms of Securities of such series and the Indenture with respect to the Securities of such series, and the Company has specified to the Trustee whether the Securities are being defeased to such due date for payment or to a particular
redemption date; 
 (b) the Company has delivered to the Trustee an Opinion of Counsel confirming that
(a) the Company has received from, or there has been published by, the Internal Revenue Service a ruling or (b) since the issue date, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that,
and based thereon such opinion of counsel will confirm that, the Holders of the outstanding Securities of such series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such defeasance and will be subject to
U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such defeasance had not occurred; 
 (c) no default or Event of Default shall have occurred and be continuing on the date of such deposit (other than a default or Event of Default resulting from the borrowing of funds to be applied to such
deposit); 
 (d) the defeasance will not result in a breach or violation of, or constitute a Default under, any
material agreement or instrument (other than this Indenture) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound; 

(e) the Company has deliver to the Trustee an Officer’s Certificate stating that the deposit was not made by the
Company with the intent of preferring the Holders of Securities of such series over the other creditors of the Company with the intent of defeating, hindering, delaying or defrauding any creditors of the Company or others; and 

(f) the Company has delivered to the Trustee and Officer’s Certificate and an Opinion of Counsel, each stating that
all conditions precedent relating to the defeasance have been complied with. 

  
 45 

 Section 8.06 Defeasance of Certain Obligations. (1) The Company may omit to comply
with, and this Indenture shall no longer be in effect with respect to the obligations of the Company set forth in, any term, provision or condition set forth in, Sections 4.04 and 4.08, and any term, provision, condition, covenant or other
obligation with respect to the Securities of such series specified pursuant to Section 2.03 or 9.01 and (2) Section 6.01(c) and Section 6.01(d), and any Event of Default specified pursuant to Section 2.03 or 9.01, shall no longer
constitute an Event of Default; provided that the following conditions have been satisfied: 
 (a) with
reference to this provision, the Company has deposited or caused to be irrevocably deposited with the Trustee, in trust, specifically pledged as security for, and dedicated solely to, the benefit of the Holders of the Securities of such series,
money or the equivalent in U.S. Government Obligations, or any combination thereof, sufficient, in the opinion of a nationally recognized investment bank, appraisal firm or firm of independent public accountants, for payment of all (x) the
principal of, premium, if any, and each installment of interest on the outstanding Securities of such series on the due dates thereof and (y) any Mandatory Sinking Fund Payments or analogous payments applicable to the Securities of such series
on the day on which such payments are due and payable in accordance with the terms of Securities of such series and the Indenture with respect to the Securities of such series, and the Company has specified to the Trustee whether the Securities are
being defeased to such due date for payment or to a particular redemption date; 
 (b) the Company has delivered
to the Trustee an Opinion of Counsel confirming that the Holders of the outstanding Securities of such series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such defeasance and will be subject to U.S.
federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such defeasance had not occurred; 
 (c) no default or Event of Default shall have occurred and be continuing on the date of such deposit (other than a default or Event of Default resulting from the borrowing of funds to be applied to such
deposit); 
 (d) the defeasance will not result in a breach or violation of, or constitute a Default under, any
material agreement or instrument (other than this Indenture) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound; 

(e) the Company has deliver to the Trustee an Officer’s Certificate stating that the deposit was not made by the
Company with the intent of preferring the Holders of Securities of such series over the other creditors of the Company with the intent of defeating, hindering, delaying or defrauding any creditors of the Company or others; and 

(f) the Company has delivered to the Trustee and Officer’s Certificate and an Opinion of Counsel, each stating that
all conditions precedent relating to the defeasance have been complied with. 
 Section 8.07 Reinstatement. If the
Trustee or Paying Agent is unable to apply any monies or U.S. Government Obligations in accordance with this Article 8 to pay any principal, premium, if any, or interest, if any, with respect to the Securities of any series by reason of any

  
 46 

 
legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the Company’s obligations
under this Indenture and the Securities of such series shall be revived and reinstated as though no deposit had occurred pursuant to this Article 8 until such time as the Trustee or Paying Agent is permitted to apply all such monies or U.S.
Government Obligations in accordance with this Article 8; provided, however, that if the Company has made any payment of principal of, premium, if any, or interest, if any, on any Securities of such series because of the reinstatement
of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the monies or U.S. Government Obligations held by the Trustee or Paying Agent. 

Section 8.08 Indemnity. The Company shall pay and indemnify the Trustee (or other qualifying trustee, collectively for purposes of
this Section 8.08 and Section 8.02, the “Trustee”) against any tax, fee or other charge, imposed on or assessed against the U.S. Government Obligations deposited pursuant to Section 8.01, 8.05 or 8.06 or the principal or
interest received in respect thereof other than any such tax, fee or other charge which by law is for the account of the Holders of the Securities and any coupons appertaining thereto. 

Section 8.09 Excess Funds. Anything in this Article 8 to the contrary notwithstanding, the Trustee shall deliver or pay to the
Company from time to time upon request of the Company any money or U.S. Government Obligations (or other property and any proceeds therefrom) held by it as provided in Section 8.01, 8.05 or 8.06 which, in the opinion of a nationally recognized
investment bank, appraisal firm or firm of independent public accountants, are in excess of the amount thereof which would then be required to be deposited to effect a discharge or defeasance, as applicable, in accordance with this Article 8.

 Section 8.10 Qualifying Trustee. Any trustee appointed pursuant to Section 8.05 or 8.06 for the purpose of
holding money or U.S. Government Obligations deposited pursuant to such Sections shall be appointed under an agreement in form acceptable to the Trustee and shall provide to the Trustee a certificate, upon which certificate the Trustee shall be
entitled to conclusively rely, that all conditions precedent provided for herein to the related defeasance have been complied with. In no event shall the Trustee be liable for any acts or omissions of said trustee. 

ARTICLE 9 

AMENDMENTS, SUPPLEMENTS AND WAIVERS 
 Section 9.01 Amendments Without Consent of Holders. The Company and the Trustee may, at any time and from time to time, amend, supplement or waive the Indenture or the Securities of any series
without notice to or the consent of any Holder for any of the following purposes: 
 (i) to cure any ambiguity,
omission, defect or inconsistency that does not materially adversely affect the interests of Holders of the Securities of such series; 

  
 47 

 (ii) to provide for the assumption by a successor to the obligations of the
Company under this Indenture; 
 (iii) to provide for uncertificated Securities in addition to or in place of
certificated Securities; 
 (iv) to provide for the issuance of, or establish the form or terms of, additional
Securities in accordance with this Indenture; 
 (v) to add guarantors or co-obligors with respect to the
Securities of any series; 
 (vi) to secure the Securities of any series; 

(vii) to change or eliminate any of the provisions of this Indenture, but only if the change or elimination becomes
effective when there are no outstanding Securities of any series, or related coupon, which are entitled to the benefit of such provision and as to which such modification would apply; 

(viii) to evidence and provide for the acceptance of appointment by a successor trustee and to add to or change any of the
provisions of this Indenture to facilitate the administration of the trusts by more than one trustee; 
 (ix) to
conform the text of this Indenture or the Securities of any series to any provision of a description of such Securities appearing in a prospectus or prospectus supplement or an offering memorandum or offering circular pursuant to which such
Securities were offered to the extent that such provision was intended to be a verbatim recitation of a provision of this Indenture or the Securities of such series; 

(x) to add to the covenants of the Company or Events of Default for the benefit of the Holders of the Securities of such
series or surrender any right or power conferred upon the Company; 
 (xi) to effect any provision of this
Indenture; 
 (xii) to comply with requirements of the Commission in order to effect or maintain the
qualification of this Indenture under the Trust Indenture Act; or 
 (xiii) to make other provisions that do not
adversely affect the rights of any Holder of outstanding Securities of such series. 
 Section 9.02 Amendments with Consent
of Holders. (a) Subject to Section 9.02(b), this Indenture and the Securities of any series may be amended, supplemented or waived with the consent of the Holders of a majority in aggregate principal amount of the Securities
(including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, Securities). 
 (b) Notwithstanding the provisions of Section 9.02(a), without the consent of each Holder of outstanding Securities of any series affected, an amendment, supplement or waiver may not 

(i) extend the final maturity of the principal of any Securities of such series; 

(ii) reduce the principal amount of any Securities of such series; 

(iii) reduce the rate or extend the time of payment of interest on any Securities of such series; 

(iv) reduce any amount payable on redemption of any Securities of such series; 

(v) change the currency in which the principal of, premium, if any, or interest on any of the Securities of such series is
payable; 

  
 48 

 (vi) expressly subordinate any Security of such series to any other
Indebtedness; 
 (vii) impair the right to institute suit for the enforcement of any payment on any of the
Securities of such series when due; or 
 (viii) make any change in the percentage in principal amount of the
Securities of such series, the consent of the Holders of which is required for any such amendment or any supplement to this Indenture or the waiver of any provision under this Indenture. 

A supplemental indenture which changes or eliminates any covenant or other provision of this Indenture which has expressly been included
solely for the benefit of one or more particular series of Securities, or which modifies the rights of Holders of Securities of such series with respect to such covenant or provision, shall be deemed not to affect the rights under this Indenture of
the Holders of Securities of any other series or of the coupons appertaining to such Securities. 
 It shall not be necessary
for the consent of any Holder under this Section 9.02 to approve the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such consent approves the substance thereof. A consent to any supplement,
amendment or waiver under this Indenture by any holder of Securities given in connection with a tender of such Holder’s Securities will not be rendered invalid by such tender. 

An amendment, supplement or waiver under this Section shall become effective on receipt by the Trustee of written consents from the
Holders of the requisite percentage in principal amount of the outstanding Securities affected thereby. After an amendment, supplement or waiver under this Section 9.02 becomes effective, the Company shall give to the Holders affected thereby a
notice briefly describing the amendment, supplement or waiver. The Company shall mail supplemental indentures to Holders upon request. Any failure of the Company to mail such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any such supplemental indenture or waiver. 
 Section 9.03 Revocation and Effect of Consent. Until
an amendment, supplement or waiver becomes effective, a consent to it by a Holder is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the Security of the consenting
Holder, even if notation of the consent is not made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to its Security or portion of its Security. Such revocation shall be effective only if the Trustee receives
the notice of revocation before the date the amendment, supplement or waiver becomes effective. 
 The Company may, but shall
not be obligated to, fix a record date (which may be not less than five nor more than 60 days prior to the solicitation of consents) for the purpose of determining the Holders of the Securities of any series affected entitled to consent to any
amendment, supplement or waiver. If a record date is fixed, then, notwithstanding the immediately preceding paragraph, those Persons who were such Holders at such record date (or their duly designated proxies) and only those Persons shall be
entitled to consent to such amendment, supplement or waiver or to revoke any consent previously given, whether or not such Persons continue to be such Holders after such record date. No such consent shall be valid or effective for more than 90 days
after such record date. 

  
 49 

 After an amendment, supplement or waiver becomes effective with respect to the Securities of
any series affected thereby, it shall bind every Holder of such Securities unless it is of the type described in Section 9.02, in which case the amendment, supplement or waiver shall bind each such Holder who has consented to it and every
subsequent Holder of a Security that evidences the same indebtedness as the Security of the consenting Holder. 
 Section
9.04 Notation on or Exchange of Securities. If an amendment, supplement or waiver changes the terms of any Security, the Trustee may require the Holder thereof to deliver it to the Trustee. The Trustee may place an appropriate notation on the
Security about the changed terms and return it to the Holder and the Trustee may place an appropriate notation on any Security of such series thereafter authenticated. Alternatively, if the Company or the Trustee so determines, the Company in
exchange for the Security shall issue and the Trustee shall authenticate a new Security of the same series and tenor that reflects the changed terms. 
 Section 9.05 Trustee to Sign Amendments, Etc. The Trustee shall be entitled to receive, and shall be fully protected in relying upon, an Officer’s Certificate and Opinion of Counsel stating
that the execution of any amendment, supplement or waiver authorized pursuant to this Article 9 is authorized or permitted by this Indenture. The Trustee may, but shall not be obligated to, execute any such amendment, supplement or waiver that
affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise. 
 Section 9.06 Conformity
with Trust Indenture Act. Every supplemental indenture executed pursuant to this Article 9 shall conform to the requirements of the Trust Indenture Act. 
 ARTICLE 10 
 MISCELLANEOUS 

Section 10.01 Trust Indenture Act of 1939. This Indenture shall incorporate and be governed by the provisions of the Trust
Indenture Act that are required to be part of and to govern indentures qualified under the Trust Indenture Act. 
 Section 10.02
Notices. Any notice or communication shall be sufficiently given if written and (a) if delivered in person when received or (b) if mailed by first class mail 5 days after mailing or (c) as between the Company and the Trustee if
sent by facsimile transmission, when transmission is confirmed, in each case addressed as follows: 
 if to the Company:

 First American Financial Corporation 

1 First American Way 
 Santa Ana, CA 92707-5913 
 Facsimile No.: (714) 250-3403

 Attention: Chief Financial Officer 

  
 50 

 with a copy to: 
 White & Case LLP 
 1155 Avenue of the Americas 

New York, NY 10036 
 Facsimile No.: (212) 354-8113 
 Attention: Gary Kashar 

if to the Trustee: 
 U.S. Bank National Association 
 Global Corporate Trust Services
 

Two Midtown Plaza
 
 1349 W. Peachtree Street, Suite 1050
 
 Atlanta, GA 30309
 

Facsimile No.: (404) 898-2467
 
 Attention: Jack Ellerin 
 The Company or the Trustee by written notice to the
other may designate additional or different addresses for subsequent notices or communications. 
 Any notice or communication
shall be sufficiently given to Holders of any Unregistered Securities, by publication at least once in an Authorized Newspaper and by mailing to the Holders thereof who have filed their names and addresses with the Trustee pursuant to
Section 313(c)(2) of the Trust Indenture Act at such addresses as were so furnished to the Trustee and to Holders of Registered Securities by mailing to such Holders at their addresses as they shall appear on the Security Register. Notice
mailed shall be sufficiently given if so mailed within the time prescribed. Copies of any such communication or notice to a Holder shall also be mailed to the Trustee and each Agent at the same time. 

Failure to mail a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other Holders.
Except as otherwise provided in this Indenture, if a notice or communication is mailed in the manner provided in this Section 10.02, it is duly given, whether or not the addressee receives it. 

Where this Indenture provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such
notice, either before or after the event, and such waiver shall be the equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in
reliance upon such waiver. 
 In case it shall be impracticable to give notice as herein contemplated, then such notification as
shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder. 

  
 51 

 Section 10.03 Certificate and Opinion as to Conditions Precedent. Upon any request or
application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee: 
 (a) an Officer’s Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and

 (b) an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have
been complied with. 
 Section 10.04 Statements Required in Certificate or Opinion. Each certificate or opinion with
respect to compliance with a condition or covenant provided for in this Indenture (other than the certificate required by Section 4.03) shall include: 
 (a) a statement that each person signing such certificate or opinion has read such covenant or condition and the definitions herein relating thereto; 

(b) a brief statement as to the nature and scope of the examination or investigation upon which the statement or opinion
contained in such certificate or opinion is based; 
 (c) a statement that, in the opinion of each such person,
he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(d) a statement as to whether or not, in the opinion of each such person, such condition or covenant has been complied
with. 
 Section 10.05 Forms of Documents Delivered to Trustee. In any case where several matters are required to be
certified by, or covered by an opinion of, any specified Person, it is not necessary that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one
such Person may certify or give an opinion with respect to some matters and one or more other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. 

Any certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a certificate or
opinion of, or representations by, counsel, unless such officer or counsel knows, or in the exercise of reasonable care should know, that the certificate or opinion or representations with respect to the matters upon which his or her certificate or
opinion is based are erroneous. Any Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the Company stating that the information with respect
to such factual matters is in the possession of the Company. 

  
 52 

 Where any Person is required to make, give or execute two or more applications, requests,
consents, certificates, statements, opinions, or other instruments under this Indenture, they may, but need not, be consolidated and form one instrument. 
 Section 10.06 Evidence of Ownership. The Company, the Trustee and any agent of the Company or the Trustee may deem and treat the Holder of any Unregistered Security and the Holder of any coupon as
the absolute owner of such Unregistered Security or coupon (whether or not such Unregistered Security or coupon shall be overdue) for the purpose of receiving payment thereof or on account thereof and for all other purposes, and neither the Company,
the Trustee, nor any agent of the Company or the Trustee shall be affected by any notice to the contrary. The fact of the holding by any Holder of an Unregistered Security, and the identifying number of such Security and the date of his holding the
same, may be proved by the production of such Security or by a certificate executed by any trust company, bank, banker or recognized securities dealer wherever situated satisfactory to the Trustee, if such certificate shall be deemed by the Trustee
to be satisfactory. Each such certificate shall be dated and shall state that on the date thereof a Security bearing a specified identifying number was deposited with or exhibited to such trust company, bank, banker or recognized securities dealer
by the person named in such certificate. Any such certificate may be issued in respect of one or more Unregistered Securities specified therein. The holding by the person named in any such certificate of any Unregistered Securities specified therein
shall be presumed to continue for a period of one year from the date of such certificate unless at the time of any determination of such holding (1) another certificate bearing a later date issued in respect of the same Securities shall be
produced or (2) the Security specified in such certificate shall be produced by some other Person or (3) the Security specified in such certificate shall have ceased to be outstanding. Subject to Article 7, the fact and date of the
execution of any such instrument and the amount and numbers of Securities held by the Person so executing such instrument may also be proven in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in any other
manner which the Trustee may deem sufficient. 
 The Company, the Trustee and any agent of the Company or the Trustee may deem
and treat the person in whose name any Registered Security shall be registered upon the Security Register for such series as the absolute owner of such Registered Security (whether or not such Registered Security shall be overdue and notwithstanding
any notation of ownership or other writing thereon) for the purpose of receiving payment of or on account of the principal of and, subject to the provisions of this Indenture, premium or interest on such Registered Security and for all other
purposes; and neither the Company nor the Trustee nor any agent of the Company or the Trustee shall be affected by any notice to the contrary. 
 Section 10.07 Rules by Trustee, Paying Agent or Registrar. The Trustee may make reasonable rules for action by or at a meeting of Holders. The Paying Agent or Registrar may make reasonable rules
for its functions. 
 Section 10.08 Payment Date Other Than a Business Day. Except as otherwise provided with respect to
a series of Securities, if any date for payment of principal, premium, if any, or interest on any Security shall not be a Business Day at any place of payment, then payment of principal of, premium, if any, or interest on such Security, as the case
may be, need not be made on such date, but may be made on the next succeeding Business Day at any place of payment with the same force and effect as if made on such date and no interest shall accrue in respect of such payment for the period from and
after such date. 

  
 53 

 Section 10.09 Governing Law. The laws of the State of New York shall govern this
Indenture and the Securities, without regard to conflicts of law principles thereof. 
 Section 10.10 No Adverse
Interpretation of Other Agreements. This Indenture may not be used to interpret another indenture or loan or debt agreement of the Company or any Subsidiary of the Company. Any such indenture or agreement may not be used to interpret this
Indenture. 
 Section 10.11 Successors. All agreements of the Company in this Indenture and the Securities shall bind its
successors. All agreements of the Trustee in this Indenture shall bind its successors. 
 Section 10.12 Duplicate
Originals. The parties may sign any number of copies of this Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 Section 10.13 Separability. In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby. 
 Section 10.14 Table of Contents, Headings, Etc. The
Table of Contents and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms and provisions hereof.

 Section 10.15 No Personal Liability of Directors, Officers, Employees and Stockholders. No director, officer,
employee, incorporator or equityholder of the Company or any of its Subsidiaries will have any liability for any obligations of the Company under any of the Securities or this Indenture or for any claim based on, in respect of, or by reason of such
obligations or their creation. Each Holder of the Securities by accepting a Security waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Securities. Such waiver and release may not be
effective to waive liabilities under the U.S. federal securities laws, and it is the view of the Commission that such a waiver is against public policy. 
 Section 10.16 Force Majeure. In no event shall the Trustee be responsible or liable, nor shall the Company be responsible or liable to the Trustee, for any failure or delay in the performance of
its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural
catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee or the Company, as the case may be, shall use reasonable efforts
which are consistent with accepted practices to resume performance as soon as practicable under the circumstances. 

  
 54 

 Section 10.17 Communication by Holders of Securities with Other Holders of
Securities. Holders of Securities of any series may communicate pursuant to Trust Indenture Act Section 312(b) with other Holders of that series with respect to their rights under this Indenture or the applicable Securities. The Company,
the Trustee, the Registrar and anyone else shall have the protection of Trust Indenture Act Section 312(c). 

  
 55 

 SIGNATURES 
 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed, all as of the date first written above. 

 

			
	FIRST AMERICAN FINANCIAL CORPORATION
		
	By:	 	 /s/ Max O. Valdes

		 	 Name: Max O. Valdes

Title:   Executive Vice President, Chief Financial Officer

	
	 U.S. BANK NATIONAL ASSOCIATION,
 as Trustee

		
	By:	 	 /s/ Jack Ellerin

		 	 Name: Jack Ellerin

Title:  Vice President

  
 56Exhibit 10.9.2

 EXHIBIT 10.9.2 
 Supply Agreement 
 THIS SUPPLY AGREEMENT (the “Agreement”) dated as of
July 16, 2012 (the “Effective Date”), is made by and between: 
 LIPOSCIENCE, INC., a corporation organized and existing
under the laws of the State of Delaware having its offices at 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (“LipoScience”) as customer. 
 And 
 AGILENT TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State
of Delaware having its offices at 5301 Stevens Creek Blvd, CA 95051 (“Agilent”) as vendor. 
 LipoScience and Agilent are hereafter
referred to individually as a “Party” or collectively as the “Parties.” 
  

			
		 	Table of Contents
		
	 1.
	 	 Definitions

		
	 2.
	 	 Term

		
	 3.
	 	 Scope of Supply

		
	 4.
	 	 Ordering

		
	 5.
	 	 Terms of Delivery

		
	 6.
	 	 Price, Payment and Order Lead Times

		
	 7.
	 	 Quality Assurance

		
	 8.
	 	 Installation and Product Warranty

		
	 9.
	 	 Service & Support

		
	 10.
	 	 Demand Planning

		
	 11.
	 	 Exclusivity

		
	 12.
	 	 Representations, Warranties and Indemnity

		
	 13.
	 	 Force Majeure

		
	 14.
	 	 Regulatory Compliance

		
	 15.
	 	 Confidentiality

		
	 16.
	 	 Intellectual Property Ownership

		
	 17.
	 	 Governing Law; Disputes

  
 Page 1 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

			
	 18.
	 	 Software Licence

		
	 19.
	 	 Damages

		
	 20.
	 	 Assignment

		
	 21.
	 	 Severability

		
	 22.
	 	 Sole Terms

 WHEREAS, LipoScience has developed and markets the NMR LipoProfile® test, a clinical diagnostic tool which uses NMR
measurements and has experience and expertise in developing, utilizing and marketing its clinical diagnostic applications utilizing NMR measurement results; and 
 WHEREAS, Agilent develops and commercializes certain NMR Technology and has extensive experience in the development and use of NMR Technology 
 WHEREAS, LipoScience and Varian, Inc. signed a Collaboration Agreement dated as of April 22, 2005 (the “Collaboration Agreement”); 
 WHEREAS Agilent is successor in interest to Varian, Inc.; and 
 WHEREAS, the Parties now wish to
define the terms under which Agilent will supply NMR Subsystems to LipoScience for integration into Vantera Analyzers in furtherance of the commercialisation and world-wide supply of the Vantera Analyzer in a LipoScience Field of Use; 

NOW THEREFORE, in consideration of the promises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	1.	DEFINITIONS 

 For purposes of this
Agreement, the terms defined in this Section shall have the meanings specified below, whether used in their singular or plural form: 
 “Affiliate” shall mean any corporation or other entity that controls, is controlled by, or is under common control with a Party to this Agreement. A corporation or other entity shall be
regarded as in control of another corporation or entity if it directly or indirectly owns or controls more than fifty per cent (50%) of the voting stock or other ownership interest of the other corporation or entity, or if it possesses,
directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint more than fifty per cent (50%) of the members of the governing body of the
corporation or other entity. 

  
 Page 2 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 “Approval” shall mean any approval, clearance, certification, license or
other authorization required to be obtained from applicable regulatory authorities in any jurisdiction in order to lawfully market and sell the Vantera Analyzer in such jurisdiction, including, but not limited to, FDA 510(k) approval for the Vantera
Analyzer. The term “Approved” shall mean the receipt of Approval. 
 “CLIA” shall mean the Clinical
Laboratory Improvement Act and the regulations issued thereunder. 
 “Components” shall mean individual
components of the NMR Subsystem listed at Section 3.1, Items 1A through 1E and Section 3.2 Items 2A through 2D. 

“Control Subsystem” shall mean the software and any hardware integrating and controlling the various subsystems in the
Vantera Analyzer; in particular, integrating and communicating with the NMR Subsystem, the auto-sampler and any IVD or other software programs that may be employed with the Vantera Analyzer. 

“in vitro Diagnostic Application” or “IVD” shall have the meaning defined in Section 11.1.b.3.

 “Effective Date” shall mean the date first set forth above in the preamble. 

“FDA” shall mean the United States Food and Drug Administration or any successor agency with responsibilities comparable
to those of the United States Food and Drug Administration. 
 “Laboratory Developed Test” shall mean a
clinical diagnostic test for use in the diagnosis of disease or other conditions that was developed by a CLIA certified clinical laboratory for use in that laboratory. 
 “LipoScience Field of Use” shall have the meaning defined in Section 11.1. 
 “LipoScience Specimen Types” shall have the meaning defined in Appendix L. 
 “NMR” shall mean nuclear magnetic resonance. 
 “NMR
Subsystem” shall mean the Agilent device used in the Vantera Analyzer, including the components thereof and any subsequent versions, improvements, derivatives and adaptations thereto, that exposes the sample material to magnetic energy and
detects the sample’s resonance response to such exposure and consists of an NMR magnet assembly, an NMR sample probe, controlling electronics, and acquisition software that communicates with a control subsystem (the “Console”), and
any Components, each as further referenced in Section 3.2. 
 “NMR Technology” shall mean NMR flow cell
probes, NMR components, NMR controlling electronics and acquisition software, all of which are capable of use with an NMR magnet. 

  
 Page 3 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 “Products“ shall mean the Agilent products and services set forth at
Section 3.2, below. 
 “Product Specifications” shall mean the functional and technical specifications and
requirements for stand-alone Products or Components as listed in Appendix A-1 as attached hereto (if applicable) or otherwise as consistent with Agilent’s standard published specifications. 

“Purchase Order“ shall have the meaning set for in Section 2.2. 

“System Specifications” shall mean the functional and technical specifications and requirements for a complete
NMR Subsystem attached hereto as Appendix A-1. 
 “Term” shall have the meaning set forth in Section 2.1

 “Third Party” shall mean any person or entity other than LipoScience, Agilent or their respective
Affiliates. 
 “Vantera Analyzer” shall mean the system designed and made by LipoScience, as such system may be
modified, improved or enhanced during the Term, which consists of the NMR Subsystem, an auto-sampler and a Control Subsystem. 
  

	2.	Term 

 2.1 Term. This Agreement
shall come into force upon the Effective Date and shall be valid for a period of ten (10) years from the Effective Date; however, this Agreement may be renewed for subsequent five year terms upon mutual written agreement of the Parties
(“Term”). If either Party determines that it does not intend to renew the Agreement for an additional term, as a courtesy, such Party shall provide not less than one (1) year written notice to the other Party of its intent not to renew the
Agreement at the end of the initial term or any subsequent five year term. 
 2.2 Termination. 

a. Voluntary. The Parties may terminate this Agreement and/or any open purchase orders for Products issued
by LipoScience hereunder (“Purchase Orders”) at any time upon written agreement of both Parties. 

b. Default by Either Party. Either Party may terminate this Agreement and/or any open Purchase Orders for
Products by notification, in writing, (i) upon the occurrence of a breach of a material term of this Agreement if the breaching Party fails to remedy such breach (if such breach is a failure to make payment) or demonstrate its ability to remedy
such breach (if such breach is other than a failure to make payment) within thirty (30) days after notice thereof by the non-breaching Party or, with respect to a breach (other than a failure to make payment) that cannot be cured within such
period, then such longer period (up to 90 days) as may be reasonably necessary, using commercially reasonable efforts, to cure the breach, or (ii) if the other Party files for protection under the bankruptcy laws, makes an assignment for the
benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition 

  
 Page 4 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
under any bankruptcy or insolvency act or has any such petition filed against it and such proceeding remains un-dismissed or un-stayed for a period of more than thirty days. Agilent shall not be
obligated to accept additional Purchase Orders during any period LipoScience has undisputed past due receivables which remain unpaid after thirty days written notice. 

c. Termination by Agilent. Agilent may terminate this Agreement in the event that Agilent (and its
Affiliates, if applicable) discontinues the sale of all the NMR Technology. In such event, Agilent shall provide LipoScience with a written certification, signed by an officer of Agilent, stating that Agilent has made a final decision to discontinue
the sale of NMR Technology. Notwithstanding the foregoing, Agilent shall provide LipoScience with not less than two years prior written notice of any such termination due to such discontinuation of the sale of NMR Technology. If this Agreement is
terminated in accordance with this section 2.2(c), Agilent shall [ * * * ] to a third party chosen by LipoScience [ * * * ] at the time of termination [ * * * ]. 

d. Effect of Expiration or Termination of the Agreement. Except as expressly provided herein, the expiration or
termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination (including performance of any open Purchase Orders accepted by Agilent). 

If for any reason Agilent elects not to renew this Agreement pursuant to Section 2.1, or if LipoScience terminates this Agreement due
to a material breach by Agilent, Agilent agrees to sell to LipoScience and its Affiliates, the NMR Subsystem as then incorporated in the Vantera Analyzer until: (a) such time as either LipoScience has developed, received necessary Approvals for
and commenced marketing of a replacement or successor to the Vantera Analyzer which does not incorporate or require the NMR Subsystem, or (b) the period of [ * * * ] from the expiration of the Term, or (c) [ * * * ] from the date of
termination by LipoScience due to uncured material breach by Agilent, whichever of (a) or (b) or (c) is applicable and shortest. Agilent shall have no on-going supply obligations to LipoScience if this Agreement is terminated due to
material breach by LipoScience. Any subsequent Purchase Orders placed by LipoScience pursuant to this Section after this Agreement is terminated, shall be subject to the terms of this Agreement. 

e. Survival of Provisions Upon Expiration or Termination. Any provision of this Agreement which by its
nature is intended to survive its expiration or termination shall survive such expiration or termination, including but not limited to Sections 1, 2.2, 8.4, 8.5,, 9, 11.3,12, 14, 15, 16, 17, 18, 19, 21 and 22. 

  
 Page 5 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	3.	Scope of Supply, 

 3.1 As of the Effective
Date, LipoScience has made a final lifetime purchase of Products listed in Schedule 1 below which shall conform and be delivered in accordance with the provisions of the appropriate Product Specification or System Specification. Products listed in
Schedule 1 may be delivered after the Effective Date, but as of the Effective Date are no longer available for purchase by LipoScience: 

Schedule 1: 
  

					
	 Component
	  	 Part Number
	  	 Description

	 1A
	  	G8506A	  	 Agilent NMR magnet, 400MHz 54mm LipoScience
  

•     Agilent NMR Magnet, 400MHz 54mm ASP

 

•     Automation Sample Delivery System ,400/54 Agilent Magnet, ZPFG

 
 •     Shim
Tube 27 Channel, 400 54 ASP

			
	 1B
	  	0199004071	  	400 MHZ 1H/2H TL IFC NMR PROBE
			
	 1C
	  	0191816700	  	 SHIP KIT,

ANALYTICAL
 CONSOLE, 400 MHZ

			
	 1D
	  	0191683410	  	CONSOLE, 400 SERIES (INCLUDING ACQUISITION SOFTWARE FOR COMMUNICATION WITH CONTROL SUBSYSTEM)
			
	 1E
	  	191827200	  	SYSTEM INTERCONNECT, 400-MR

 3.2 Agilent shall provide the Products listed in Schedule 2 below to LipoScience and shall deliver these in accordance
with the provisions of the appropriate Product Specification or System Specification and with Purchase Orders accepted by Agilent beginning on the Effective Date and until notice by Agilent of technical modification, product change or obsolesence in
accordance with Section 9.5 hereof. Item 2B may be purchased on a stand-alone basis or together with Item 2A, 2C and 2D as a complete system. 
 It is acknowledged and agreed by both parties hereto that LipoScience has not yet ordered and Agilent has not yet provided the Products listed in Schedule 2 for evaluation, testing and validation by
LipoScience. To the extent that such Products are not equivalent for purposes of replaced products referenced in Schedule 1, then Agilent will work with LipoScience in good faith and Agilent will use commercially reasonable efforts to promptly
address issues arising from such product differences. 

  
 Page 6 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

							
	 Component
	  	 Product
Number
	  	 Description

				
	 2A
	  	G8303A	  		  	400-MR DD2 Console LipoScience
				
		  		  		  	With the following subcomponents:
				
		  		  	 •     
	  	400-MR Console
				
		  		  	 •     
	  	Ship Kit, 400-MR
				
		  		  	 •     
	  	400-MR Computer Kit
				
		  		  	 •     
	  	Sample Kit, 400-MR
				
	 2B
	  	G8506A	  		  	Agilent NMR magnet, 400MHz 54mm LipoScience
				
		  		  	 •     
	  	Agilent NMR Magnet, 400MHz 54mm ASP
				
		  		  	 •     
	  	Automation Sample Delivery System ,400/54 Agilent Magnet, ZPFG
				
		  		  	 •     
	  	Shim Tube 27 Channel, 400 54 ASP
				
	 2C
	  	199004071	  		  	400 MHz 1H/2H TL IFC Probe
				
	 2D
	  	GXXXXAA	  		  	VnmrJ 3.X Media Kit LipoScience

 3.3 On-site Installation is limited to the superconducting magnet system only (Items 1A and 2B), as set forth at Appendix
B 
 3.4 Agilent shall provide the Service parts listed at Appendix C (“Service Parts”) and Field Service and Support as listed at
Appendix D 
  

	4.	Ordering. 

 4.1 Agilent shall accept
LipoScience Purchase Orders for Products consistent with Table 6A or consistent with a valid quote as provided by Agilent under the terms and conditions of this Agreement within [ * * * ] business days of receipt. Orders that are consistent with
either Table 6A or a valid quote provided by Agilent shall be deemed accepted, regardless of whether such 

  
 Page 7 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
Orders are accepted by Agilent within such timeframe. Orders that are not consistent with Table 6A or a valid quote and are not accepted by Agilent within such timeframe shall be deemed rejected.
Agilent’s acceptance of a Purchase Order placed by LipoScience means that a separate, binding purchase contract exists between Parties. The terms and conditions of supply shall be the terms and conditions set forth in this Agreement and shall
apply exclusively to all Purchase Orders placed for Products. 
 4.2 This Agreement shall be part of each quotation issued by Agilent for the
Products and each Purchase Order issued by LipoScience for the Products, whether or not referenced on such quotation or Purchase Order. The Parties may modify the terms and conditions of this Agreement by written amendment signed by authorized
representatives with respect to any Purchase Order, specifically referring to this Agreement and their intent to modify its terms for a specific Purchase Order only. 
 4.3 All Purchase Orders are subject to acceptance by Agilent in accordance with Section 4.1. Purchase Orders are governed by the applicable trade term specified on the quotation or agreed to by
Agilent as defined in Incoterms 2000. Agilent shall respond to LipoScience’s Purchase Orders either by accepting them and then shipping the Products as specified in the Purchase Order, by rejecting them (in accordance with Section 4.1,
above), or by notifying LipoScience of proposed modifications for Purchase Orders that are not consistent with Table 6A. When an acknowledgment contains additions or modifications to the Purchase Order, the acknowledgment shall not be effective and
the Purchase Order shall not be binding upon either Party unless and until the Parties mutually agree upon any changes in writing. Agilent agrees to meet the applicable “Order Lead Time” set forth on Table 6.A hereof for LipoScience’s
Purchase Orders which conform to the requirements of this Agreement and are accepted by Agilent pursuant to the terms and conditions of Section 4.1 (but subject to modifications thereof in accordance with Section 6 hereof). Subject to
Section 5.3 hereof, all Purchase Orders accepted by Agilent shall be binding and non-cancellable by LipoScience. 
  

	5.	Terms of Delivery. 

 5.1 Unless otherwise
specified in the quotation or specified in the Purchase Order and accepted by Agilent, LipoScience shall take title and risk of loss of the Products at point of delivery for Products shipped by Agilent to a non-U.S. destination and at point of
shipment in all other cases. 
 5.2 Each separately-priced section of the Purchase Order shall be divisible and severable from every other, and
shipment, performance, acceptance (if applicable), passage of title and risk of loss, warranty terms (including commencement of warranty period), invoicing and payment shall be determined and shall occur independently for each such section.

 5.3 Unless delivery is delayed by more than [ * * * ] days from the date specified in Table 6A as may be amended in accordance with this
Agreement, Agilent’s failure to deliver a Product by any specified date will not be sufficient cause for cancellation by LipoScience, nor will Agilent be liable for any direct, indirect, consequential or other economic loss due to delay in
delivery. Agilent will use commercially reasonable efforts to meet delivery dates and will promptly notify 

  
 Page 8 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
LipoScience if Agilent anticipates a delay in delivery of any Product. If Agilent is unable to meet a delivery date as requested, the Parties will work in good faith and Agilent shall use
commercially reasonable efforts to fulfill such Purchase Order as promptly as possible thereafter. If Agilent is unable to deliver within ninety (90) days of the scheduled delivery date, LipoScience’s sole remedy is to cancel any such
Purchase Order in its sole discretion and Agilent will promptly refund or credit any advance payment by LipoScience for such Product. 
 5.4 For
Products where installation is not purchased by LipoScience, LipoScience shall have [ * * * ] days from the date of delivery to inspect such Product or Components for compliance with this Agreement, the Purchase Order and the applicable
Specifications. If LipoScience fails to inspect for compliance within [ * * * ] days, acceptance of the Product will occur on the [ * * * ] day after delivery. 
 5.5 For Products where installation is purchased, acceptance occurs when the Product passes Agilent’s acceptance tests and procedures. Agilent shall promptly notify LipoScience if any Product fails
to meet such requirements. In such event, Agilent will promptly repair or replace such Product at no additional cost to LipoScience. LipoScience shall provide any necessary permits, facilities and utilities ensure compliance with regulatory
requirements and comply with Agilent’s reasonable pre-installation instructions in a timely fashion. Unless otherwise noted, cryogens and hoist/rigging rental for installation are not included in Agilent prices. If LipoScience schedules or
delays installation by Agilent more than [ * * * ] days after delivery, acceptance of the Product will occur on the [ * * * ] day after delivery. 
  

	6.	Price, Payment and Order Lead Times. 

 6.1 Subject to Purchase Order acceptance according to Section 4.1, during the Term, LipoScience may purchase and Agilent agrees to sell Products to LipoScience at the prices and subject to the Order
Lead Times specified below, as such prices and/or Lead Times may be modified from time to time in accordance with this Section 6. The initial prices and Lead Times set forth at Table 6.A, below shall remain firm and shall not increase during
the initial [ * * * ] month period of the Agreement. Thereafter, the Parties will review prices at least annually in order to assess whether changes in prices, Lead Time or both are appropriate given market conditions, volumes, forecasts and
inflation. Agilent shall be entitled to increase prices and adjust Lead Times annually after the initial [ * * * ] month period of the Agreement as necessary in Agilent’s reasonable discretion to recoup any increased costs, whether the result
of new requirements or features, enhancements, third party royalties, or cost increases beyond the Parties’ reasonable control, such as supplier price increases or inflation, or otherwise; provided however, in no event shall the price be more
than [ * * * ] higher than the prevailing price for the NMR Subsystem or [ * * * ] higher than the aggregate increase in Agilent’s actual costs of parts and labor, whichever is higher. 

In addition, the Parties may negotiate price decreases or reduction in Lead Times where warranted (such as to account for volume
discounts or where the Parties are able to bring efficiencies to bear). In the event the Parties cannot agree to the amount of any such increase or decrease, such disagreement shall constitute a dispute subject to resolution under the Disputes
provision set forth at Section 17, below. 

  
 Page 9 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Table 6.A 
  

											
	 Item
	  	 Product Description
	  	Total
Annual
Demand
Volume	  	Unit Price ($USD)
[***]	  	Order Lead Time
	  	  	  	  	Up to 2
units/month	  	Add’l units
	 1A
	  	NMR Subsystem Component (i) (MRCA 400/54/ASC Superconducting NMR Magnet System)	  	[ * * * ]	  	[ * * * ]	  	[ * * * ] Weeks	  	As quoted by Agilent
	  	  	> [ * * * ]	  	[ * * * ]	  	[ * * * ] Weeks	  	As quoted by Agilent
						
	 1B
	  	NMR Subsystem Components (ii), (iii), (iv), and (v) (probe, console ship kit, console and interconnect kit)	  	[ * * * ]	  	[ * * * ]	  	[ * * * ] Weeks	  	As quoted by Agilent
	  	  	> [ * * * ]	  	[ * * * ]	  	[ * * * ] Weeks	  	As quoted by Agilent
						
	 2
	  	On-site Installation – (super conducting magnet system only) (North America)*	  	Per Unit	  	[ * * * ]	  	[ * * * ] Weeks	  	As quoted by Agilent
						
	 2
	  	On-site Installation – (super conducting magnet system only) (Outside North America)	  	Per Unit	  	As quoted by Agilent	  	[ * * * ] Weeks	  	As quoted by Agilent
					
	 3
	  	Service Parts	  	Per Unit	  	As set forth on App C	  	As quoted by Agilent
					
	 4
	  	Field Service and Support	  	Per Unit	  	As set forth on App D	  	As quoted by Agilent
					
	 5
	  	Components	  	Per Unit	  	As quoted by Agilent	  	As quoted by Agilent

  

	*	Price of on-site Installation for North America includes cryogens, on-site engineering time, engineer travel and accommodations, and standard installation equipment
freight costs. Special, site specific equipment requirements (e.g. alternative rigging) will be subject to additional charge. 

  
 Page 10 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 6.2 Agilent shall invoice LipoScience for each shipment no earlier than the date of actual shipment and
shall provide LipoScience with shipping notices, bills of lading, and receipts promptly after shipment. Payment shall be due and owing [ * * * ] days from invoice unless reasonably disputed by LipoScience. 

6.3 Agilent shall package, label and ship all Products using Agilent’s standard shipping, packaging and procedures and in compliance with all
applicable laws, rules and regulations. If LipoScience supplies packaging and shipping requirement information at the time it submits the Purchase Order, Agilent shall have no liability for any loss or damage to Products due to Agilent’s
compliance with LipoScience shipping instructions. 
 6.4 Except as otherwise specified in the Purchase Order, Agilent’s prices exclude and
LipoScience is responsible for all sales, use, excise, value-added or other taxes and duties. 
 6.5 LipoScience shall fall into arrears if it
fails to pay within [ * * * ] business days of a payment demand notice received after payment has become due. From the time the payment falls into arrears LipoScience shall be liable to pay [ * * * ]% per month of the Agreement amount or the maximum
amount permitted by law. Agilent reserves the right to suspend shipments if payment on any undisputed invoice remains unpaid after [ * * * ] days written notice. Agilent reserves the right to terminate in accordance with Section 2.2b if payment
on any undisputed invoice remains unpaid more than ninety (90) days after written notice. 
  

	7.	Quality Assurance. 

 7.1 Agilent shall
ensure that Products are manufactured and supplied in accordance with Agilent’s quality management systems, registered under: ISO 9001:2008. 
 Certificate number FM 32479: The design, manufacture, installation, servicing and repair of cryogenic and superconducting magnet systems and their associated components. 

Certificate number FM 21797: The design, development, manufacture and consumables operation of mass spectrometers, including related data
systems. 
 7.2 Right to Audit. During the Term of the Agreement, Agilent shall (i) permit LipoScience to conduct reasonable, annual
audits during regular Agilent business hours and at LipoScience’s sole expense of Agilent’s compliance with the current ISO 9001:2008 standard and Agilent quality system procedures as may be required by third party regulatory agencies and
this Agreement, (ii) reasonably respond to any audit deficiencies with a corrective action plan within [ * * * ] days of receiving the written audit report from LipoScience, and (iii) maintain its ISO and any similar certifications.

  

	8.	Installation and Product Warranty. 

 8.1
LipoScience is responsible for executing and coordinating installation and qualification of Vantera Analyzers. Agilent shall provide installation services for the superconducting magnet system of the NMR Subsystem in accordance with the prices
listed in Table 6.A of this 

  
 Page 11 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
Agreement, Section 5 regarding acceptance, in accordance with Appendix B and in accordance with prices and Lead Times set under terms of this Agreement. This service is limited to
installation of the magnet system only, through to and including room temperature shimming. 
 8.2 Additional days of engineer time required due
to circumstances beyond the control of Agilent shall be billed by Agilent and paid by LipoScience at Agilent’s standard then-current daily rate. 
 8.3 The installation price set forth at table 6.A above is valid for installations in North America only and is subject to LipoScience completing all other work required for installation of the Vantera
Analyzer within a period of up to six (6) months following shipment of the NMR Subsystem from Agilent. In all other cases, additional charges may apply. 
 8.4 Agilent warrants each NMR Subsystem to be free from defects in material and workmanship and in substantial conformance with the System Specifications, such warranty to be for the period beginning upon
delivery and ending [ * * * ] later, in each case as determined separately for items set forth in the separately-priced sections of the Purchase Order. Agilent warrants any other Product sold hereunder, including but not limited to Components,
service parts, accessories and software, if sold other than as part of an NMR Subsystem sale, to be free from defects in material and workmanship and in substantial conformance with applicable portions of the Product Specifications for a period
beginning upon delivery and ending [ * * * ] days thereafter. Agilent warrants services sold hereunder to be performed in a professional and workmanlike manner for a period beginning upon performance and ending [ * * * ] days thereafter. Agilent
does not warrant the operation of any software to be uninterrupted, bug free or error free. Notwithstanding the foregoing, Agilent acknowledges that as part of the quality management system of LipoScience, there will be a risk assessment process in
accordance with ISO 9001:2008 to ensure that any known bugs or errors are not critical to the performance of the NMR Subsystem, and will not create a safety issue for the operator of the Vantera Analyzer. Agilent shall use reasonable commercial
efforts to promptly mitigate bugs or errors that are discovered by LipoScience subsequent to the release of the NMR Subsystem that are critical to the performance of such NMR Subsystem. 
 The foregoing warranties are void in the event of Product abuse, alteration, misuse, improper operation or maintenance, use in an unsuitable physical environment, or use with inadequate facilities or
utilities, improper repair or calibration by LipoScience or a third party, and these warranties do not cover products, components, or services warranted by another party. LipoScience’s sole and exclusive remedies for any defective or
non-conforming Product during its warranty period shall be repair or replacement (at Agilent’s sole option) of defective or non-conforming Products returned to Agilent and service support for Second Tier and Third Tier escalations as set forth
in Section 9.2, below, or, if such remedies fail of their essential purpose, credit or refund of the purchase price, and such remedies shall be available only for defects reported during the applicable warranty period. Agilent shall ship
replacement Products at its expense to LipoScience or LipoScience’s customer, as directed by LipoScience, for installation and/or repair by LipoScience in accordance with Section 9.2(e), below. LipoScience shall return any defective or
non-conforming Products to Agilent in accordance with Agilent’s then-current RMA process and at Agilent’s expense within [ * * * ] days of receiving replacements. Any repaired or fully replaced Products or services shall be subject to the
original warranty period, which shall not be extended due to such repair or replacement, except to the extent required by any mandatory non-waivable provision of applicable law. With respect to any breach of the

  
 Page 12 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
foregoing warranty on performance of services, Agilent will promptly and at no additional cost to LipoScience (including the cost of replacement parts) re-perform the nonconforming services. THE
FOREGOING WARRANTIES AND THE WARRANTIES IN SECTION 12 ARE EXCLUSIVE AND IN LIEU OF ALL OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 

	9.	Service & Support. 

 9.1
Routine Technical Service and Support. 
 LipoScience will provide routine maintenance and service (as defined at Appendix E) for the NMR
Subsystem of any Vantera Analyzer either directly or through a Agilent Certified product support affiliate. 
 9.2 Escalation.

 The following escalation procedures shall apply both for warranty and non-warranty service: 

a. First Tier. LipoScience shall provide all first tier service support and failure analysis to LipoScience customers for the
Vantera Analyzer, including the NMR Subsystem incorporated therein. First tier service support includes but is not limited to telephone support, Component replacement and recalibration of the NMR Subsystem. Replacement service parts shall be
provided by Agilent at no additional cost during the applicable warranty period as set forth at Section 8.4 (and subject to all conditions and limitations set forth therein), and shall be purchased by LipoScience under Purchase Order
thereafter. First tier support will be provided by LipoScience pursuant to agreements entered into by LipoScience and its customers.
 b. Second Tier. Agilent shall provide second tier service support for LipoScience customers for the Vantera Analyzer for issues which LipoScience is unable to resolve through first tier support.
Agilent will provide such support by telephone, instrument remote access, or e-mail to LipoScience support personnel or, at the mutual agreement of LipoScience and Agilent, directly to the LipoScience customer. LipoScience agrees to use
commercially reasonable efforts to address customer support issues prior to requesting such assistance from Agilent. Second tier support shall be provided by Agilent at no additional cost during the applicable warranty period and shall be
billed to LipoScience at Agilent’s standard then-current rates thereafter. 
 c. Third Tier. Agilent shall provide
third tier service support for LipoScience customers for the Vantera Analyzer as a result of a LipoScience field escalation events. Agilent will provide such support to LipoScience support personnel at LipoScience customer sites. LipoScience agrees
to use commercially reasonable efforts to address customer support issues prior to requesting assistance from Agilent. Agilent will use commercially reasonable efforts to respond to requests for third tier service support within [ * * * ]
during regular business hours Pacific Standard Time in the United States of receiving a Third Tier request from LipoScience to Agilent as part of a LipoScience field escalation event. Third tier support shall be provided at no

  
 Page 13 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
cost during the warranty period and billed to LipoScience at Agilent’s standard then-current rates after such warranty period. A minimum eight hours will be charged on any call for
third-tier support. 
 d. Process. Escalation events shall be managed through the escalation process set forth at
Appendix F. Agilent shall use commercially reasonable efforts to achieve the response times set forth in Appendix G, and subject to Agilent using such commercially reasonable efforts to achieve such response times, Agilent shall have no liability
should such targets not be met. 
 e. Returns. With respect to Products returned to Agilent for repair or replacement,
including but not limited to the Top Loading 60uL NMR Flow Probe , LipoScience shall: (1) prepay the cost of shipping; (2) be responsible for loss or damage in transit; and (3) in keeping with Agilent Technologies Recommendations for
Decontamination of Probes Contaminated with Bloodborne Pathogens (reprinted in Appendix K, herein “Decontamination Recommendations”), completely remove and identify on Agilent’s Request for Return form any toxic or hazardous materials
to which they may have been exposed, and indemnify and hold Agilent harmless against any claims resulting from a failure to do so. Agilent shall have the right to update the Decontamination Recommendations in its reasonable and sole discretion upon
written notice to LipoScience and LipoScience shall adhere to the updated Decontamination Recommendations for all returns shipped to Agilent, provided however that LipoScience shall not be in breach of this provision if LipoScience complies with the
previous version of the Decontamination Recommendations for returns shipped to Agilent within [ * * * ] days of receiving such update. 
 9.3
Service Parts and Supplies. 
 Following the warranty period, during the Term, service parts will be offered for sale by Agilent as
available at prices to be mutually agreed. 
 9.4 Continuing Support. 
 Unless terminated by Agilent pursuant to Section 2.2 due to an uncured material breach by LipoScience, Agilent agrees to provide the support set forth in Section 9.2 for a period of [ * * * ]
following the last date of shipment of an NMR Subsystem, provided that LipoScience shall be obligated to pay Agilent for such services as set forth above. 
 9.5 Training and Product Support Certification. 
 Once per year, Agilent will offer
a training certification course at an Agilent facility at no charge for up to three LipoScience engineers in NMR instrument maintenance and troubleshooting and NMR magnet cryogen filling and maintenance as set forth in Appendix H. Such training
shall be sufficient to permit a qualified engineer to perform the service and support contemplated in Sections 9.1 and 9.2. Additional training shall be billed to LipoScience at at Agilent’s then-current standard rates. Agilent will provide
relevant Product support documentation and related media to attending service engineers. All travel and related costs for LipoScience employees or agents shall be at Liposcience’s expense. 

  
 Page 14 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 9.6 Technical Modification, Product Developments & Product Change Protocols. 

a. Agilent will provide LipoScience technical support management with updates to relevant service support documentation and media as it
relates to the NMR Subsystem. 
 b. Agilent will distribute to LipoScience technical support management all relevant field
service bulletins for the NMR Subsystem. In the event that an Agilent service bulletin requires field service action, Agilent certified LipoScience service engineers will perform the service action. 

c. From time to time, Agilent may deem it necessary to make changes to the NMR Subsystem. For the purpose of assisting LipoScience in
evaluating the impact of these on applicable System Specifications, Agilent shall make commercially reasonable efforts to inform LipoScience of such intended changes prior to the intended change implementation and to provide to LipoScience copies of
the NMR Subsystem engineering change orders on such changes as engineering change orders are generated by Agilent. LipoScience shall treat such communications as Confidential Information of Agilent. 

d. LipoScience agrees to evaluate all proposed hardware and software changes in good faith and with the intention of accepting such
changes, and will notify Agilent as to LipoScience’s classification of the change within thirty (30) business days of receiving the change notification from Agilent. However, in keeping with the change classifications listed below,
LipoScience reserves the right to reject or delay changes that LipoScience reasonably determines will or may alter the NMR Subsystem conformance with applicable System Specifications, including but not limited to such cases where the proposed
changes will or may compromise the FDA clearance status of products utilizing the NMR Subsystem. 
 Product changes will be
classified by LipoScience in one of the following categories: 
  

	 	1.	Acceptable changes that require no validation 

 Changes in this category shall be considered acceptable by LipoScience with no further action required by either Party 
  

	 	2.	Acceptable changes that require validation 

 Changes in this category shall be considered acceptable to LipoScience conditional on the completion of a successful validation by LipoScience that substantiates that the changed NMR Subsystem is still in
compliance with the System Specifications. LipoScience shall be responsible for such validation and will provide a schedule including a deadline for approval of the changes. Agilent shall use commercially reasonable efforts to support such
validation such as making available advanced Components for testing and evaluation if needed. 
  

	 	3.	Unacceptable “hardship” changes 

 Changes in this category shall be considered unacceptable to LipoScience on the basis that they compromise the conformance to the System Specifications. LipoScience shall provide Agilent with a
justification for this assessment. 
 e. Subject to Section 9.6(k), Agilent will not implement any changes to the Product
Specifications of the NMR Subsystem provided to LipoScience for Products ordered under open Purchase Orders without consent from LipoScience. Changes shall be applied prospectively to new Products ordered after notice of the change as set forth
herein. 

  
 Page 15 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 f. Subject to Section 9.6(k), if Agilent proposes hardware or software changes that
LipoScience reasonably determines will or may fall within the circumstances set forth in Section 9.6(d)(2) or (d)(3), Agilent agrees to accept Purchase Orders for Products without such change and consistent with Sections 5 (Terms of Delivery)
and 6 (Price, Payment and Order Lead Times) herein for up to [ * * * ] after giving written notice to LipoScience of the change, or until LipoScience completes the validation and approves the change, whichever is the shorter. Prior to termination of
the [ * * * ], LipoScience may purchase from Agilent such quantity of the original NMR Subsystem as LipoScience deems necessary for its future requirements, which total quantity shall be delivered at a rate of a shipment total of [ * * * ] or as
otherwise agreed between the Parties. 
 g. In the event that Agilent proposes or implements any design or engineering changes
to the NMR Subsystem which are not reasonably acceptable to LipoScience after diligent and reasonable review and assessment, Agilent will continue to supply the unmodified NMR Subsystem to LipoScience, provided however, that the parties shall
negotiate in good faith a fair price for such continuing supply, but in no event shall the price be more than [ * * * ] than the prevailing price or [ * * * ] than the aggregate increase in cost of parts and labor, whichever is higher. 

h. Except for changes otherwise permitted in this Section including changes pursuant to Section 9.6(k), Agilent shall not make
changes to the NMR Subsystem that require validation more than once in a twelve month period without LipoScience’s prior written consent. 
 i. Over the life of the NMR Subsystem, Agilent will offer open communication with LipoScience to provide forward looking information regarding NMR Subsystem design changes for the purpose of assisting
LipoScience in evaluating the impact of such changes to applicable System Specifications. The expectation is that this will be facilitated through regular, on-going meetings. 
 j. Agilent reserves the right to implement engineering change orders at its own discretion for all NMR Subsystems and any variants provided to customers other than LipoScience; provided, however, that all
such variants shall remain subject to the exclusivity provisions set forth in Section 11 herein. 
 k. Notwithstanding
anything to the contrary elsewhere herein, Agilent reserves the right to implement engineering change orders at its own discretion at any time and at any frequency where the changes address material safety issues or those required for compliance
with regulatory requirements, in Agilent’s reasonable discretion, or due to NMR Subsystem component obsolescence; provided however, that the Parties shall work in good faith to minimize the disruption and cost to LipoScience associated with any
such change, and to avoid, to the extent reasonably possible, the necessity of conducting a new clinical trial associated with such changes. If a new clinical trial is necessary, the Parties shall work in good faith to minimize the costs to
LipoScience associated with any such clinical trial. 

  
 Page 16 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 l. Implementation of engineering change orders that Agilent has determined require field
retrofit or rework of existing NMR Subsystems will be the responsibility of LipoScience service personnel. Agilent will provide material for field retrofits pursuant to the conditions of Agilent’s warranty as set forth in Section 8.4, if
applicable, or otherwise pursuant to Purchase Orders issued by LipoScience. 
 m. Implementation of engineering changes orders
that Agilent has defined as not requiring field retrofit or rework of existing NMR Subsystems will be done only at the discretion of LipoScience and will be the responsibility of LipoScience service personnel. Material required for implementation of
this type of Engineering Change Order will be subject to service material pricing in effect at the time of implementation. 
 n.
The VnmrJ software (“Software”) as listed in Section 3.2 shall be a version of the Agilent standard software as of the Effective Date. The Software shall be available to LipoScience at no cost to LipoScience for the duration of the
Agreement. Media kits for the software shall be made available to LipoScience at the then prevailing Agilent price. LipoScience may request in writing that the Software be updated to Agilent’s then current version of the software at which time
the updated “Software” shall be the version available to LipoScience. Content and timing of updates applied to Agilent’s standard NMR software product for all customers other than LipoScience shall be in Agilent’s sole
discretion. 
  

	10.	Demand Planning. 

 Each month, LipoScience
shall provide to Agilent a non-binding twelve-month rolling forecast of LipoScience’s anticipated Product needs broken down into monthly increments. LipoScience will use its reasonable efforts to provide Agilent with market data and forecasts
to optimize production planning in the short, medium and long term. All such short, medium and long term forecasts shall be good faith estimates of LipoScience and shall not be binding on either Agilent or LipoScience. The Parties shall communicate
in writing or orally not less than each quarter during the Term of the Agreement to review anticipated requirements of LipoScience and address any issues relating thereto. Such forecasts and market data shall be the Confidential Information of
LipoScience and marked as such by LipoScience. 
  

	11.	Exclusivity. 

 11.1
Limited Exclusivity of Supply: During the first ten (10) years of this Agreement, Agilent and each of Agilent’s Affiliates shall not sell all or any part of the NMR Technology to a customer who (i) Agilent is aware, or reasonably should
be aware, after due inquiry, at the time of the sale by Agilent or such Affiliate, intends to use all or any part of the NMR Technology to pursue FDA registration or develop a Laboratory Developed Test to analyze any of the LipoScience Specimen
Types for the screening, detection, prognosis or monitoring of diseases in the Cardiovascular, Cancer, Endocrine, Central Nervous System (CNS) or Autoimmune subfields (the underscored language above being defined herein as the “LipoScience
Field of Use”), or (ii) is one of the customers listed in Appendix J-1 and Agilent is aware, or reasonably should be aware, after due inquiry, at the time of the sale by Agilent or such Affiliate, that such customer intends to use all or any
part of the NMR Technology to analyze a LipoScience Specimen Type. Notwithstanding anything to the contrary herein, Agilent may sell all or any part of the NMR Technology to any customer, solely for the analysis of [***], who is licensed, at the
time of sale by Agilent, to certain patents owned or licensable by [***] relating to the analysis of [***]. 
 a. In connection
with the limitations described above, Agilent agrees that all quotations and proposals for NMR Technology provided by Agilent to a third party for potential use within the LipoScience Field of Use will be provided on the basis of and for Research
Use only or Investigative Use only, which will be clearly and prominently indicated on any such quotation or proposal. Agilent further agrees that all product literature, labeling, documentation, operating manuals and similar product
materials for NMR Technology sold for Research Use only as set forth above within the LipoScience Field of Use will expressly designate the NMR Technology as for Research Use only. Agilent will not support, assist or otherwise facilitate any FDA or
CLIA registration, application or certification for an IVD, or development of a Laboratory Developed Test, in the LipoScience Field of Use, by any third party with respect to the of NMR Technology. 

  
 Page 17 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 b. Except as set forth herein, Agilent shall not be restricted in any other way and shall be
free to sell NMR Technology to all customers, expressly excluding the customers specified in Appendix J-1, for Research Use only and Investigative Use only to measure LipoScience Specimen Types. Agilent shall also be free to sell NMR Technology to
any customer who would develop IVDs outside the LipoScience Field of Use including, but not limited to, all IVDs analyzing Tissue and Cell Suspension. 
  

	 	1.	“Research Use” shall mean an application for purposes of research, development, manufacturing or analysis, but in no event shall “Research Use“ mean
the analysis of any LipoScience Specimen Types in the LipoScience Field of Use for which a patient or third party payor (such as Medicare, an insurance company or a managed care plan) typically pays or reimburses the cost thereof.

  

	 	2.	“Investigative Use” shall mean an application using the NMR Technology that is intended for use in clinical investigations to generate clinical data to
support an IVD or LDT as permitted by the FDA or its foreign equivalent. 

  

	 	3.	“in vitro Diagnostic Application” or “IVD” shall mean an application using NMR Technology that is subject to regulatory approval requirements
under applicable law, regulations or policies of regulatory approving agencies such as the United States Food and Drug Administration (FDA) or its foreign equivalent for commercialization as a medical device or diagnostic product or where use of the
application is subject to CLIA requirements as a Laboratory Developed Test. 

  

	 	4.	“LipoScience Specimen Types“ shall mean those fluids set forth and itemized on Appendix L. 

c. Solely with respect to the subfield of cancer, if, during the first ten years of this Agreement, (i) LipoScience fails to make
Reasonable Progress during any twelve (12) month period, then Agilent’s agreement not to sell all or any part of the NMR Technology for use in the subfield of cancer shall terminate; provided however, that if Agilent reasonably believes that
LipoScience has not made Reasonable Progress in the subfield of cancer, then Agilent shall first notify LipoScience, and LipoScience shall have ninety (90) days in which to provide evidence to Agilent of such Reasonable Progress. If LipoScience
provides such evidence of Reasonable Progress, the restrictions above shall continue in full force and effect for the subfield of cancer. If LipoScience fails to provide the foregoing, then upon such termination, Agilent is free to sell NMR
Technology to any customer for use in the subfield of cancer who intends to pursue FDA approval of IVDs in the subfield of cancer for any of the LipoScience Specimen Types. Notwithstanding the foregoing and in the event that LipoScience fails to
show Reasonable Progress, LipoScience shall continue to have the nonexclusive right to develop in vitro Diagnostic Applications using NMR Subsystems for cancer based on any LipoScience Specimen Type. 

d. “Reasonable Progress” in the subfield of cancer shall mean any one of the following: 

 

	 	1.	Authoring a peer reviewed publication on IVD using NMR measurements for which cancer is a primary subject, 

 

	 	2.	Entering into a written agreement with a third party to develop or commercialize an in vitro Diagnostic Application using NMR measurement for cancer,

  

	 	3.	Participating in an active internal or external research program with committed resources, a written project plan, and formal documentation relating to a Diagnostic
Application using NMR measurement for cancer, 

  

	 	4.	Engagement in pre-IDE or other substantive formal regulatory discussions with the FDA or other applicable regulatory authority concerning approval of an IVD using NMR
measurement for cancer, 

  

	 	5.	Filing of a patent application in any country relating to an IVD using NMR measurement for cancer, 

 

	 	6.	Substantively responding to any patent office on a patent application filed in any country relating to an IVD using NMR measurement for cancer, or

  

	 	7.	Offering, enabling use or selling an IVD commercial product using NMR measurement for cancer. 

e. Provided that Agilent has complied with the limitations set forth in Section 11.1.a. Agilent shall not be in breach of this Agreement
if any NMR Technology sold by Agilent and labeled Research Use Only is used within the LipoScience Field of Use if Agilent did not know or reasonably should not have known of such intended use at the time of sale. 

11.2 LipoScience Use. During the first ten (10) years of this Agreement, LipoScience shall not sell a product using NMR Technology to customers
for Research Use and agrees not to develop IVDs using NMR Technology outside the LipoScience Field of Use including, but not limited to, IVDs analyzing tissue and cell suspensions (e.g. FFPE Tissue, fine needle asperates and embedded cell

  
 Page 18 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
pellets), provided however that LipoScience is not restricted from developing IVDs using NMR Technology for Investigative Use outside the LipoScience Field of Use. If LipoScience fails to make
Reasonable Progress in the subfield of cancer, it is acknowledged and agreed hereby that LipoScience shall not be restricted from developing IVDs using the NMR Technology in such subfield based on the use of any LipoScience Specimen Types and using
NMR Technology. LipoScience shall not be in breach of this Agreement if any product using NMR Technology sold by LipoScience is used for Research Use Only if LipoScience did not know or should not have reasonably known of such intended use at the
time of sale. 
 11.3 Survival of Section 11. The provisions of this Section 11 shall not survive termination or expiration of this
Agreement except in the case of termination for Agilent’s uncured and material breach (but in any event, except for LipoScience’s breach of this Agreement, the provisions of Section 11.2 shall not survive termination of this Agreement).
The restrictions set forth in Section 11.1 and 11.2 apply to sales and activities in the United States. Notwithstanding the foregoing, the Parties agree that within three (3) months of LipoScience receiving FDA approval for the Vantera Analyzer, the
Parties will meet to discuss and negotiate in good faith generally similar terms and conditions applicable to the territory outside of the United States. 
 11.4 Exclusivity of Purchase. During the term of this Agreement, and except as expressly otherwise provided herein or to support non-Agilent based systems deployed prior to the Effective Date of
this Agreement, LipoScience will obtain exclusively from Agilent all Products for use in the Vantera Analyzer. LipoScience may seek another supplier for Products as expressly provided herein, and to fufill those Purchase Orders (i) rejected by
Agilent, (ii) cancelled by LipoScience in the event delivery exceeds ninety (90) days past the quoted delivery date, or (iii) as otherwise agreed if Agilent consents in writing. 

 

	12.	Representations, Warranties and Indemnity. 

12.1 Representations and Warranties of LipoScience. LipoScience represents and warrants that as of the Effective Date: 

(a) LipoScience is a corporation duly organized, validly existing and in corporate good standing under the laws of Delaware and is duly
qualified and authorized to transact business, and is in good standing as a foreign corporation, in each jurisdiction where such qualification is necessary; 
 (b) LipoScience has the legal right, authority and power to enter into this Agreement and to extend the rights and licenses granted to Agilent in this Agreement; 

(c) LipoScience has taken all reasonable action necessary to authorize the execution and delivery and performance of this Agreement;

 (d) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of
LipoScience enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally
and except as enforceability is considered in a proceeding in equity (regardless of whether such enforceability is considered); and 
 (e) the performance of its obligations under this Agreement will not conflict with its charter documents or result in a breach of any agreement, contract or other arrangement to which it is a party;

 12.2 Representations and Warranties of Agilent: Agilent represents and warrants that as of the Effective Date: 

(a) Agilent is a corporation duly organized, validly existing and in corporate good standing under the laws of Delaware and is duly
qualified and authorized to transact business, and is in good standing as a foreign corporation, in each jurisdiction where such qualification is necessary; 
 (b) Agilent has the legal right, authority and power to enter into this Agreement and to extend the rights and licenses granted to LipoScience in this Agreement; 

(c) Agilent has taken all reasonable action to authorize the execution and delivery and performance of this Agreement; 

(d) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Agilent
enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as
enforceability is considered in a proceeding in equity (regardless of whether such enforceability is considered); 

  
 Page 19 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 (e) the performance of its obligations under this Agreement will not conflict with its
charter documents or result in a breach of any agreement, contract or other arrangement to which it is a party; and 
 (f) To the
best of Agilent’s knowledge, as of the Effective Date, Agilent has received no written claim threatening or asserting that, the sale, use, distribution or practice of Agilent’s NMR Subsystem infringes the patent rights of any third party.

 (g) the NMR Subsystems delivered to LipoScience hereunder shall have been manufactured in accordance with all laws, rules and
regulations, including without limitation all FDA quality system requirements applicable to the manufacture of the NMR Subsystem at Agilent’s manufacturing site. 
 12.3 Warranty Disclaimer: EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NON-INFRINGEMENT, WHICH ARE HEREBY EXPRESSLY DISCLAIMED. 
 12.4 Indemnity. 

12.4.1 LipoScience Indemnity of Agilent. Subject to the limitation of liability clause in Section 19, LipoScience will defend,
indemnify and hold Agilent, its Affiliates and their respective directors, officers, employees and agents and their respective heirs and assigns harmless from any third party claims for bodily injury, death or tangible property damage, including
reasonable attorney’s fees, arising as a result of LipoScience’s negligence, recklessness or wilful misconduct or arising as a result of sales or use of the Vantera Analyzer provided that any indemnification by LipoScience shall be
diminished in proportion to the amount of negligence attributed to Agilent. 
 12.4.2 Agilent Indemnity of LipoScience.
Subject to the limitation of liability clause in Section 19, Agilent will defend, indemnify and hold LipoScience, its Affiliates and their respective directors, officers, employees and agents and their respective heirs and assigns harmless from
any third party claims for bodily injury, death or tangible property damage, including reasonable attorney’s fees, arising as a result of Agilent’s negligence, recklessness or wilful misconduct or arising as a result of sales of the NMR
Subsystem to LipoScience provided that any indemnification by Agilent shall be diminished in proportion to the amount of negligence attributed to LipoScience or attributed to a user of the Vantera Analyzer. Other than [ * * * ], for which there is [
* * * ]. 
 12.5 Procedure. If an Indemnified Party intends to claim indemnification under this Agreement, the Indemnified Party shall
notify the Indemnifying Party of any loss in respect of which the Indemnified Party intends to claim such indemnification, and the Indemnifying Party shall assume the defense thereof with counsel mutually satisfactory to the Parties. The Indemnified
Party shall provide reasonable assistance to the Indemnifying Party and its legal 

  
 Page 20 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
representatives, at the Indemnifying Party’s expense, in the investigation of any action, claim or liability covered by this indemnification. The Indemnifying Party shall not, without the
written consent of Indemnified Party, settle or compromise any loss or consent to the entry of any judgment with respect to any loss (a) that does not release Indemnified Party from all liability with respect to such loss or (b) which may
materially adversely affect Indemnified Party or under which Indemnified Party would incur any obligation or liability, other than one as to which Indemnifying Party has an indemnity obligation hereunder. 

12.6 Intellectual Property Claims. 

With respect to a claim of indemnification by LipoScience against Agilent with respect to intellectual property claims, the following process shall be
followed: 
  

	a)	Agilent will defend or settle any claim against LipoScience that a Product infringes an intellectual property right, provided LipoScience promptly notifies Agilent in
writing and provides control of the defense or settlement, and assistance, to Agilent. 

  

	b)	In defending or settling an infringement claim under Section 12.6(a), Agilent will pay infringement claim defense costs, settlement amounts and court-awarded
damages. If such a claim appears likely, Agilent may, at its option, modify or replace the Product or procure any necessary license. If Agilent determines that none of these alternatives is reasonably available, Agilent will refund
LipoScience’s purchase price upon return of the Product. 

  

	 	c)	Agilent has no obligation for any claim of infringement arising from: Agilent’s compliance with, or use of, LipoScience’s designs, specifications,
instructions or technical information; Product modifications by LipoScience or a third party; Product use prohibited by or outside the scope of Specifications or related application notes; or use of the Product with products not supplied by Agilent.

  

	13.	Force Majeure. 

 Neither Agilent nor
LipoScience shall be liable to the other for failure to perform any obligation under the Agreement to the extent such failure to perform is due to labour unrest, riot, war, fire, accident, weather or other natural disasters, lack of energy supplies,
supplier delays, compliance with law, failure to obtain all necessary licenses, permits or approvals after reasonable efforts, or any unforeseen circumstances or other causes beyond such Party’s reasonable control. 

 

	14.	Regulatory Compliance. 

14.1 Duty To Comply. LipoScience represents and warrants that LipoScience will comply with all applicable laws, rules and
regulations imposed by the United States Food and Drug Administration or any successor agency with responsibilities comparable to those of the United States Food and Drug Administration (“FDA”) and any comparable foreign regulatory
authority in each jurisdiction in which LipoScience markets and sells the Vantera Analyzer. LipoScience will be solely responsible for preparing all regulatory filings for the Vantera Analyzer for use by LipoScience or its customers, including all

  
 Page 21 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 
filings required for Approval, and will be responsible for submitting to the FDA or any other regulatory authority such applications or other filings for Approval, with all such Approvals
required for the Vantera Analyzer in the name of LipoScience. LipoScience will be solely responsible for all regulatory matters related to the Vantera Analyzer, including communicating with the FDA and any other regulatory authority. LipoScience
will be solely responsible for obtaining Approvals and for subsequent maintenance of Approvals for the Vantera Analyzer. Agilent will reasonably cooperate with and provide all reasonably requested information and assistance for such Approvals,
including information and records required for FDA Approval and European Community In Vitro Diagnostic Directive. 
 14.2
Field Corrections and Medical Device/Adverse Event Reporting. Agilent shall promptly notify LipoScience of any product safety issues that may impact the performance of the NMR Subsystem or that may warrant a recall or field correction.
Agilent will provide reasonable and diligent support to LipoScience in the investigation of customer complaints regarding performance problems associated with the NMR Subsystem and if reasonably required, will jointly work with LipoScience to
promptly investigate and resolve any documented performance and/or safety issues. 
 14.3 Export Controls. If LipoScience
exports, re-exports, transfers or imports products, technology or technical data purchased hereunder, LipoScience will comply with applicable US and other laws, rules and regulations, and will obtain any required export and import authorizations.

  

	15.	Confidentiality. 

 15.1 If, during the
Term, a Party receives or has access to certain Confidential Information belonging to the other Party, the Parties will be bound by the terms of the Confidential Disclosure Agreement (the “CDA”) attached as Appendix K. For purposes of
Section I(1)(b) of the CDA, Confidential Information includes, without limitation, forecasts, costs, pricing, provided that such information is marked as “Confidential” in accordance with Section I(1)(c) of the CDA. For purposes of Section
II(1)(a) and II(1)(b) of the CDA, Confidential Information may only be used for purposes related to this Agreement. To the extent of any conflicts between the terms of the CDA and the terms of this Agreement, the terms of this Agreement will control
and take precedence. The Parties further agree that any Confidential Information disclosed prior to the Effective Date in connection with the collaboration and development activities of the Parties with respect to the Vantera Analyzer shall be held
in accordance with the CDA, provided, however, that any information disclosed by either Party prior to the Effective Date shall only be treated as Confidential Information if such information was marked as Confidential by such other Party.

 15.2 No Publication. Neither party may publicize or disclose the terms of this Agreement to any third party without the written
consent of the other Party. Without limiting the generality of the foregoing sentence, no press releases may be made without the mutual written consent of the Parties. 

  
 Page 22 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	16.	Intellectual Property Ownership. 

 16.1
Pre-Existing IP. Each Party retains all patents, copyrights, trade secrets, trademarks and other property rights in its intellectual property developed before or independent of this Agreement (“Pre-Existing IP”). Both Parties hereby
acknowledge and agree that as of the Effective Date and as between LipoScience and Agilent, LipoScience owns all intellectual property rights to the Vantera Analyzer as distinct from the NMR Subsystem and Agilent owns all intellectual property
rights to the NMR Subsystem. 
 16.2 Developed IP. Any intellectual property developed after the Effective Date and in the performance of
this Agreement, either solely by one Party or jointly by the Parties (“Developed IP”), will be owned as follows: 
 LipoScience will
own all intellectual property rights to Developed IP that are: 
 i) Solely developed by employees or agents of LipoScience or

 ii) Jointly developed by employees or agents of LipoScience and Agilent that primarily concerns the Vantera Analyzer as
distinct from the NMR Subsystem (“Vantera IP”). Agilent hereby assigns all of its intellectual property rights to such jointly developed Vantera IP to LipoScience, and agrees to execute such additional documents as may be required to
document and enforce its rights. LipoScience hereby grants to Agilent a royalty and fee free, nonexclusive, worldwide, transferable, non-terminable license without a right to sublicense to make, have made, use, sell, import, export, copy, prepare
derivative works, perform, display and distribute products embodying the Vantera IP. 
 Agilent will own all intellectual property rights to
Developed IP that are: 
 i) Solely developed by employees or agents of Agilent or 

ii) Jointly developed by employees or agents of Agilent and LipoScience that primarily concerns the NMR Subsystem (”NMR IP”).
LipoScience hereby assigns all of its intellectual property rights to jointly developed NMR IP to Agilent, and agrees to execute such additional documents as may be required to document and enforce its rights. Agilent hereby grants to LipoScience a
royalty and fee free, nonexclusive, worldwide, transferable, non-terminable license without a right to sublicense to make, have made, use, sell, import, export, copy, prepare derivative works, perform, display and distribute products embodying the
NMR IP. 
 16.3 Developed IP in Dispute. Should the Parties be unable to agree on whether jointly Developed IP is Vantera IP or NMR IP,
the Parties will jointly own the Developed IP with both Parties having an equal right to practice the invention, including an urestricted right to assign or sublicense, without a duty to account to the joint owner. 

  
 Page 23 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 16.4 Marks. As used in this Section, “Marks” means the trademarks, service marks, trade
dress, trade names, logos, insignia, symbols, designs or other marks identifying Agilent or its products. LipoScience will not use Agilent’s Marks in any of its advertising or marketing literature without Agilent’s prior written consent.
LipoScience will not remove, modify, alter or tamper with serial or identification numbers, labels or Marks on Products sold to LipoScience under this Agreement. Agilent will have the sole and exclusive right in its sole discretion to bring legal
actions for trademark infringement with respect to any Agilent Marks. 
  

	17.	Governing Law; Disputes. 

 This Agreement
shall be governed by the laws of the State of Delaware, U.S.A. (excluding choice of law rules and the provisions of the Convention for the International Sale of Goods (CISG)). 
 In the event that the Parties are unable to agree upon any matters pursuant to this Agreement, the disputed matter will be referred to the [ * * * ] of [ * * * ] and [ * * * ]. If these two
representatives cannot reach a mutually acceptable agreement within thirty (30) days or within such time as the Parties mutually agree, the matter will be referred to [ * * * ] and [ * * * ]. In the event they cannot reach a mutually acceptable
resolution within another thirty (30) days or within such time as the Parties mutually agree, either Party will be entitled to seek all available remedies, including legal remedies. Notwithstanding the foregoing, either Party may seek
injunctive relief with respect to any disputed matter without following the dispute resolution procedure set forth above. 
  

	18.	Software License. 

 Title to all software
provided as separate modules or embedded in the Products (“Software”) shall remain the property of Agilent or Agilent’s licensors. Agilent grants to LipoScience a non-exclusive, limited license to use the Software solely in
conjunction with or embedded in the Products. Agilent further grants to LipoScience a non-exclusive, limited license to distribute the Software together with the Products provided LipoScience passes through Agilent’s license terms whenever
Software is distributed to an end user. Neither LipoScience nor LipoScience customers shall decompile, disassemble or otherwise reverse engineer the Software, or create derivative works without the prior written approval of Agilent. 

 

	19.	Damages. 

 To the extent that limitation
of liability is permitted by law, in no event shall either Party be liable for incidental, consequential, indirect, punitive, or special loss or damages of any kind, including but not limited to lost revenues, lost profits, loss of goodwill or lost
production, however caused, whether based on contract, tort (including negligence) or any other legal theory. The foregoing limitation of liability shall not apply to either Party’s breach of confidentiality under this Agreement, to damages
resulting from either Party’s gross negligence or wilful misconduct or to either Party’s breach of the exclusivity obligations set forth in Section 11 hereof. 

  
 Page 24 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	20.	Assignment. 

 This Agreement may not be
assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that (a) LipoScience may, without such consent from Agilent, assign its rights together with its obligations under this
Agreement to any entity acquiring substantially all of its assets or stock, or its business relating to the Vantera Analyzer, or with which it may merge and (b) Agilent may, without consent from LipoScience, assign its rights together with its
obligations under this Agreement to any entity acquiring substantially all the assets of its NMR business, or with which it may merge; provided, however, that such Party’s rights and obligations under this Agreement shall be assumed by its
successor in interest in any such transaction. Any purported assignment in violation of the preceding sentence shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 

 

	21.	Severability. 

 If any term, covenant or
condition of this Agreement shall be held to be invalid or unenforceable under applicable law, then (a) the remainder of this Agreement shall not be affected and shall otherwise be valid and enforced to the fullest extent permitted by law, and
(b) the Parties shall use their commercially reasonable efforts to replace such void or unenforceable provisions of this Agreement with a valid and enforceable provision that will achieve, to the greatest extent possible, the economic, business
and other purposes of such void or unenforceable provision. 
  

	22.	Sole Terms. 

 This Agreement and any
Purchase Orders issued hereunder set forth the entire agreement between Agilent and LipoScience with respect to their subject matter and supersede all previous written or oral agreements and understandings, including the Collaboration Agreement. To
the extent of any conflict between this Agreement and any Purchase Order, the provisions of this Agreement shall control. This Agreement may not be amended nor may compliance with any provision herein or therein be waived, except by a written
document duly and validly executed by both Agilent and LipoScience, or in the case of a waiver, the Party waiving compliance. Any part of this Agreement held to be void, invalid or unenforceable shall be treated as severable, leaving valid the
remainder. 

  
 Page 25 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	
	Signed on behalf of Agilent Technologies, Inc:
	
	/s/ Nicolas H. Roelofs
	
	Printed name: Nicolas H. Roelofs, Ph.D.
	
	Position: Life Sciences Group President
	
	Date: 7/11/12
	
	Signed on behalf of LipoScience, Inc:
	
	/s/ Richard O. Brajer
	
	Printed name: Rick Brajer
	
	Position: President and CEO
	
	Date: 7/13/12

  
 Page 26 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix A1: Product Specifications 

 

	I.	NMR Subsystem Product Specifications 

 NMR Subsystem Specifications consist of the following documents set forth in this Appendix A1: 
  

	 	1)	NMR Probe Specification 

  

	 	2)	NMR Console Specification 

  

	 	3)	NMR Magnet Specification 

  

	 	1)	NMR Probe Specifications 

 [ * * * ] IFC Top Loading Probe, 400 MHz 
 Description: NMR Probe for flow
sample handling. [ * * * ] 
 [ * * * ] 
 Does not includes IFC Tool Kit (required for changing or removing flow cell). 
 [ * * * ]

 Resolution and Lineshape: 
 [ * * * ] 
 Signal/Noise: 

Sample 

[ * * * ] 
 Pulse
Performance: 
 [ * * * ] 

  
 Page 27 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

			
	Gradient Strength:	  	Gradient Recovery:
	 [ * * * ]
	  	[ * * * ]
		
	Variable Temperature Range:	  	
	 [ * * * ]
	  	
		
	Sample Volume:	  	
	 [ * * * ]
	  	

  
 Page 28 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	2a).	Console Specifications 

  

			
	 RF channels
	 	
	 Highband
	 	 [ * * * ]

	 Lowband
	 	 [ * * * ]

	 Each channel is configured with
	 	 [ * * * ]

	 Waveform generator
	 	 [ * * * ]

	 Timing resolution
	 	 [ * * * ]

	 Minimum delay between modulated pulses
	 	 [ * * * ]

	 Minimum event time, phase, amplitude
	 	 [ * * * ]

	 Phase settling time
	 	 [ * * * ]

	 Phase resolution
	 	 [ * * * ]

	 Fine amplitude settling time
	 	 [ * * * ]

	 Fine amplitude control
	 	 [ * * * ]

	 Coarse amplitude control
	 	 [ * * * ]

	 Base frequency resolution
	 	 [ * * * ]

	 Minimum frequency resolution, SLP
	 	 [ * * * ]

	 Highband amplifier, nominal
	 	 [ * * * ]

	 Lowband amplifier, nominal
	 	 [ * * * ]

		
	 Digital receiver
	 	
	 Controller
	 	 [ * * * ]

	 Digitizer/max oversampling rate
	 	 [ * * * ]

	 Maximum spectral width
	 	 [ * * * ]

	 Data compression, digital filtering
	 	 [ * * * ]

	 Quad artifacts
	 	 [ * * * ]

		
	 Lock
	 	
	 Controller
	 	 [ * * * ]

	 Lock capture
	 	 [ * * * ]

	 Frequency
	 	 [ * * * ]

	 Lock sample and hold
	 	 [ * * * ]

		
	 PFG
	 	
	 Controller
	 	 [ * * * ]

	 Waveform generator
	 	 [ * * * ]

	 Timing resolution
	 	 [ * * * ]

	 Amplitude control
	 	 [ * * * ]

	 Minimum gradient pulse length
	 	 [ * * * ]

		
	 Temp. Control
	 	
	 Standard
	 	 [ * * * ]

	 Optional
	 	 [ * * * ]

  
 Page 29 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

	3).	Magnet Specifications 

 1. DESCRIPTION THE SYSTEM 
 [ * * * ] 

2. THE SUPERCONDUCTING MAGNET 
 i) General Description 
 [ * * * ] 

  
 Page 30 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 ii) Magnet specifications  

 

			
	Magnet type	  	[ * * * ]
		
	Central field	  	[ * * * ]
		
	Field stability	  	[ * * * ]
		
	Operating current	  	[ * * * ]
		
	Typical time to energise magnet to full field	  	[ * * * ]
		
	Stored Energy	  	[ * * * ]
		
	Fringe field (5 Gauss line)*	  	[ * * * ]
		
	[ * * * ]	  	

 iii) Superconducting Shim Coils 

 

			
	Coil Details:-	  	
		
	Shims provided	  	[ * * * ]
		
	Coupling	  	[ * * * ]
		
	Orthogonality	  	[ * * * ]
		
	‘X’ axis alignment	  	[ * * * ]

  
 Page 31 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 [ * * * ] 
 Figure 1: Fringe field 

  
 Page 32 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 3. THE CRYOSTAT 

i) General Description 
 The cryostat is of conventional design, consisting of a central all-welded stainless-steel helium vessel, which is surrounded by a gas-cooled radiation shield and liquid nitrogen reservoir. [ * * * ]

 ii) Specifications 
 [ * * * ] 
  

			
	System Finish:-	  	
		
	 Cryostat
	  	[ * * * ]
		
	 Stand and T plate (where supplied)
	  	[ * * * ]
		
	Dimensions:-	  	
		
	See customer interface drawings	  	
		
	 Minimum ceiling height
	  	[ * * * ]
	 with low ceiling installation equipment
	  	[ * * * ]
		
	 System assembly
	  	[ * * * ]
		
	 Weight, magnet and cryostat
	  	[ * * * ]
		
	 Weight, operational including legs and cryogens
	  	[ * * * ]

  
 Page 33 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

			
	 Shipping information:
	  	
		
	 Crate dimensions (magnet and ancillaries)
	  	[ * * * ]
		
	 Crate dimensions (anti-vibration legs)
	  	[ * * * ]
		
	[ * * * ]	  	

  
 Page 34 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix B - General Procedures for Magnet Installation of NMR Subsystem 

 

	 	A.	Magnet Install – Schedule Table 

  

							
	 Day of Install (D)
	  	 Activity
	  	 Resource
	  	 Equipment

required

	[ * * * ]	  		  		  	

  
 Page 35 of 51

  

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED
HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 [ * * * ] 
  

	 	B.	Reference Documents: 

 400-MR
Pre-Installation Guide, [ * * * ] 
 Installation & Acceptance, [ * * * ] 
 Good Laboratory Practices, [ * * * ] 
 Safety Guide, [ * * * ] 

System Interconnect, [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix C: Service Parts and Initial Pricing [ * * * ] 

 

					
	 400-MR Service Parts List
	  	Part number	  	        [ * * * ]       
 
	[ * * * ]	  		  	

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix D: Field Service and Support and Initial Rates [ * * * ] 

Service Model Options: 
  

	1)	Mutual Aid Support Plan (service contract per system) 

 [ * * * ] 
  

	2)	Priority Time & Material (Per event billable) 

 [ * * * ] 
  
  

 

			
	Engineer Certification Training	  	[ * * * ]

 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix E: Routine Maintenance to be Provided by LipoScience 

Liposcience shall ensure the following requirements are met as a condition of receiving Agilent service support of LipoScience field engineering:

 [ * * * ] 

LipoScience shall perform the following tasks when providing NMR Subsystem service: 

[ * * * ] 
 LipoScience shall
perform the following tasks when performing routine maintenance on NMR Subsystems: 
 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix F: Agilent / LipoScience Escalations Process 

[ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix G: Agilent Technical Support Service Levels and Target Response Time 

Technical Support Via Phone and E-mail: 
 [ * * * ] 
 Remote Access Diagnostics: 

[ * * * ] 
 On Site Service
Support by Agilent Service Personnel 
 [ * * * ] 
 Service Parts Shipment 
 [ * * * ] 

 
  

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix H: [ * * * ] MR Service Training Curriculum 

LENGTH: 
 Length
of class: 10 days 
 LOCATION: 
 All Classes are held at the Agilent Training Center, Santa Clara, California. 
 PURPOSE:

 [ * * * ] 

PREREQUISITES: 
  

	 	•	 	 Basic knowledge of using test equipment. 

  

	 	•	 	 Basic knowledge of RF/digital circuits 

  

	 	•	 	 Basic knowledge of safety procedures related to handling of cryogenic fluids 

COURSE CONTENT: (All Course material will be provided.) 
 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 APPENDIX J-1 

 

			
	 Name
	  	 State

 [ * * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix J-2 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

			
	 

  
	  	         CONFIDENTIAL DISCLOSURE
AGREEMENT
  

 

 Effective Date:             

The parties as specified below agree on the following terms: 
  

	I.	Definition of Confidential Information 

  

	 	1.	In this Agreement, Confidential Information shall mean information exchanged on or after the Effective Date, which: 

 

	 	(a)	is disclosed by both parties, or, if checked here, is disclosed  ̈ only by Participant or  ̈ only by Agilent, 

  

	 	(b)	concerns             , 

 

	 	(c)	is MARKED AS BEING CONFIDENTIAL at the time of disclosure, or if unmarked (e.g. orally or visually disclosed), is designated as being
confidential at the time of disclosure and is confirmed as such in writing by the disclosing party within thirty days of the disclosure, 

 ; and 
  

	 	(d)	prior to receipt from the disclosing party was neither publicly available nor in the receiving party’s possession without a duty of confidentiality.

  

	 	2.	Information shall cease to qualify as Confidential Information once it becomes publicly available without breach of this Agreement, is rightfully obtained by the
receiving party from another source without a duty of confidentiality, or is independently developed or ascertained by the receiving party without use or reference to the Confidential Information 

 

	 	3.	A receiving party shall be permitted to disclose Confidential Information to the extent required by law provided that the receiving party gives the disclosing party
prior written notice of such requirement and takes reasonable steps to maintain the confidentiality of such disclosure and reasonably cooperates with the disclosing party to contest the necessity or scope of the disclosure or to obtain a protective
order. 

  

	 	4.	In this Section I, the term ‘receiving party’ shall include such party’s Associates. 

An Associate is any subsidiary, parent, subsidiary of the parent, or corporate affiliate of a receiving party, whether any such
relationship is of direct or indirect nature. 
  

	II.	Obligations 

  

	 	1.	Confidential Information may only be used: 

  

	 	(a)	if received by Participant or its Associates, for the purpose of:              

 

	 	(b)	if received by Agilent or its Associates, for the purpose of:              

 

	 	2.	A party receiving Confidential Information shall use the same degree of care, but in any case no less than a reasonable degree of care, to prevent unauthorized use,
dissemination or publication thereof, as it uses to protect its own information of a similar confidential nature. 

  

	 	3.	This Confidential Disclosure Agreement shall terminate as of termination of the Supply Agreement to which it pertains. The obligations under this Section II shall
terminate three years or, if filled in here, then five (5) years              after the date of disclosure of the Confidential Information. 

 

	III.	Warranties 

  

	 	1.	A receiving party may pass Confidential Information to its Associates and hereby warrants that these Associates will abide by all terms and conditions of this
Agreement. A receiving party shall remain liable for any breach by any Associate to which such Confidential Information is disclosed. 

  

	 	2.	Each party warrants that it has the right to make the disclosures under this Agreement. 

 

	 	3.	NO OTHER WARRANTIES ARE MADE BY EITHER PARTY UNDER THIS AGREEMENT. CONFIDENTIAL INFORMATION IS PROVIDED “AS IS” WITH NO WARRANTY AS TO ITS ACCURACY OR
COMPLETENESS. 

  

	IV.	Miscellaneous 

  

	 	1.	Without regard to choice of law provisions, this Agreement is governed by and will be construed in accordance with the laws of the State of New York and the USA or, if
filled in here, then the laws of:             . 

  

	 	2.	Neither party acquires any intellectual property rights under this Agreement except the rights granted in Section II.1. 

 

	 	3.	This Agreement imposes no obligation on either party to purchase, sell, license, transfer or otherwise dispose of any technology, services or products.

  

	 	4.	This Agreement docs not create any agency or partnership relationship. 

  

	 	5.	Any modification to this Agreement must be made in writing and signed by the party against whom such modification is sought to be enforced. 

 

	 	6.	A receiving party will comply with all applicable export laws.

 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

			
	Agilent	  	Participant
		
	Agilent Technologies             	  	Company Name:
	(e.g. Inc.; France S.A.; Japan, Ltd.; UK Ltd.; Deutschland GmbH; etc.)	  	Address:
	Address:	  	Address:
	Address:	  	Authorized Signature:
	Senior Mgr.’s Signature:	  	Printed Name:
	Printed Name:	  	Title:
	Title, Entity/Division:	  	

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 

 
 APPENDIX K 
 Agilent Technologies Recommendations for 
 Decontamination of Probes
Contaminated with 
 Bloodborne Pathogens 
 In order to provide maximum protection for our employees Agilent Technologies requires that any equipment that has come into contact with bloodborne pathogens or other bodily fluids must be decontaminated
before returning to Agilent for service. 
 Purpose: This decontamination guide provides instruction for the recommended decontaminated
procedure for probes that may have come in contact with bloodborne pathogens or other bodily fluids. 
 [ * * * ] 

I certify that all necessary actions for cleaning and decontaminating probes have been taken. 

 

			
	Name:	 	  

			
	Position:	 	  

			
	Date:	 	  

			
	Signature:	 	  

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix K -Supplemental Information and References 

[ * * * ] 
 References 

 

	1.	 Biological Safety Principles and Practices, 4th Edition, D. O. Fleming and D. L. Hunt Ed.; American Society for Microbiology Press, pg 376 (2006)

  

	2.	US NIH, Division of Occupational Health and Safety; Decontamination and Sterilization 

 

	3.	U.S. OSHA; OSHA Letter of Interpretation on the Use of BBP disinfectants (1999) 

 

	4.	Disinfection and Sterilization Principles; Association for Professionals in Infection Control and Epidemiology (2005) 

 

	5.	US EPA: List D: EPA’s Registered Antimicrobial Products Effective Against Human HIV-1 and Hepatitis B Virus from Selected EPA-registered
Disinfectants 

  

	6.	G. E. McDonnell; Antisepsis, Disinfection, and Sterilization; American Society for Microbiology Press, pg 90-92 (2007) 

 

	7.	Principles & Practices of Biosafety; American Biological Safety Association Training Course (January 2008) 

 

	8.	W. W. Bond, et al.; Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals: J Clin Microbiol. 1983 September; 18(3):
535-538. 

  

	9.	CDC Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 

 

	10.	Reproductive Health on Line (an affiliate of Johns Hopkins University), Infection Prevention Guidelines 

 

	11.	Disinfection, Sterilization, and Preservation, Fifth Ed; Editor: Seymour S. Block; Lippincott Williams & Wilkins (2000). 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Appendix L 
 “LipoScience Specimen Types” shall have the following meaning: 
 Those [
* * * ] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A
CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]